N,Title,Nchar
1,"Analysis of 245,388 Diverse Participants in the NIH All of Us Cohort Identifies VEXAS Resiliency in UBA1 M41L Somatic Mutation Carriers",135
2,Mutational Analysis of UNC93B1 Identifies Regulatory Regions Mutated in Human SLE,81
3,Efficacy and Safety of Targeted Therapies in VEXAS Syndrome: Retrospective Study from the French VEXAS Group,108
4,"EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension): Topline and Key Secondary Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in Subjects with Knee Osteoarthritis",215
5,DICKENS: A Multicentre Randomised Controlled Trial of Diacerein for Knee Osteoarthritis with Effusion-Synovitis,111
6,Improvement in Clinical and Patient-Reported Outcomes for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) 6 Months to 2 Years After Autologous Stem Cell Transplantation (ASCT),179
7,3-year Results of Tapering TNFi to Withdrawal Compared to Stable TNFi Among Rheumatoid Arthritis Patients in Sustained Remission: A Multicenter Randomized Trial,160
8,"Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation",229
9,Efficacy and Safety of LNK01001 in Chinese Patients with Moderate to Severe Active Rheumatoid Arthritis with an Inadequate Response to Conventional Synthetic DMARDs: 24-week Results from a Phase 2 Trial,202
10,"Dazodalibep, a CD40L Antagonist, in a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial of Subjects with Sjögren’s Disease Having Unacceptable Symptomatic Burden but Limited Extraglandular Organ Involvement",227
11,Risk of Cardiovascular Events According to Biological Agent Exposure in Patients with Ankylosing Spondylitis: A Korean Population-based Study,141
12,"Efficacy and Safety Outcomes of TAK-279, a Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial in Patients with Active Psoriatic Arthritis",204
13,"An Open-label, Multicenter, Phase 1/2 Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323, a Rapid Manufacturing CAR-T Cell Therapy Targeting CD19 on B Cells, for Severe Refractory Systemic Lupus Erythematosus: Preliminary Results",243
14,Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study,197
15,"AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography",214
16,"Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial",190
17,"Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study",191
18,Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren’s Syndrome Revealed by Molecular Classification of Salivary Glands,142
19,A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks,97
20,"Telitacicept, a Human Recombinant Fusion Protein Targeting and Neutralizing B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Rheumatoid Arthritis (RA) Patients with an Inadequate Response to Methotrexate (MTX): A Randomized, Double-Blind, Phase 3 Study",282
21,You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis,104
22,Patient Centered Care: The Complete Picture,43
23,Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime,64
24,Bouncing Back: How I Found My Running Shoes Using a Rebounder for My Psoriatic Arthritis,88
25,Relief Redefined: A Patient’s Journey to Reducing the Impact of Her PsA Flare Ups,81
26,Dana’s Data Dashboard: Applying a Familiar Framework for Efficient and Effective Health Management,98
27,"How “Coming Out” About My Lupus Diagnosis Allowed Me to Connect With Patients, Get Involved With Research, and Spread Awareness",127
28,Finding Gratitude in Adversity: The Impact of Finding the Right Rheumatologist,78
29,Practicing Mindfulness to Improve Quality of Life,49
30,Saved by Plants: How a Necessary Lifestyle Change Led to a Happier Life with Decreased Rheumatoid Arthritis Pain and Fatigue,124
31,"We Suffered For Decades, But Then She Was Born",46
32,Sjögren’s-Fatigue: Non-Therapeutic Lifestyle Adjustments to Help Manage My Most Problematic Symptom,99
33,"My Four Pillars of Wellness: How Sleep, Diet, Exercise and Stress Reduction Enable Me to Define My Life and not let Sjögren’s Define Me",135
34,Putting Lived Experience into Action: Flipping the Script on Living with a Chronic Disease,90
35,Toward a Frontier Beyond the Barriers of Position and Prejudice,63
36,Peer Health Coaches Help Scleroderma Patients Cope with Isolation,65
37,Utilizing Support Networks to Improve Patient Outcomes,54
38,Loss of the Complement Regulator CD55 Alters Marginal Zone B Cell Homeostasis,77
39,Population Pharmacokinetic and Pharmacodynamic Analyses of Obexelimab in Healthy Volunteers and in Patients with Rheumatoid Arthritis or IgG4-Related Diseases,158
40,Expanded Extrafollicular B Cells Were Improved by RTX in IgG4-related Disease,77
41,CD22 X CD79b Bispecific Ab Potently Inhibits B Cell Activation and Plasmablast Accumulation,91
42,Obexelimab Inhibits B Cell Activation and May Interfere with B Cell Chemotaxis in IgG4-Related Disease,102
43,Preclinical Characterization of a Novel anti-CD40 Antagonist Antibody-glucocorticoid Conjugate with Superior Preclinical Efficacy and Favorable Safety Profile,158
44,Targeting NF-κB Signalling in B Cells from ANCA-associated Vasculitis Impairs B Cell Biology as a Potential Novel Target,120
45,Differential Induction of Anti-Muscarinic Type-3-Receptor Antibodies by Immunization with 4-Hydroxy-2-nonenal-Modified Ro60 in BALB/c Mice,138
46,Impact of Psilocybin on Peripheral Cytokine Production,54
47,A Potential Mechanism for Major Adverse Cardiac Events Associated with JAK Inhibitors: JAK Inhibitor Withdrawal Causes Urokinase Release by Primed STAT Signaling,161
48,Clock Gene Bmal1 Promotes Transcriptional Activity of NF-κB to Regulate Production of Inflammatory Mediators in RA-FLS,118
49,Immune-cell Derived Cytokines Synergistically Interact to Drive Synovial Fibroblast Invasive Function and Metabolic Capacity,124
50,A Proliferating T Cell Signature in Blood Is Associated with Response to JAK Inhibitor Therapy in Rheumatoid Arthritis Patients,127
51,The 330 Genetic Risk Loci of Systemic Lupus Erythematosus (SLE) Now Known Are Consonant with Multiple Causal Mechanisms Involving Epstein-Barr Virus (EBV)-Encoded Transcription Co-factors (TFs) in EBV-Infected B Cells,217
52,Genetic Predisposition to a Positive Antinuclear Antibody Test Is Not Associated with Increased Risk of Disease,111
53,Role of TP53 in Inflammatory Reprogramming of Rheumatoid Arthritis Synovial Fibroblasts,87
54,Xist Ribonucleoproteins Promote Female Sex-biased Autoimmunity,62
55,Alternative Splicing and Expected Protein Changes in Muscle Biopsies from Different Types of Idiopathic Inflammatory Myopathies,127
56,Use of High-plex Data Reveals Novel Insights into the Temporal Artery Processus of Giant Cell Arteritis,103
57,The Inflammatory Proteome in Sjögren’s Syndrome Identifies New Biomarkers and Relevant Clinical Subgroups,105
58,Shared Genetic Susceptibility Between Rheumatoid Arthritis and Bipolar Disorder: Analyses from Genome-Wide Association Studies,126
59,Validation of a Transcriptomic-Based Machine Learning Model to Establish the Endotype of SLE Patients,101
60,Proteomic Analysis of Plasma-derived Extracellular Vesicles Renders Glutathione Peroxidase 3 a Biomarker for Dermatomyositis,124
61,Detection of Synovial Signatures in Peripheral Blood of Patients with Rheumatoid Arthritis via a Novel Blood-Based DNA Capture Assay,132
62,Relationship Between Genetic Variants in Cannabinoid Receptor 2 and Self-Reported Effectiveness of Cannabis for Pain Management in Rheumatoid Arthritis,151
63,Mapping Cellular Landscape of Esophageal Epithelium in Systemic Sclerosis Using Single-cell Transcriptomics,107
64,Association of HLA-DRB1 and ANKRD55/IL6ST Regions with Polymyalgia Rheumatica Diagnosis: A Genome Wide Association Study from UK Biobank and FinnGen,148
65,Adenosine Deaminase 2 Is Expressed as a Short Isoform Lacking Deaminase Activity in the Endothelium: Implications for DADA2 Vasculitis,134
66,Post-translationally Modified Fibrinogen Activated Macrophages Drive the Expression of Fibrotic Genes in Human Lung Fibroblasts,127
67,A Pathogenetic Model of IgG4-related Disease Developed from Familial IKZF1 and UBR4 Gene Variants,97
68,A Systematic Approach for Identifying Causal Variants and Their Target Genes on JIA Risk Haplotypes,99
69,Quantification of the Escape from X Chromosome Inactivation with the Million Cell-scale Human Blood Single-cell RNA-seq Datasets Reveals Heterogeneity of Escape Across Immune Cells and Escape in the Autoimmune Disease Conditions,228
70,A Novel Transcriptome-Based Machine Learning Pipeline Predicts Phenotypes of Lupus Patients,91
71,Genome-Wide Association Study for Loci Associated with Positive Antinuclear Antibodies in a Large Hospital Biobank,114
72,Using Genotyping and Functional Data from Monocytes to Identify Risk-Driving SNPs on JIA Risk Haplotypes,104
73,Using Genotyping and Chromatin Data in CD4+ T Cells to Nominate Causal Variants on JIA Risk Haplotypes and to Identify Their Target Genes,137
74,New Histological Approach in Spatial Transcriptomics Implicates Glandular Cell Involvement in Pathophysiology of Sjögren’s Disease,130
75,Specific Binding of Uric Acid to NDFIP1 Associates with Hyperuricemia-induced Ferroptosis,89
76,Enrichment of Rare Variants of Hemophagocytic Lymphohistiocytosis Genes in Systemic Juvenile Idiopathic Arthritis,113
77,Cytokine-induced Transcriptome Modification Elucidates the Similarity and Dissimilarity Across 10 Immune-related Diseases,121
78,Non-canonical NF-κB Signalling Is Required for Extrathymic AIRE Expression and Immunoregulatory Molecules in Cells of the Dendritic Lineage,139
79,Interactions Between Synovial Fibroblasts and Macrophages: Implications for Tissue Remodeling in Chronic Inflammatory Diseases and Macrophage Differentiation in Response to the Immune Microenvironment,200
80,Effect of the Inflammatory Microenvironment Induced by Monocytes on Fibroblasts and Modulatory Action of Human Dental Pulp Stem Cells,133
81,Assessing the Ability of Human Dental Pulp Stem Cells to Modulate the Macrophages Phenotype,91
82,Aberrant Mevalonate Metabolite Farnesyl Pyrophosphate-Induced Neutrophil Hyperactivation in Behçet’s Disease Pathogenesis,121
83,"Discovery and Characterization of a Selective, Orally Bioavailable PAD4 Inhibitor to Target NETs Driven Autoimmune and Inflammatory Diseases",140
84,"Circulating Monocytes in RA, SSc, and SLE Have Radically Altered and Unique Transcriptional & Epigenetic Profiles",113
85,Identification of Specific Monocyte Epigenetic Signatures in Sarcoidosis and Tuberculosis,89
86,Monosodium Urate Crystals Activate an Immune Tolerance Program That Restrains the Activation of Inflammatory Signaling in Macrophages During Gout Flares,152
87,Soluble Uric Acid Is an Endogenous Inhibitor of CD38,52
88,"Anti-Citrullinated Histone Antibody CIT-013, a Dual Action Therapeutic for Neutrophil Extracellular Trap Associated Autoimmune Disease",134
89,CD14+CD64+ Classical Monocytes Are the Main Producers of IL-23 at the Enthesis,78
90,"Possible Involvement of TLR4 in the Pathogenesis of Primary Sjögren’s Syndrome Through Induction of the Expression of BAFF Receptor, BR3 in Peripheral Monocytes",160
91,Nintedanib Downregulates the Profibrotic M2 Phenotype of Macrophages Obtained from Systemic Sclerosis Patients Affected by Interstitial Lung Disease,148
92,"RA Monocytes and Monocyte-Derived Macrophages Display Heightened Inflammatory Responses, Reduced Endocytic Capacity and Distinct TET Expression Compared to PsA Monocytes",169
93,Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses,123
94,The Activation of cGAS-STING Pathway in Systemic Lupus Erythematosus,68
95,GM-CSF receptor/SYK/JNK/FOXO1/CD11c Signaling Enhances Cell Migration to Promote Atherosclerosis,96
96,Macrophage Extracellular Traps Induced by Monosodium Urate or Calcium Pyrophosphate Crystals Form Independently of NLRP3 Inflammasome Activation,144
97,GM-CSF by Natural Killer Cells Drives Inflammatory Arthritis in HIV-Infected Humanized Mice,91
98,Serpin B1 Modulation of Immune Complex-Mediated Neutrophil Activation and NET-formation Requires Its Chymotrypsin-like Inhibitory Activity,138
99,Discovery of a RIPK2 Scaffolding Inhibitor for the Treatment of Joint Autoimmune Diseases,89
100,"Differential Metabolic Profiles, Activation and Circadian Dynamics in Rheumatoid Arthritis and Psoriatic Arthritis Circulatory Monocytes",136
101,Investigating Macrophage Repopulation in the Synovium,53
102,Correlation of Anti-DFS70 Autoantibodies by ELISA with HEp-2 Cells DFS Pattern by IFA,85
103,Mitochondrial Dysfunction and Fatigue in Sjögren’s Disease,58
104,Dimethyl Fumarate Modulates T Cell Metabolism and Function in Systemic Lupus Erythematosus Patient Samples,106
105,Anti-TNFR2 VHH Agonistic Antibodies Promote and Stabilize Treg Immunosuppressive Activity,89
106,All-trans Retinoic Acid (atRA) Enhances FoxP3 Protein Stability Under Inflammatory Conditions Through Altering the FoxP3 Protein-interactome,140
107,Activation of Joint CD8+ TRM Localize Autoantibody Mediated Arthritis,69
108,"Sex Based Differences in Morphological and Functional Niches of the Human Thymus, Identified by Non-supervised Spatial Transcriptomic Profiling, May Underlie Sex Bias in Autoimmune Disease",188
109,Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons,141
110,"PD-1hi Cells Are Highly Present in the Rheumatoid Joint, and Express Regulatory Capacities",90
111,Distinct PD-1 Receptor Engagement Leads to Different Pharmacodynamic Effects,76
112,"Proteomic, Transcriptomic, and T-Cell Receptor (TCR) Profiling of Synovial Integrin-Expressing (InEx) T Cells in Axial Spondyloarthritis (axSpA)",144
113,Characterizing GMCSF Producing T-cells in Rheumatoid Arthritis and Effect of Methotrexate on Them,97
114,Circulating CD4+CXCR5-PD-1hiICOS+ Cells Are Elevated in Patients with Newly Diagnosed Giant Cell Arteritis and Associate with the Clinical Outcome,146
115,Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Are Elevated in Patients with Rheumatoid Arthritis and Predict Treatment Response to Abatacept or TNF Blockers,165
116,CD4 T Cell Repertoire Features in RA Patients with High-risk HLA-DRB1 Alleles,77
117,"Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses",192
118,RA Disease Activity Influence the Frequency and Phenotype of Citrulline Reactive CD4 T Cells in DRB1*04:04 ACPA+ RA Patients,124
119,"A VAV1-Directed Molecular Glue Degrader, MRT-6160, Reduces Joint Inflammation in a Collagen-Induced Arthritis Autoimmune Disease Model",134
120,Expression of mRNA Vaccine Antigen in Hematopoietic Cells Is Necessary for Induction of Optimal Vaccine-Specific CD4+ T Cell Responses,134
121,Excess IL-18 Protects from Experimental Autoimmune Encephalomyelitis Mainly via Preferential Augmentation of Suppressor/Regulatory over Autoreactive T-cell Function,164
122,Fibroblasts Promote Upregulation of Cannabinoid Type 2 Receptor on Inflammatory Cells in Dermatomyositis,104
123,"Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody",123
124,"Immune Checkpoint Inhibitor Therapy Expands an Activated, anti-PD-1 Drug-bound CD8 T Cell Population That Is Clonally Linked in Blood and Synovial Fluid of ICI-arthritis Patients",178
125,SLAMF4 Orchestrates the Pathological Cytotoxic Response of CD4+ T Cells in Rheumatoid Arthritis,95
126,"Pre-Clinical Characterization of MTX-101, a Novel Bispecific CD8 Treg Modulator with the Potential to Restore CD8 Treg Functions in Patients with Rheumatological Autoimmune Diseases",181
127,Reduced Frequency of RORγt+ Regulatory T Cells Is Associated with Secukinumab Response in Axial Spondyloarthritis,113
128,Impaired X-Chromosome Inactivation Maintenance in T Cells Is Associated with Features of Reduced Disease Severity in a Toll-Like Receptor 7-Driven Model of Systemic Autoimmunity,177
129,Multi-omics Immune Profiling of Cytotoxic T Cells from Ankylosing Spondylitis Patients Identified a Subset of Clonally Exapnded CTLs That Evade Immune Exhaustion,161
130,Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients,161
131,Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium,73
132,Kynurenine Is a Proinflammatory Metabolite That Activates a Positive Feedback Loop of Rab4A-dependent CD98 Expression and mTORC1 and mTORC2 Activation in SLE,157
133,Performance Assessment of Lupus Anticoagulant Tests Using Taipan and Ecarin Snake Venom Clotting Times: An International Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratories,246
134,Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”),263
135,Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository “Registry”,237
136,Cell-bound Complement Activation Products in Antiphospholipid Antibody-positive Patients Without Other Systemic Autoimmune Diseases,131
137,The Clinical Relevance of Different Antiphospholipid Antibody Profiles in Pediatric Rheumatology Patients,105
138,Non-Criteria Antiphospholipid Antibodies and Calprotectin as Potential Biomarkers in Pediatric Antiphospholipid Syndrome,120
139,The Subtype and Prognosis of Acute Myocardial Infarction in Antiphospholipid Syndrome Patients,94
140,"Criteria and Non-criteria Antiphospholipid Autoantibodies Screening in Women with Unexplained Fetal Death, Pre-eclampsia And/or Fetal Growth Restriction: A Cross-sectional Study",177
141,Cluster Analysis of Antiphospholipid Antibodies Associated Adverse Pregnancy Outcome Patients: Based on a 13-year Longitudinal Cohort Study,139
142,Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis,125
143,Positive Antiphospholipid Antibodies Are Associated with a Higher Risk of Cerebral Microbleeds,94
144,Impact of Antiphospholipid Syndrome on Mortality of Hospitalized Ischemic Stroke Patients: A Retrospective Analysis of the National Inpatient Sample Database 2020,162
145,Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database,116
146,Persistent Prothrombotic Activation of Platelet Pannexin 1 Channels in Antiphospholipid Syndrome,96
147,Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss,119
148,Hippo-YAP1-CCN2 Signaling by Microvascular Endothelial Cells Licenses Vascular Smooth Muscle Cell Proliferation in Antiphospholipid Syndrome,140
149,Molecular Stratification of Antiphospholipid Syndrome Patients Through Integrative Analysis of the Whole-blood RNA Transcriptome,128
150,Serum Myeloperoxidase (MPO)-DNA Complexes and Serum Calprotectin Differentiate Isolated Thrombotic Antiphospholipid Syndrome from Isolated Obstetric Antiphospholipid Syndrome,174
151,Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS,81
152,Risk Factors of First Thrombosis in Obstetric Antiphospholipid Syndrome,71
153,Integrated Metabolomic and Proteomic Analyses Stratified Patients with Antiphospholipid Syndrome According to Their Atherothrombotic Risk,137
154,The Patient Journey to a First Diagnosis of Systemic Sclerosis: Temporal Disease Pattern Identification Using Machine Learning and Data Mining Among US and Japanese Patients,173
155,Physical Performance Among Individuals with Systemic Lupus Erythematosus in a Diverse Population-Based Cohort,109
156,Mortality-related Health Metrics in Systemic Autoimmune Diseases: An Epidemiological Analysis of a Nationwide Register-based Cohort,131
157,"Incidence and Prevalence of Systemic Lupus Erythematosus in Urban China, 2013-2017: A Nationwide Population-based Study",119
158,High Prevalence of Mental Health Disorders Among Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus,116
159,"Depression, Anxiety and Post-Traumatic Stress Disorder in Association with Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program",205
160,Improving Interpretation of Work Outcomes in Patients with Inflammatory Rheumatic Musculoskeletal Disease: General Population Reference Curves for Work Ability and At-work Productivity,184
161,Utility of the 2019 EULAR/ACR SLE Classification Criteria Score as Predictor for Mortality and Hospitalizations in a Population-Based Cohort: The Lupus Midwest Network,167
162,"Decreasing Ischemic Heart Disease, but Increasing Cancer Among the Underlying Causes of Death in Decedents with Lupus Nephritis",127
163,Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population,88
164,"Time Trends, Cumulative Incidence, and Impact on Survival of Interstitial Lung Disease in Systemic Sclerosis: Results from a Population-based Cohort Study",154
165,"Incidence, Trends, and Determinants of Multimorbidity in Systemic Sclerosis: Data from a Population-based Cohort",112
166,Rising Incidence and High Mortality of Systemic Sclerosis: A Population-based Cohort Study (2010-2020),102
167,"Association of HLA-DRB1 Alleles with Coronary Artery Calcium, Abdominal Aortic Calcium, and Carotid Intima-media Thickness in a Multi-ethnic Community-living Population",168
168,Identifying Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease: Development and Validation of a Real-Time Risk Model,147
169,Feasibility of a Real-Time Risk Model to Identify Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease,131
170,COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Systemic Lupus Erythematosus: Results from the COVAD Study,130
171,Stressful Life Events in the Year Prior to Their Diagnosis Are Associated with Adult and Pediatric Systemic Rheumatic Diseases,126
172,Cancer Incidence and Risk Factors in Patients with Newly Diagnosed Systemic Lupus Erythematosus,95
173,The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-term Hydroxychloroquine Use,100
174,Incidence of and Risk Factors for Myelodysplastic Syndromes in Patients with Rheumatologic Diseases,99
175,Prevalence and Incidence of Sjögren’s Syndrome: A Systematic Literature Review,78
176,Systemic Vasculitides in Portugal and Brazil: Preliminary Results from the Reuma.pt/vasculitis Registry,103
177,Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database,122
178,"In-patient Outcome Difference in Systemic Lupus Erythematous Patient Between Medicare and Non-Medicare Group, a Nationwide Analysis",131
179,New-Onset Systemic Autoimmune Diseases Following COVID-19 Vaccination – Results from the COVAD Study,100
180,Cancer Incidence in Familial Mediterranean Fever,48
181,COVID-19 Infection in People with Immune Mediated Inflammatory Diseases Who Received SARSCo-V2 Vaccines,103
182,Sexual Health and Function Screening in Patients with Rheumatic Diseases,72
183,Sexual Health and Self-Perception in Rheumatologic Patients: Has Your Rheumatologist Ever Talked to You About Sexual Health?,124
184,Leukotriene Inhibitors Effect on Post-Traumatic Osteoarthritis: A Real-World Evidence Comparative Effectiveness Study,117
185,"Recreational Activities in Adults with Rheumatoid Arthritis: Relevance, Difficulty, and Associations with Clinical Outcomes",123
186,Impacts of Social Determinants of Health and the Immune System in Adults with Acute-to-Chronic Low Back Pain: An Observational Study,132
187,"Self-reported Levels of Physical Activity and the Association to Pain, Fatigue, Anxiety and Depression Among Patients with Idiopathic Inflammatory Myopathies",157
188,"Long Covid in Persons with Self-Reported Arthritis – Symptoms, Associated Factors and Functional Limitations",108
189,Diminished Vibration Perception and Greater Pressure Pain Sensitivity Are Associated with Worse Knee Osteoarthritis Outcomes Across Sex and Race,144
190,Impact of Social Determinants of Health (SDoH) on Survey Response Times Among Lupus Patients,92
191,Cost Analysis of Subcutaneous Methotrexate Compared to Oral Methotrexate Treatment for Rheumatoid Arthritis,107
192,Factors Associated with Adherence to Cervical Cancer Screening in Ethnically Diverse Women with Systemic Lupus Erythematosus,124
193,"Discovering the Potential of Digital Biomarkers in the Work Process of the Rheumatology Healthcare Professionals, a Design Thinking Approach; Preliminary Results of the Healthcare Professionals Perspective",205
194,Analyzing User Log Data to Track Provider Use of an EHR-based Dashboard for Rheumatoid Arthritis Outcomes,105
195,Understanding the Economic Impact of Autoimmune Eye Disease in the United States,80
196,Spine and Sacroiliac Joints Findings in Young Males and Females with Chronic Back Pain Undergoing Magnetic Resonance Imaging in Clinical Practice,145
197,Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe,195
198,"Assessing Reproductive Health Counseling and Provider Attitudes in Rheumatology Post Roe v. Wade in Houston, Texas",114
199,Uncovering Discrepancies: Analysis of Glucocorticoid Exposure Among Patients with Rheumatoid Arthritis in Electronic Health Record Data versus Medicare Claims,158
200,Development and Validation of a Virtual Musculoskeletal Examination Method for Disease Activity Assessment in Rheumatoid Arthritis Patients,139
201,Hypothyroidism Is Associated with Worse Clinical and Utilization Outcomes After Primary Total Knee Arthroplasty,111
202,Annual Economic Burden for Patients with Familial Hypophosphatemia in the United States,87
203,Healthcare Resource Utilization Associated with Tumor-Induced Osteomalacia: Review of Patient Histories Prior to Entry in Clinical Trial UX023T-CL201,149
204,What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment,122
205,Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective,163
206,Gender Equity Amongst Rheumatology Professionals: Preliminary Findings of the Coalition for Health and Gender Equity E-survey (CHANGE Group),140
207,A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews,142
208,Barriers and Strategies to Enhance Patient Research Partner Involvement in Rheumatology Research: A Systematic Literature Review,128
209,Review of Published Literature Reporting Economic Burden of Treatment Switching in Rheumatoid Arthritis,103
210,"Evaluation of Healthcare Utilization in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus",128
211,Predicting Cost-Related Medication Non-Adherence in US Adults with Chronic Arthritis: A Machine Learning Approach,113
212,"Impact of Social Determinants of Health Factors on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus",163
213,"Cost-Related Medication Non-Adherence Among US Adults with Chronic Arthritis: Trends, Comparisons, and Disparities",114
214,Traditional and Lupus-Specific Risk Factors for Cardiovascular Events Among Patients with Systemic Lupus Erythematosus,118
215,Social Disparities and Pathology Markers at Lupus Nephritis Diagnosis Predict Worse Kidney Outcomes,99
216,Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review,132
217,Increased Prevalence of and Acute Hospital Events Among Medicare Systemic Lupus Erythematosus Patients Living in Socially Vulnerable Counties in the United States,162
218,Impact of Neighborhood-level Child Opportunity on Disease Activity in Children with Lupus,89
219,Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN),153
220,Material Need Insecurities Are Associated with Worse Patient-Reported Outcomes Among Individuals with SLE,105
221,Classifying Individuals with Rheumatic Conditions as Financially Insecure Using Electronic Health Record Data and Natural Language Processing: Algorithm Derivation and Validation,178
222,Retention in Rheumatology Care and on Hydroxychloroquine and SLE Outcomes by Neighborhood Disadvantage: A Medicare Cohort Study of Acute Care and Kidney Failure,160
223,Advancing Health Equity with Lupus Stakeholders to Close Care Gaps and Disparities,82
224,Association Between Area Deprivation Index and Organ Damage Accumulation in a Statewide Incident Lupus Cohort,109
225,Influence of Social Support on Systemic Lupus Erythematosus (SLE) Outcomes in a Health Disparity Population,107
226,Racial Disparities in Self-reported Extent and Reasons for Nonadherence in SLE,78
227,Reproductive Health Discussions Between Rheumatology Providers and Systemic Lupus Erythematosus Patients: A Survey of English and Spanish-Speaking Patients,155
228,Demographic and Clinical Factors That Contribute to Clinical Study Enrollment in Systemic Lupus Erythematosus,109
229,Social Vulnerability Associations with Mortality in a Lupus Cohort,66
230,Reproductive Health Conversations with a Primarily Hispanic Systemic Lupus Erythematosus Population: Influences and Barriers,124
231,Assessing Cardiovascular Risk in Black and Latino Patients with Systemic Lupus Erythematosus,92
232,Limited Regulatory T Cell Response in Post-Chikungunya Viral Arthritis: A Therapeutic Opportunity?,98
233,Development of a Chikungunya Arthritis Disease Activity Score,61
234,Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership,129
235,Experience in Real-World Conditions of the Effectiveness of the Vaccine Against Herpes Zoster Virus,99
236,Herpes Zoster Prevalence in Patients with Rheumatic Diseases,60
237,Tolerability and Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases – A Prospective Longitudinal Study over 12 Months,168
238,Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA),172
239,Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization,136
240,Risk of Severe Infections Associated with Immunoglobulin Deficiency Under Rituximab Therapy in Immune Mediated Inflammatory Diseases,132
241,Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy,131
242,Risk of Hepatitis B Virus Reactivation in Patients with Rheumatoid Arthritis Receiving JAK Inhibitor or IL-6 Inhibitor: A Systematic Review and Meta-Analysis,157
243,Role of Pneumocystis Jirovecii Pneumonia Prophylaxis with Trimethoprim-Sulfamethoxazole Among Patients with Autoimmune Inflammatory Diseases Receiving High-Dose Glucocorticoids: A Systematic Review and Meta-Analysis,215
244,"Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System",195
245,Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies,116
246,Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors,116
247,COVID-19 Outcome and Association to Anti-Spike Antibody Levels in Patients on Immunosuppressive Therapy; A Prospective Cohort Study,131
248,The Impact of Immunosuppression on the Humoral Immunogenicity of SARS-CoV-2 mRNA Vaccines in SLE,96
249,When Should I Get My Next Booster? Active Surveillance of COVID-19 Breakthrough Infections in Canadian Patients with Immune-Mediated Inflammatory Diseases,154
250,"COVID-19 Vaccine Uptake, Hesitancy, and Flare in a Large Rheumatology Practice Network",86
251,Effectiveness of Three Doses of SARS-CoV-2 Vaccines in Brazilian Patients with Systemic Vasculitides: Preliminary Results of a Real-life Prospective Cohort,155
252,High Immunogenicity of mRNA Covid-19 Vaccine Booster in Immune Mediated Inflammatory Disease,92
253,Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study,155
254,Incidence and Risk Factors for Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients with Systemic Autoimmune Rheumatic Diseases,140
255,Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab,168
256,"Paxlovid (Nirmatrelvir Plus Ritonavir) in Patients with Underlying Rheumatological Diseases, in Preventing COVID-19 Related Hospitalization and Death",149
257,Post-COVID-19 Autoimmune Serologies and Immunophenotypes,56
258,Predictors of Adverse Prognosis Following Hospitalization for COVID-19 Infection in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab,158
259,Severity and Risk Factors of Hospitalization of Omicron in Patients with Rheumatoid Arthritis,93
260,Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study,136
261,Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study,124
262,Relationships Among Parameters of Mineral Metabolism and Bone Turnover During Acute COVID-related Hospitalization and Subsequent Follow Up: A Pilot Study,153
263,Associations of DMARDs with Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases: A Prospective Study,136
264,A Comprehensive Retrospective Analysis of Polymyalgia Rheumatica in Long COVID Patients at an Academic Medical Center in the Midwest,132
265,Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout,93
266,Looking Beyond Infections in Job Syndrome: Peripheral Calcium Pyrophosphate Deposition Disease in a Cohort of Patients with Job Syndrome,136
267,Febuxostat Dose Requirement for Achieving Target Serum Urate Levels According to Renal Function: A Retrospective Cohort Study,125
268,Incident Gout After Recombinant Zoster Vaccination in Adults Aged ≥65 Years in the USA,86
269,"Impaired Anti-oxidant Function of HDL and Its Associated Protein, Paraoxonase-1, in Patients with Gout",102
270,Identifying Optimal Serum Urate Levels to Reduce Gout Flares in Patients Taking Urate Lowering Therapy: A Post-hoc Cohort Analysis of CARES with Consideration of Drop-out,170
271,Fractures in Patients with Acute CPP Crystal Arthritis versus Matched Comparators in a Large Cohort Study,105
272,Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings,148
273,Oral Urate-Lowering Therapy Use and Efficacy Following Pegloticase Treatment: Findings from a Rheumatology Network Database,123
274,Adherence to the Gout and Crystal Arthritis Network (G-CAN) Consensus Statements for Gout Nomenclature,102
275,Incidence and Prevalence of Cardiovascular and Metabolic Diseases Following Gout Diagnosis in the United Kingdom Using the THIN Database,136
276,Gout: A Gateway to Chronic Opioid Use?,38
277,Gout Flares During the Initiation and Escalation of Treat-to-Target Urate Lowering Therapy: A Post-hoc Analysis of a Randomized Multicenter Comparative Effectiveness Trial,171
278,Venous Thromboembolism in Patients with Gout in the US,54
279,Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant Center,131
280,"Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients",179
281,Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout,125
282,"Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies",188
283,Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United States,116
284,"In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with Gout",125
285,Comorbidities of Gout: Results from the Korean National Health and Nutrition Examination Survey,95
286,Validation of Singe-Shot Computational Polarized Microscopy for Crystal Analysis of Synovial Fluid,98
287,"Sodium-glucose Cotransporter-2 Inhibitor Initiation, Risk of Recurrent Gout Flares, and Mortality in Patients with Gout and Type 2 Diabetes: A Population-based Cohort Study",172
288,"Characterizing Granulomatous Mastitis: A Retrospective, Single-Institutional Case Series of a Racially and Ethnically Diverse Cohort",132
289,"Clinical Phenotypes in Patients with Isolated Anti-Sm/RNP Common Motif Antibody Positivity, Compared to Those with or Without Associated Anti-RNP Antibody Reactivity",165
290,Microvascular and Cutaneous Assessment in Adult Patients with Hypermobile Ehlers-Danlos Syndrome,96
291,Lymphoid Mass in the Inferior Turbinate with IgG4 Producing Cells: A Nasal Manifestation of IgG4-RD or a Distinct Chronic Inflammatory Disease?,143
292,Nintedanib in Combination with Immunosuppressive Agents Improves Forced Vital Capacity in Connective Tissue Disease-associated PF-ILD: A Single-center Study,156
293,Activity of IgG4-related Disease Differs Depending on the Presence or Absence of Concomitant Hypocomplementemia,111
294,Understanding Monogenic Behçet’s Disease Pathophysiology: Impact of Pathogenic Variant L227X Associated with Autoinflammatory A20 Haploinsufficiency on Cellular Survival and Proliferation,187
295,Preliminary Experience with a Novel “Fix” for Deep Epitope and Transcriptional Phenotyping of Fragile Cells from Autoinflammatory Flares,136
296,Phenotypes of the Patients with More Than One Autoinflammatory Gene Variant: Classified Diseases and Mixed Autoinflammatory Disorders (MAID),140
297,Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results,71
298,Destructive Arthritis in Whipple Disease. a Single-center Case Series of 14 Patients,84
299,"Patient, Disease, and Treatment Factors in Remission of Inflammatory Eye Disease",80
300,A Novel Role for Rheumatologists: Managing Idiopathic Granulomatous Mastitis,76
301,Differential and Combinatorial Mechanism of Action of Golimumab and Guselkumab in Ulcerative Colitis Induction Therapy: IL-23 Blockade Drives Restoration of Normal Epithelium and Mucosal Healing,194
302,"E-selectin, ICAM-1 and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases",153
303,Variations in Approach to the Diagnosis and Management of Polymyalgia Rheumatica Among Australian Rheumatologists,113
304,Safety and Efficacy of CT-guided Percutaneous Infra-Renal Periaortic Biopsies in Suspected Retroperitoneal Fibrosis,115
305,Acute Kidney Injury and Plasma Cell-Rich Acute Interstitial Nephritis in VEXAS Syndrome: An Under-recognized Disease Feature,124
306,Exploring the Potential of Oral Administration of 5-aminolevulinic Acid/sodium Ferrous Citrate in Adult-onset Still’s Disease: Preclinical Study in Mice and Pilot Investigation in Humans to Assess Efficacy and Safety,216
307,Successful Treatment of Refractory IgG4-Related Disease with Tofacitinib: Experiences from 7 Patients,101
308,Risk Factors for Severe Outcome in Susac Syndrome: A National Cohort Study,74
309,Disease Characteristics and Pancreatic Damage in IgG4-Related Disease with Pancreatic Involvement,97
310,A Mix-and-match COVID-19 Vaccination Strategy in Patients with Rheumatic Diseases on Rituximab,94
311,No Cumulative Effect of Infection Rates in Children Receiving Long-term Canakinumab Treatment in Autoinflammatory Periodic Fever Syndromes − Data from the RELIANCE Registry,172
312,Disease Control in Patients with Monogenetic Autoinflammatory Diseases Under Canakinumab Treatment – Comparison of 30 Months Interim Data from the RELIANCE Registry,164
313,Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis,132
314,NOD2 Genotyping Landscape in Yao Syndrome,41
315,Therapeutic Exploration of Immune Checkpoint Inhibitor Induced Inflammatory Arthritis In Vivo,93
316,Immunosuppression in the Treatment of Susac Syndrome: A Retrospective Evaluation of the Largest Cohort of Susac Syndrome,120
317,Is There a Decreased Risk of Developing CF Arthropathy in CF Patients Undergoing Treatment That Targets the F508del Mutation?,125
318,DNA Methylation Markers in Peripheral Blood as Effective Diagnostic Biomarkers for Adult-onset Still’s Disease,110
319,Transcriptomic Profiles in Muscle Biopsies from Systemic Sclerosis Patients with Different Autoantibodies,105
320,Phenotyping Calcinosis: A Rare Manifestation of Rare Diseases,61
321,"Patient Reported Physical Function, Mental Health, and Treatment Patterns in Dermatomyositis",92
322,Relationship Between High Resolution Computed Tomography(HRCT) Quantitative Scores and Physiological and Clinical Features in Antisynthetase Syndrome Related Interstitial Lung Disease,183
323,6-Minute Walk Distance Associates with Physiologic Measures and Physician/Patient Reported Outcomes in Myositis Related Interstitial Lung Disease,145
324,Proinflammatory Bioactive Lipid Mediators (BLM) Are Associated with Worse Anti-Oxidant Function of High Density Lipoproteins (HDL) in Patients with Idiopathic Inflammatory Myopathies (IIM),188
325,Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity,159
326,Patient-reported Quality of Life and Working Status Outcomes in Ambulatory Patients with Idiopathic Inflammatory Myopathy,121
327,Myopathy Related to Small-to-medium-sized Vessel Vasculitis: Immunopathological Characteristics,95
328,Comparison of Cardiovascular Risk of Myositis Patients and the General Population,81
329,Characteristics and Outcomes of Idiopathic Inflammatory Myositis Associated Interstitial Lung Disease in Rural Appalachia,121
330,Tofacitinib Treatment in Rheumatoid Arthritis Is Associated with Increased Lower Limb Muscle Volume: The Rheumatoid Arthritis and Muscle (RAMUS) Study,150
331,Pneumocystis Jirovecii Pneumonia in Patients with Inflammatory Myopathies,73
332,Does Presence of Anti-SSa and Ro52 Influence the Progression of Interstitial Lung Disease (ILD) in Idiopathic Inflammatory Myopathies (IIM),139
333,Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population: Case Series,125
334,Accuracy of the 2017 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) Classification Criteria and Myositis-Specific Autoantibodies-Based Classification Criteria for Classifying Patients with Idiopathic Inflammatory Myopathy,272
335,Trends and Outcomes of Hospitalized Patients with Idiopathic Inflammatory Myopathy and Venous Thromboembolism: A Nationwide Inpatient Sample Analysis from US (2016-2019),169
336,Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathy Compared with Healthy Controls,95
337,Inflammatory Myopathies and Their Relationship with Cancer in a Colombian Cohort,80
338,Remission in Anti-HMGCR Positive Immune-mediated Necrotizing Myopathy Without the Use of Glucocorticoids: A Multicentric Study of 24 Patients,141
339,Development of a Human Cytotoxic Myoinjury Model with CD8+ T Cells and Muscle Cells Differentiated from Human Induced Pluripotent Stem Cells,140
340,Incidence of Disease Flares Following COVID-19 Vaccination in a Diverse Idiopathic Inflammatory Myopathy Cohort,111
341,Prevalence and Clinical Significance of anti-Ro52 Antibodies in Antisynthetase Syndrome,87
342,Fitbit Is a Valid and Reliable Physical Activity Monitor in Idiopathic Inflammatory Myopathy,92
343,Long-term Prognosis and Recurrence in anti-MDA-5 Antibody-positive Dermatomyositis,82
344,Burden of Osteoarthritis Attributable to High BMI in 38 OECD Countries: A Benchmarking Analysis,95
345,"Efficacy, Safety, Pharmacokinetics and Immunogenicity of Repeated Dosing of GSK3858279 in Patients with Knee Osteoarthritis: A Phase I, Randomized, Double-Blind, Placebo-Controlled Study",186
346,Implementing an Osteoarthritis Management Program to Deliver Guideline-Driven Care for Knee and Hip Osteoarthritis in a U.S. Academic Health System,147
347,Heterogeneity and Natural History of Medial Fixed Joint Space Width in Healthy Knees Among Women and Men: Data from Three Large Cohort Studies,142
348,Frontal Lobe Activation and Gait Alterations During Single- and Dual-task Walking in People with Knee Osteoarthritis: A Functional Near-infrared Spectroscopy Study,163
349,The Influence of Pain Catastrophizing on Pain and Function After Knee Arthroplasty for Osteoarthritis,101
350,Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial,156
351,Identification of Calcium Crystals in End-Stage Osteoarthritis with Raman Spectroscopy,86
352,Relationship of Sensitization to Pain Severity in Patients with Knee Osteoarthritis,83
353,Long-term Effectiveness of a Lifestyle Program for Osteoarthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial,138
354,The Association of CT-Detected Intra-Articular Mineralization with MRI-Detected Effusion-Synovitis and Hoffa’s Synovitis in Knee OA: The Multicenter Osteoarthritis Study,169
355,Knee Flexion Contracture Was Associated with Articular Cartilage Loss in the Central Region but Cartilage Preservation in the Posterior Region of the Tibia: Data from the Osteoarthritis Initiative,196
356,Feasibility and Acceptability of Geniculate Artery Embolization for the Treatment of Painful Knee Osteoarthritis,112
357,Use of Proton Pump Inhibitors and Risk of Hip/knee Joint Replacement Among Patients with Osteoarthritis and Rheumatoid Arthritis,128
358,Validation of NICE Criteria for the Diagnosis of Knee Osteoarthritis,68
359,"A Randomized, Double-blind, Placebo-controlled, Repeat Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP) – Study 304",267
360,"A Randomized, Double-blind, Placebo-controlled, Single Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (OAKP) – Study 301",265
361,Understanding the Burden of Cutaneous Lupus: A Subset Analysis from the 2022 World Lupus Federation Global Impact (WLFGI) Patient Survey,136
362,Assessment of Depression in Ankylosing Spondylitis Using Center for Epidemiologic Studies Depression Scale,106
363,Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre,157
364,From Patient Needs to Platform Design: Using Patient Preference to Guide the Development of a Post-Viral Fibromyalgia Management App,132
365,Factors Associated with Suicidal Ideation Among Patients with Inflammatory Rheumatic Musculoskeletal Disease: A Case-Control Study,130
366,Patient-Reported Experiences and Comorbidities in Patients with IgG4-Related Disease with and Without Pancreatic Involvement,124
367,Assessment of Patient Adherence to “Sick Day Rules”: A Cross-sectional Study of Rheumatology Outpatients Prescribed Immunosuppressive Medications,145
368,Initial Characterization of a Skin Symptom Questionnaire for Patients with Systemic Sclerosis,93
369,Ankylosing Spondylitis Patient Perspective on Living with Flares and Impact on Quality of Life,94
370,Association of a Self-Report Screening Tool for Sarcopenia (SARC-F) with Functional Status Outcomes in Systemic Lupus Erythematosus,131
371,Meta-Analysis of the Cost-Effectiveness of Social Media Advertising as a Recruitment Tool,89
372,Core Signs Associated with the Subtypes of Cutaneous Lupus Erythematosus: Concept Elicitation Interviews with Dermatologists and Rheumatologists,144
373,Impact of Photosensitivity on Quality of Life in Dermatomyositis,64
374,"Comparative Disease Burden in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis: Data from COVAD Patient-reported E-survey",154
375,Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort,195
376,Rheumatology Patients’ Experiences of a Nationwide Transition to an Adalimumab Biosimilar: A Cross-Sectional Study,114
377,Patient Perspectives on the Usability of a Rheumatoid Arthritis Patient-reported Outcomes Electronic Health Record-based Dashboard: A Mixed-Methods Study,153
378,Assessing the Known-group Validity of the IDEOM MSK-Q Using Data from the National Psoriasis Foundation Annual Survey,117
379,Sjögren’s Disease Patient Experiences with Dry Mouth and Content Validity of the Xerostomia Inventory,101
380,"Patient Engagement and Adherence to Digital Study Tasks: WEARable Activity Tracker Study Exploring Rheumatoid Arthritis Patients’ Disease Activity Using Patient-Reported Outcome Measures, Clinical Measures, and Biometric Sensor Data (the WEAR Study)",249
381,"Jadas10- and cjadas10-based Disease Activity States for Psoriatic Arthritis, Enthesitis-related Arthritis, and Rf+ Polyarthritis",128
382,"Use, Safety and Persistence of Biosimilars in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events of Targeted Therapies in Rheumatic Diseases (BIOBADASER)",215
383,Towards Effective Shared Decision Making – Development and Validation of a Prediction Model for Personalized Probabilities of Side Effects in the Initial Treatment of Juvenile Idiopathic Arthritis,196
384,The Use of Ruxolitinib for Improved Disease Control in Systemic Juvenile Idiopathic Arthritis (sJIA) and Recurrent Macrophage Activation Syndrome (MAS),151
385,Disease Activity of Juvenil Idiopathic Arthritis in Transitional Care,69
386,"Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience",106
387,Needs Assessment Survey of Critical Data Element Completion in Telemedicine Visits for Juvenile Idiopathic Arthritis in the Post-Pandemic Period,144
388,Musculoskeletal Ultrasound Findings in Children with Psoriasis,62
389,Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis Using Machine Learning Methods,118
390,"Open-label Phase 3 Study of Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis: Pharmacokinetics, Effectiveness, Safety, and Immunogenicity over 252 Weeks",186
391,Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis,67
392,PRINTO Provisional Enthesitis/Spondylitis-Related JIA Criteria: Performance in Youth Classified as Axial Disease in Juvenile Spondyloarthritis,142
393,Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting,107
394,Baseline Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis Associated Lung Disease (SJIA-LD) Cohort,199
395,Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment,147
396,Increasing the Etanercept Dose in Juvenile Idiopathic Arthritis Patients: Does It Help Reaching the Treatment Target? A Post-hoc Analysis of the Best4Kids Randomised Clinical Trial,180
397,Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience,108
398,Adverse Childhood Experiences Are Associated with Disease Outcomes in Youth with Juvenile Idiopathic Arthritis,110
399,Allogenic Hematopoietic Stem Cell Transplant for Children with Refractory Systemic Juvenile Idiopathic Arthritis and sJIA-Associated Lung Disease: 6-month Post-Transplant Outcomes from an International Cohort,208
400,Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis,91
401,Establishing a Multidisciplinary Registry for Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: Insights into Patient Outcomes and Management Challenges,170
402,Active Joint Acoustic Emissions on the Achilles Tendon: A Digital Biomarker of Enthesitis Related Arthritis,107
403,Adolescents and Young Adults Taking Methotrexate: Knowledge and Behaviours,74
404,Surveying Psychological Resilience and Pain in a Cross-Section of JIA Patients,78
405,Trajectory of Progression in Transition Readiness in Adolescents with JIA and jSLE,82
406,Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis,104
407,Assessing Methotrexate Adherence in JIA Using Electronic Health Record-Linked Pharmacy Dispensing Data,102
408,Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial,125
409,Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study,75
410,Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry,131
411,Treatment of Methotrexate Intolerance in Juvenile Idiopathic Arthritis Using Eye Movement Desensitization and Reprocessing (EMDR) Can Be Improved by Bi-lateral Alternating Stimulation Tactile (BLAST) Armbands,208
412,Switching Patterns of Biological and Targeted Synthetic Therapies in Juvenile Idiopathic Arthritis,98
413,Disease Activity and New Medication Start at Two Consecutive Registry Visits for Patients with Juvenile Idiopathic Arthritis,124
414,Characteristics of Macrophage Activation Syndrome in Systemic JIA Patients Receiving Anakinra as First-line Treatment,117
415,Clinical Evolution of Patients Diagnosed of Juvenile Idiopathic Arthritis After the Transitional Care Consultation,114
416,Use of Digital Health Tools to Evaluate Change in Clinical and Patient-Reported Outcomes Among Patients with Rheumatoid Arthritis Initiating Treatment with a JAKi or TNFi,170
417,"Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data",130
418,Heterogeneity Within a “difficult to Treat” Rheumatoid Arthritis Patients Cohort: 36% May Have a More Benign Course and Have Distinct Characteristics at bDMARD or tsDMARD Initiation,181
419,Identification of Contributing Factors to Difficult-to-Treat Rheumatoid Arthritis (D2T RA) in a Cohort of 972 Patients Using a Natural Language Processing (NLP) Approach,169
420,Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR,81
421,Heterogeneity of the Joint Location Supports the Importance of Local Factors in Early RA Synovitis : Analysis of the ERA UCLouvain Brussels Cohort,146
422,Functional Disability and Disease Activity Are Affected by Social Determinants of Health in Patients with Rheumatoid Arthritis,126
423,"The Association Between Inflammation, High-Sensitivity Cardiac Troponin T, and Cardiovascular Events in Rheumatoid Arthritis",124
424,Left Ventricular Geometry Abnormalities Are Related to Higher Clinical Activity in Rheumatoid Arthritis Patients,112
425,The Role of anti-CCP3 Antibodies in anti-CCP2 Antibody Negative Patients with Musculoskeletal Symptoms,102
426,Statins Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis,167
427,Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis,105
428,"Novel Diagnostic Markers for Rheumatoid Arthritis Including Anti-CarP (Carbamylated Protein), Anti-Sa (Citrullinated Vimentin) and Anti-CEP1 (Citrullinated Enolase Peptide1) Are Frequently Positive in Diagnostic Profiles",220
429,Pulmonary Involvement in Patients with Seropositive and ACPA Positive Rheumatoid Arthritis (RA-ILD) – Novel Screening Protocol for Early Detection of Pulmonary Involvement,171
430,Higher Intakes of Red Meat Are Associated with an Increased Risk of Developing Seropositive but Not Seronegative Rheumatoid Arthritis – Results from a Nested Case-Control Study,176
431,Prevalence of Objectively Measured Sleep Disturbance in Rheumatoid Arthritis (RA),81
432,"Hydroxychloroquine Is Associated with a Decreased Risk of Non-alcoholic Fatty Liver Disease in Patients with Rheumatoid Arthritis: A Population-based, Cohort Study",163
433,Obesity Is Associated with Worse Flare Symptoms and Quality of Life in Early Rheumatoid Arthritis: Insights from the RA Flare Questionnaire,139
434,Identification of Disease Activity-related miRNAs Through Artificial Neural Network Analysis in Rheumatoid Arthritis,116
435,Differential Synovial Tissue Enrichment of Oxylipins and Their Mediators Across Rheumatoid Arthritis Trajectory,111
436,Thresholds of Presenteeism Measurement Instruments for Unacceptable Work Participation and Future Adverse Work Outcomes in Rheumatoid Arthritis,143
437,Resolution of Swollen Joint Count Is an Important Clinical Objective in Early Rheumatoid Arthritis : Analysis of the UCLouvain Brussels ERA Cohort and Comparison with the Remission Composite Index,196
438,"Automated Detection and Quantification of Hand Joint Swelling in Rheumatoid Arthritis: Computer Vision, Deep Neural Network Models, and a Potential Biomarker for Disease Activity Monitoring",189
439,Disease Activity Is Associated with Frailty in Veterans with Rheumatoid Arthritis,81
440,Persistent Pain and Its Predictors After Start of Anti-TNF Therapy in Rheumatoid Arthritis – Is Line of Treatment Linked to Different Pain Patterns?,148
441,Clinical Features of Anti-Th/To Antibodies-positive Systemic Sclerosis Patients: A Single-center Retrospective Study,116
442,Obesity Is a Risk Factor for Poor Response to Treatment in Early Rheumatoid Arthritis – a NORD-STAR Spin-Off Study,114
443,Meteorological Conditions Contribute to the Joint Ultrasound Findings in Patients with Rheumatoid Arthritis: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study,198
444,The Role of Synovial Biopsy in Evaluating Rheumatoid Arthritis Acitivity in Patients: Findings from a Study of 30 Patients Treated with Adalimumab,146
445,"Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis",147
446,Usefulness of RAPID3 in Assessing Unmet Needs of Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity　-a Multicenter Observational Study: T-FLAG Study-,175
447,The Impact of Patient-reported Outcomes on Boolean 2.0 Remission Criteria in Rheumatoid Arthritis Patients in Real Clinical Practice -a Multicenter Observational Study: T-FLAG Study-,182
448,COVID Antibody Response to Third Dose Anti-SARS-COV2 mRNA Vaccine in Patients with Seropositive Rheumatoid Arthritis on Immunosuppressive Therapy,145
449,Transcriptomic Analysis of Peripheral Blood Mononuclear Cells Reveals Pain and Inflammation Specific Alterations in Difficult-to-treat Rheumatoid Arthritis,155
450,Association of a Treat-to-Target Management Approach with Physician and Patient Reported Outcomes Among Real – World Patients with Rheumatoid Arthritis Receiving Advanced Therapy in Europe,188
451,Serious Infections Hospital Admissions and Mortality in Patients with Early Inflammatory Arthritis: Results from a Large UK Cohort,130
452,Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study,93
453,The Role of Rheumatoid Arthritis Flare in the Risk of Alzheimer’s Disease and Related Dementias: A Population-based Cohort Study,128
454,Synovial Fluid Cell Counts Associated with Joint Histopathology in Rheumatoid Arthritis,87
455,No Clinically Relevant Changes in Coagulation Activation Between Patients Initiating TNF-blockers versus JAK-inhibitors,119
456,Associations and Mortality Impact of Machine Learning-derived Quantitative Computed Tomography Parenchymal Lung Features in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort of Smokers,214
457,Bioinformatics Platform to Study the Genetics of Biologic DMARD Non-responders: Design and Protocol of the RA Non-responders to Treatment (RANT) Study,150
458,Electronic Health Record-Based Machine Learning Model for Predicting Disease Activity in Patients with Rheumatoid Arthritis,123
459,Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis,168
460,Real-World Effectiveness of Upadacitinib in Patients with Moderate/Severe Rheumatoid Arthritis: 6-Month Data from the Observational UPHOLD Study,144
461,Long-term Safety of Rituximab in Rheumatoid Arthritis: A Systematic Review and Meta-analysis,92
462,The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis,129
463,Molecular Characterization of Biologic and Targeted Synthetic DMARDs Effects Through Ex- vivo Studies in Rheumatoid Arthritis Immune Cells,138
464,Real World Patterns of Advanced Therapy Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort,125
465,Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study,130
466,"A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis",137
467,Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment,123
468,"Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice",125
469,DMARD Initiation in Older Adults with New Diagnosis of Late-Onset Rheumatoid Arthritis,86
470,Effects of B/tsDMARDs on Non-inflammatory Pain in Patients with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-,119
471,Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following Release of Safety Data,144
472,Patients with Difficult-to-treat Rheumatoid Arthritis Have Higher Levels of Inflammation on Ultrasound,102
473,Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis,144
474,Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review,105
475,Humoral Immune Response to 13 Valent-conjugate and 23-valent Polysaccharide Pneumococcal Vaccines in RA Patients Treated with Abatacept: Results of the Open Randomized Controlled Trial VACINA (Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients),276
476,Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis,181
477,"Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors",121
478,Infliximab Clearance a Predictive Factor of Pharmacokinetic Origin in Relation to Suboptimal Pharmacokinetics and Immunogenicity in United States Based Rheumatology Practices,174
479,The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis,123
480,"Safety, Tolerability, and Pharmacokinetics of a Novel Synthetic Disease Modifying Antirheumatic Drug, TCK-276, After Single Ascending Dose in Healthy Subjects and Multiple Ascending Doses in Patients with Rheumatoid Arthritis",225
481,"Comparison of the Efficacy, Safety and Immunogenicity of a Proposed Biosimilar MSB11456 with Tocilizumab Reference Product in Moderate-to-severe Rheumatoid Arthritis: Results of a Randomized Double-blind Study",209
482,Review of Rheumatoid Arthritis Treatment Landscape During the COVID-19 Pandemic,79
483,Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER,182
484,"Cardioprotective Impact of JAKi, Tofacitinib, on CV Risk in Rheumatoid Arthritis: JAKi CV Risk Impact Study",107
485,Parsing Pathophysiology of Rheumatoid Arthritis-associated Lymphoproliferative Disorders via Whole RNA Transcriptome Analysis: Multi-center Study in Japan,154
486,"Baricitinib versus TNF-inhibitors in Patients with Active Rheumatoid Arthritis After Failure of CsDMARDs: A Pragmatic, Multicenter, Real-Life Study in a Treat-to-Target Setting",176
487,Long-term Clinical Profile of Filgotinib in Patients with Rheumatoid Arthritis by Cardiovascular Risk Factors: A Post Hoc Subgroup Analysis,139
488,Real Life Safety and Survival of Targeted Therapies in Arthritis Patients over Age of 65,88
489,Risk of Lung Cancer in Veterans with Rheumatoid Arthritis in Relation to Use of Conventional versus Biologic or Targeted Synthetic DMARDs,137
490,"Rheumatoid Arthritis Disease Activity Indices Assess More Than Inflammation: 29%-36% of Patients with Moderate or High DAS28–ESR or CDAI Have 0 or 1 Swollen Joints, but Positive Screens on MDHAQ FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen) Indices",287
491,"Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial",239
492,The “Topics” in the Electronic Health Record of Rheumatoid Arthritis Patients Before Initiating Targeted Therapies and Association with Future Treatment Course,159
493,Biologic Disease Modifying Antirheumatic Drug Use in Immune Checkpoint Inhibitor-Treated Cancer Patients with Rheumatoid Arthritis: Utilization and Overall Survival,164
494,Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience,139
495,Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial,167
496,Knowledge Related to Fertility and Infertility Treatments Among Women with Systemic Rheumatic Disease,101
497,Self-esteem as a Determinant of Sexual Function in SLE Patients,63
498,Breastfeeding Intention in Systemic Lupus Erythematosus Patients,64
499,Appropriate Preconception Care Improves Pregnancy Outcomes in SLE Patients,74
500,Adverse Pregnancy Outcomes in Sjogren’s Disease Compared to Controls: An Interdisciplinary Approach with Maternal Fetal Medicine,128
501,The Effects of Post-Dobbs Abortion Policy on Rheumatology Clinical Practice: A Survey of Rheumatologists,104
502,Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study,88
503,Cardiovascular Events During Pregnancy: Implications for Adverse Pregnancy Outcomes in Individuals with Autoimmune Rheumatic Diseases and Antiphospholipid Syndrome,163
504,Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes,90
505,Hydroxychloroquine and Preeclampsia Risk in Lupus Pregnancy: Results from a Large Regional Integrated Health Network,116
506,Educational Intervention to Increase Contraception Screening and Documentation for Reproductive-Aged Women Seen in an Academic Rheumatology Clinic,146
507,Knowledge and Misconceptions About Contraception Among Individuals with Inflammatory Arthritis and Lupus-like Diseases,118
508,Contraception Choices in Individuals with Inflammatory Arthritis and Lupus-like Disease Differ Based on Diagnosis and Teratogen Use,131
509,The Number of Rheumatoid Arthritis Patients Who Give up Pregnancy Due to the Disease Is Decreasing,98
510,Acute Cardiovascular Events During Pregnancy and Delivery in Patients with Autoimmune Rheumatic Diseases (ARDs): An Analysis of National Inpatient Sample,153
511,Prevalence of Endometriosis and Polycystic Ovarian Syndrome in Patients with Rheumatic Diseases in the United States,116
512,Factors Associated with the Need for Assisted Reproductive Therapies in a Spanish Cohort of Patients with Rheumatic Diseases,124
513,Continuing TNFi After Pregnancy Diagnosis in Women with Chronic Rheumatic Inflammatory Diseases Is Not Associated with Worse Obstetrical or Infant Outcomes and Seems to Reduce Risk of Maternal Severe Infection: The Results of the Emulated Target Trial BioGRIC,259
514,The Long-term Neurodevelopmental Outcome of Children Born to Women with Systemic Sclerosis: Assessment Through a Self-reported Questionnaire by the Mothers and Nneuropsychiatric Evaluations of the Children,205
515,Exploring Reproductive Experiences with Women Enrolled in the Vasculitis Pregnancy Registry,91
516,Non-random Sampling in Rheumatology Randomized Controlled Trials: Evidence of Concerning Trial Conduct?,103
517,Automatically Detect Finger Joint Center and Angle on Hand X-ray: A Deep Learning Model,87
518,Preference and Relative Sensitivity of Indicators Reporting Response Rate in Pharmaceutical Trials of Psoriasis and Psoriatic Arthritis,135
519,The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA),196
520,Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study,161
521,"Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial",190
522,Identifying Serum Metabolomic Markers Associated with Psoriasis Skin Disease Activity,85
523,A Comparative Study of Serositis Between Inpatients with Psoriatic Arthritis and Rheumatoid Arthritis,101
524,Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity,170
525,Prediction of Low Disease Activity in Patients with Psoriatic Arthritis Treated with Secukinumab in Real World – Data from a German Observational Study,151
526,"Racial/Ethnic Differences in Psoriatic Arthritis Patient Responses Regarding Disease Burden, Treatment, and Communication with Care Team",136
527,Arthralgia with Risk of Progression to Psoriatic Arthritis in a Large Cohort of Patients: Role of Ultrasound,108
528,Axial Spondyloarthritis in Patients with Late-Onset Chronic Low Back Pain (Older Than 45 Years). Axial Spa or Psoriatic Disease with Axial Involvement?,151
529,Axial Disease Activity in Psoriatic Arthritis Is Higher in Patients with Carotid Plaque,87
530,Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque,128
531,Prevalence of Undiagnosed Inflammatory Bowel Disease in Patients with Spondyloarthritis: EISER Study,100
532,Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis,131
533,Effects and Tolerability of Low to Moderate Biomechanical Stress During Leisure Sport Activity in Patients with Psoriasis and Psoriatic Arthritis,145
534,Biological Therapies for Psoriasis and Psoriatic Arthritis- effects on Future Risk Development of Major Adverse Cardiovascular Events (MACE),140
535,Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry,193
536,Analysis of the Probability of Retention of Golimumab as a Two-phase Exponential Decay Curve in Rheumatoid Arthritis or Spondyloarthropathies to Identify Patients with Higher Probability of Long-term Retention,209
537,"Multicentre Study of Uveitis in Spondyloarthritis: Prevalence, Characteristics, and Prognosis",93
538,Developing Electronic Health Record Algorithms to Accurately Identify Psoriatic Arthritis Patients,98
539,Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging,145
540,Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature,90
541,Factors Associated with Minimal Disease Activity in Psoriatic Arthritis: Insights from a Registry-Based Study,109
542,Patient and Physician Global Assessment of Psoriatic Arthritis Disease Activity: High Concordance in an ArLAR Multinational Study,129
543,The Use of PSAID-12 in Remote Monitoring Correlates with In-person Clinical Examination Findings in Psoratic Arthritis,118
544,"Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA",147
545,"Assessment of Direct and Indirect Impact on Pain and Fatigue Outcomes in a Phase 2 Clinical Trial of Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Active PsA: A Mediation Analysis",220
546,"Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies",183
547,Long-term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies,153
548,Factors Associated with Treatment Pathways in Early Axial Spondyloarthritis: A Multistate Analysis of the 10-year Follow-up of the DESIR Cohort,143
549,Impact of Pregnancy on Sacroiliac Imaging in Women with Axial Spondyloarthritis: Results of the Analysis of the DESIR Cohort,124
550,Difficult-to-treat Axial Spondyloarthritis Is Associated with Psoriasis and Comorbidities: Results from a Nationwide Study,122
551,Dose Adjustment of Tumor Necrosis Factor Inhibitors Does Not Correlated with Radiographic Progression in Patients with Ankylosing Spondylitis,141
552,Drivers of Treatment Intensification in Patients with Axial Spondyloarthritis and High Disease Activity: Results from a Clinical Practice Registry,146
553,Which ASDAS Cut-Off Corresponds Best to Treatment Intensification in Patients with Axial Spondyloarthritis in Daily Practice?,125
554,Tofacitinib Efficacy and Safety in Patients with Ankylosing Spondylitis by Baseline C-Reactive Protein Levels: A Post Hoc Analysis,130
555,Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and Its Open-Label Extension,158
556,How Do Early Disease Activity and Early Clinical Response Associate with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis?,148
557,Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies,147
558,Effect of Secukinumab versus Adalimumab Biosimilar on Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis: Results from Subgroup Analyses by Baseline Syndesmophytes and C-reactive Protein Status,221
559,Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies,142
560,Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis,190
561,"Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies",199
562,Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies,156
563,Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies,225
564,Risk of Cardiovascular Disease Associated with Long-term Use of NSAIDs in Ankylosing Spondylitis,96
565,Sex-dependent Differences in Disease Characteristics Do Not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA),193
566,Impact of Upadacitinib on Wearable Device-Measured Physical Activity in Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Trial,137
567,Effects of Anti-tumor Necrosis Factor Treatment on Lipid Profiles in Patients with Ankylosing Spondylitis,105
568,Factors Associated with Cause-specific Discontinuation of Long-term Anti-tumor Necrosis Factor Agent Use in Patients with Ankylosing Spondylitis,144
569,Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and b/tsDMARDs in Daily Practice?,108
570,Tapering Tofacitinib for Axial Spondyloarthritis in Remission or Low-disease Activity State,91
571,"Pharmacologic Treatment of Ankylosing Spondylitis in a Large Urban Medical Center: Effects of Socioeconomic Status, Race/Ethnicity and Sex",138
572,Asynchronous Tele Consultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy: Patients Perspective,144
573,Asynchronous Teleconsultation by WhatsApp Chatbot in Controlled Axial Spondyloartrhitis Patients Under Biological Therapy as a More Sustainable Model Than Face-to-face Classical Consultation,190
574,The Challenge of Identifying Difficult-To-Treat Axial Spondyloarthritis in Clinical Practice: Results from La Paz-SpA Cohort,124
575,Impact of Extreme Baseline BASDAI and/or Maastricht AS Enthesitis Score on Treatment Response to Upadacitinib in Patients with Axial Spondyloarthritis,150
576,The Impact of Baseline BMI and Physical Activity on Upadacitinib Treatment Response: A Post Hoc Analysis of Patients with Ankylosing Spondylitis from the SELECT-AXIS 2 Study,173
577,Treat-to-Target Strategy Implementation in Spondyloarthritis Patients of Real-World Clinical Practice: A Cross-Sectional Single-Center Study,140
578,Two-Year Treatment Adherence and Clinical Response to Secukinumab Compared to TNF Inhibitors in Axial and Peripheral Spondyloarthritis Patients: A Single-Center Prospective Observational Study,192
579,Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015,227
580,Autoantibodies to dsDNA and Associated Proteins: Association with Proteinuria and Lupus Nephritis,97
581,Referral Pattern and Factors Associated with Time to Diagnosis for Lupus in India- multicentric Data from the SLE Special Interest Group (SIG) of the Indian Rheumatology Association (IRA),187
582,Markers of Oxidative Stress in Systemic Lupus Erythematosus Patients with Nephritis,83
583,A Spatially-resolved Single Cell Resolution Atlas of Pediatric Lupus Nephritis Uncovers Complex Interactions Between Stromal and Infiltrating Immune Cells,154
584,Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals,101
585,Development of Customized Digital Cognitive Assessment Battery: A Pilot Use Case in SLE Patients,96
586,Harnessing Machine Learning to Predict Neuropsychiatric Events in Systemic Lupus Erythematosus,94
587,Monogenic Lupus: Clinical Phenotypes and Genetic Mutations in a Cohort of Pediatric Patients,92
588,The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus,127
589,Serum Isolevuglandin IgG Antibody Concentrations Are Increased in Patients with Systemic Lupus Erythematosus versus Control Subjects and Associated with Lower 24-hour Blood Pressure,181
590,A Refined Disease Activity Immune Index Informed by Select Immune Mediators That Characterizes Clinical Disease Activity in Systemic Lupus Erythematosus,152
591,Evaluation and Management of the “False Positive” ANA and Undifferentiated Connective Tissue Disease Amongst Rheumatologists,124
592,Classical Complement Activation in Lupus Nephritis Correlates with Disease Biomarkers: Results from Two Observational Studies,125
593,Longitudinal Evaluation of Cell-bound Complement Activation Products in Patients with SLE,89
594,Elevated Serum Levels of S100A8/A9 Discriminate Systemic Lupus Erythematosus Patients with Cognitive Impairment from Patients Without Impairment,144
595,"Development of Charlson Comorbidity Index (CCI) Comorbidities and CCI Score in Danish Nationwide Cohort of 3,178 Patients with Newly Diagnosed Systemic Lupus Erythematosus",171
596,Genetic Determinants of Lupus Nephritis and Kidney Function in Systemic Lupus Erythematosus,91
597,Frequency of Anti-Ro Antibodies in Systemic Lupus Erythematosus Patients: Insights from Multicenter and National Registry,121
598,HDL-Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus,91
599,Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL) as a Mediator of the Association Between Particulate Matter Exposure and Disease Activity in Systemic Lupus Erythematosus,179
600,Risk Factors for Immune Thrombocytopenia in Systemic Lupus Erythematosus and Generation of a Predictive Model to Assess Its Risk of Development,143
601,Insulin Resistance and the Complement System Are Linked in Patients with Systemic Lupus Erythematosus,101
602,Characterization of Disease Activity Using a Novel Physiologic Biomarker in Pediatric SLE,89
603,N-Terminal Pro-Brain Natriuretic Peptide Correlates Strongly with Cardiovascular Damage in Systemic Lupus Erythematous (SLE): A Cross-sectional Study,149
604,Comparison of Plasma Protein Profiles and Endothelial Function in Patients with Pediatric-Onset Systemic Lupus Erythematosus and Healthy Controls,145
605,Serum S100A8 and S100A9 Are Useful Biomarker Indicated IFN Associated Organ Involvements in Systemic Lupus Erythematosus,120
606,BLyS Levels Are Elevated in Systemic Lupus Erythematosus Patients with Neuropsychiatric Manifestations,102
607,A Polygenic Risk Score for Systemic Lupus Erythematosus (SLE) Discriminates Between Patients with Lupus and Individuals Without Lupus and a Positive Antinuclear Antibody Test,174
608,Serum/ Urine Levels and Expression of CD163 in Lupus Nephritis,62
609,Presence of Mediterranean Fever Gene Variants Provides Protection from the Development of Lupus Nephritis in Patients with Systemic Lupus Erythematosus,151
610,Type I IFN-associated Regulation of Immune Checkpoint Genes in Patients with SLE,80
611,The Real-World Utility of a Lupus Activity Monitoring Panel in the United States Community Rheumatologist Practice,114
612,Enhancing Systemic Lupus Erythematosus Diagnosis: Comparative Performance Characteristics of TC4d and Anti-T-Cell Antibodies with Conventional Biomarkers,153
613,Analysis of Intracytoplasmic Toll – Like Receptors (TLRs) and MyD88 Expression in B Cell Subsets in Patients with Lupus Nephritis,129
614,Prospective Observational Study of Microvascular C5b-9 Deposition in Non-lesional Skin in Systemic Lupus Erythematosus Patients and Its Correlation with Active Lupus Nephritis,175
615,"Sub-types of Ischemic Stroke in Systemic Lupus Erythematosus,-associations with STAT4 and HLA-DRB1 Risk Genotypes",113
616,Performance of Conventional Cardiovascular Risk Scores in Identifying Subclinical Atherosclerosis in Systemic Lupus Erythematosus,129
617,"Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype for the Serological Detection of Eleven IgG Autoantibodies Commonly Found in Connective Tissue Diseases",204
618,Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial,178
619,"Therapeutic Potential of Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, for the Treatment of Refractory Autoimmune Disease Patients",142
620,"Targeting Key Components of SLE Pathogenesis with the Multifaceted Immunomodulatory Properties of Cenerimod, a Selective S1P1 Receptor Modulator",144
621,The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE),153
622,Therapeutic Drug Monitoring of Azathioprine and Tacrolimus in SLE Pregnancies: Preliminary Results from the LEGACY Cohort,121
623,Impact of up to 24 Months Intravenous (IV) Belimumab (BEL) Treatment on Steroid Use and Disease Activity in Patients with SLE in Clinical Practice: Additional Post Hoc Pooled Analysis of Multicountry OBSErve Cohort Data,219
624,Long Term Safety and Predictors of Serious Infections Among Patients with Systemic Lupus Erythematosus Treated with Rituximab: Audit from a Single Center Biologic Registry,171
625,A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE,134
626,Comparing Safety and Efficacy of Sodium-Glucose Co-Transporter 2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Systemic Lupus Erythematosus and Comorbid Type 2 Diabetes Mellitus,200
627,"Despite Dramatic Expansion of Approved Biologics in SLE, Unmet Needs Remain",75
628,Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS),146
629,Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus,107
630,Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease,228
631,Renal Involvement in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period,131
632,"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Systemic Lupus Erythematosus (SLE): Achievement of Sustained SRI(4), BICLA and Dual Responses over 48 Weeks",206
633,"Efficacy of Anifrolumab in Systemic Lupus Erythematosus by Overall and Organ-Specific SLEDAI-2K Improvements: Results from the Randomized, Placebo-Controlled Phase 3 Long-Term Extension Study",191
634,Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study,98
635,Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes,109
636,Identification of Subsets of SLE Patients Responsive to Baricitinib by Transcriptomic Analysis at Baseline,106
637,"Selective Disposition of Voclosporin, Cyclosporine, and Tacrolimus in Renal Tissue",82
638,Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus,153
639,Antiphospholipid Antibodies as Potential Predictors of Disease Severity and Poor Prognosis in Systemic Lupus Erythematosus Associated Thrombocytopeinia,151
640,Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments,205
641,Determining the ECG Cut-off Point in Systemic Lupus Erythematosus Patients Undergoing Hydroxychloroquine Therapy,112
642,Risk of Damage Progression with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus,121
643,CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained,123
644,Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study,151
645,Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse?,121
646,Nailfold Capillaroscopy for Prediction of Novel Severe Organ Involvement in Systemic Sclerosis,94
647,Demographics and Clinical Features Associated with Small Bowel Hypomotility in Systemic Sclerosis,97
648,COVID Vaccinations and Infections Among Individuals with Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study,148
649,Quantification of Skin Hardness of Patients with Systemic Sclerosis Using SOFTGRAM,82
650,Self-Reported Sexual Dysfunction and Perceptions of Rheumatologist Engagement on This Issue in Patients with Systemic Sclerosis,127
651,Prevalence of Barrett’s Esophagus in Patients with Systemic Sclerosis,69
652,Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study,93
653,Pulmonary Rehabilitation in Connective Tissue Disease-Related Interstitial Lung Diseases,88
654,Incident versus Prevalent Interstitial Lung Disease in Systemic Sclerosis in the EUSTAR Database: Different Disease Phenotypes and Prognosis,140
655,"Different Definitions of Disease Severity, Progression and Outcomes in Systemic Sclerosis Associated Interstitial Lung Disease: A Systematic Literature Review",158
656,Physical and Mental Health in Early Systemic Sclerosis: Baseline Results for Patient-Reported Outcomes Measurement Information System-29 from the Collaborative National Quality and Efficacy Registry,198
657,Scleroderma Renal Crisis: A Large Single-center Experience,58
658,The Effectiveness of Breath-holding Test to Predict Pulmonary Function in Systemic Sclerosis Patients Using Machine Learning Model,130
659,Nailfold Capillaroscopy in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib,130
660,Outcomes in Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Based on Serological Profiles: Focus on Anti-Centromere Antibody (ACA) and Anti-RNA Polymerase III (ARA) Antibodies,193
661,Use of Heated Gloves for Raynaud’s Phenomenon in Systemic Sclerosis,67
662,Clinical Features of Anti-hUBF Antibodies-positive Patients: A Single-center Retrospective Study,96
663,Clinical Significance of Anti-Ro/SSA Antibodies in Patients with Systemic Sclerosis: A Study from the EUSTAR Database,117
664,Interstitial Lung Disease in Very Early Systemic Sclerosis,58
665,"Negative Affect, Anxiety and Fatigue Moderate the Association Between Pain Intensity and Physical Function in People with Systemic Sclerosis",140
666,Prevalence and Risk Factors for Systemic Sclerosis Digital Ischemic Complications in the Collaborative National Quality and Efficacy Registry,141
667,Safety of Radiotherapy for Malignancy in Systemic Sclerosis. a Systematic Review,80
668,A Longitudinal Analysis of Mouth Opening in 1101 Systemic Sclerosis Patients from the French National Cohort Study,114
669,Prediction of Progressive Fibrosing Interstitial Lung Disease in Systemic Sclerosis Patients: Insight from the CRDC Cohort Study,128
670,Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study,158
671,Clinical Characteristics and Longitudinal Outcomes of Patients with Childhood-Onset Systemic Sclerosis at a Tertiary Center,123
672,Chasing Pain: Investigating Somatosensory Profiles in Patients with Rheumatological Diseases Using Quantitative Sensory Testing,127
673,Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort,159
674,Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH),199
675,Evaluating Esophageal Dysmotility by Scintigraphy in Systemic Sclerosis: Subsets and Phenotypes,95
676,Multidisciplinary and Multiparametric Evaluation of Sarcopenia in Patients with Systemic Sclerosis,98
677,The Evaluation of Lower Extremities Arterial Disease in Systemic Sclerosis Patients Through Rheumatologist-Vascular Surgeon Multidisciplinary Management: Preliminary Data from an Italian Single Center Study,206
678,"Clinical Characteristics of Systemic Sclerosis, Systemic Sclerosis Overlap Syndromes and Systemic Sclerosis-mixed Connective Tissue Disease in an Asia-Pacific Cohort- an APLAR Scleroderma Special Interest Group Study",216
679,Progression of Interstitial Lung Disease in Systemic Sclerosis Does Not Predict Further Progression,99
680,Prediction of Stable SSc-ILD Depends on Definition of ILD Progression,69
681,Continuous Progressive ILD in Systemic Sclerosis Is Associated with Mortality,77
682,Racial Variability in Immune Responses Only Partially Explains Differential Systemic Sclerosis Disease Severity,111
683,Prevalence and Risk Factors of Left Ventricular Diastolic Dysfunction in Systemic Sclerosis: Insights from New Echocardiographic Parameters,139
684,Incidence and Prevalence of Malnutrition and Its Impact on Mortality in the Multicentre Singapore Systemic Sclerosis Cohort,123
685,Early Systemic Sclerosis Definitions: Time to Rethink ‘Early’ in SSc Disease?,77
686,Understanding the Employment Landscape in People with Systemic Sclerosis,72
687,Abnormal Nailfold Video-capillaroscopy Is Independently Associated with non-UIP Radiographic Patterns in Autoimmune ILD: A Multicenter Study from the NEREA Registry,164
688,Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease,76
689,Association Between Systemic Sclerosis and Increased Risk of Ischemic Stroke: A Meta-Analysis,93
690,Comparison of Cardiovascular Risk in Patients with Systemic Sclerosis and the General Population,96
691,A Novel Association Between Lipodermatosclerosis and Key Vascular Outcomes in Systemic Sclerosis,96
692,Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression,121
693,The Value of the Six-Minute Walk Test in Detecting Cardiopulmonary Involvement in Patients with Systemic Sclerosis,114
694,"Evaluating the Associations Between Autonomic Dysfunction, Clinical Phenotype and Gastrointestinal Transit in Patients with Systemic Sclerosis",142
695,Cigarette Exposure in Systemic Sclerosis: Impact on Autoantibody Expression and Disease Manifestations: Analysis of the EUSTAR Cohort,133
696,Cigarette Smoking Increases the Risk of All-Cause Mortality in Male Patients with Systemic Sclerosis: An Analysis of the EUSTAR Cohort,134
697,Assessment of Systemic Sclerosis-Associated Myocarditis: A Single Center Case Series Study,90
698,Changes in Treatment Patterns and Their Influence on the Outcome of Systemic Sclerosis-interstitial Lung Disease (SSc-ILD) Patients: An EUSTAR Analysis,151
699,Vaccine-Preventable Diseases in Hospitalized Patients with Systemic Sclerosis: A Nationwide Cohort Analysis,107
700,Quantitative Hand Held Dynamometry to Assess Muscle Strength in Scleroderma Associated Myopathy,95
701,A Descriptive Study of Disease Characterisics of SSc Patients with the U2RNP Autoantibody,89
702,Troponin I Levels in Systemic Sclerosis Patients with Myocardial Involvement,76
703,The Risk of Stroke and Myocardial Infarction in Systemic Sclerosis: A Population-based Study,92
704,Increased Risk of Cancer in Patients with Systemic Sclerosis: A Population-based Study,86
705,Optical Coherence Tomography Angiography in Systemic Sclerosis: Correlations with Morphological and Functional Peripheral Microvascular Status,142
706,Title: Patient Characteristics and Outcomes of Scleroderma Renal Crisis versus Hypertensive Emergencies: A Nationwide Comparative Study,135
707,Decreased Odds of Malignancy with Mycophenolate Use in a Single-Center Scleroderma Cohort,89
708,Risk of New-onset Depression in Patients with Systemic Sclerosis : A Nationwide Population-based Study,102
709,"Reporting of Race, Ethnicity, Sex, Gender, Socioeconomic Status and Representativeness of Race and Ethnicity in ANCA-associated Vasculitis Randomized Trials",156
710,Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis,124
711,Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond,193
712,Mepolizumab Can Achieve Glucocorticoid Discontinuation in Eosinophilic Granulomatosis with Polyangiitis Patients Regardless of IgE Levels: A Retrospective Study at a Single Center,179
713,Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan,199
714,Benralizumab in Eosinophilic Granulomatosis with Polyangiitis,61
715,Long-term Safety of Rituximab (Mabthera) in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Rituximab Surveillance Study in VASculitis (RIVAS),168
716,Risk Factors for Hypogammaglobulinemia and Association with Relapse and Severe Infections in ANCA-Associated Vasculitis: A Retrospective Single-Centre Cohort Study,163
717,Real-World Outcomes for Remission Induction in Working-Age Adults with Severe Anti-Neutrophil Cytoplasmic Antibody-associated Vasculitis,136
718,Avacopan in ANCA-associated Vasculitis Received Intensified Induction Therapy with Cyclophosphamide Plus Rituximab – Retrospective Case Serial of 12 Patients,157
719,"Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis",203
720,Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis,139
721,Efficacy and Safety of Avacopan in Patients with ANCA-Associated Vasculitis Receiving Rituximab in a Phase 3 Trial,114
722,Safety and Efficacy of Avacopan in Patients 65 Years and Older with ANCA-Associated Vasculitis,94
723,Avacopan for the Treatment of ANCA-associated Vasculitis. Real World Experience in Spain,88
724,Efficacy and Safety Experience with Avacopan Beyond 52 Weeks in the Early Access Program (EAP),94
725,Use of Avacopan in Patients with ANCA-associated Vasculitis and Estimated Glomerular Filtration Rate < 15 mL/min/1.73m2,119
726,Treating Patients with ANCA-Associated Vasculitis and Very Severe Renal Injury with an Intensified B Cell Depletion Therapy: Comparison with a Control Cohort Receiving a Conventional Therapy,190
727,Recognizing the New Disorder “Idiopathic Hypocryoglobulinaemia” in Patients with Previously Unidentified Clinical Conditions,124
728,Behçet’s Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity,88
729,Comparison of the Cardiovascular Risk in Patients with Vasculitis and Diabetes Mellitus,87
730,Off-label Use of Biologics in Urticarial Vasculitis: A European Cohort Study,76
731,Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study,139
732,Association of Large-vessel Vasculitis with Inflammatory Bowel Diseases: A European Case-control Study,102
733,Alterations in Composition and Function of Gut Microbiota in Patients with Large-Vessel Vasculitis,98
734,"Differentiating Large Vessel Vasculitis from Vasculitis Mimickers in a Real World Setting: Clinical Presentation, Laboratory Tests and Radiographic Findings",156
735,T Cell Subset Analysis in Patients with Large-Vessel Vasculitis,63
736,A Population-Based Study of Vasculitis Among Farmers and Urban Residents in Alberta,83
737,Incidence of Neurobehçet Disease in Northern Spain 1999-2019. a Population-based Study,86
738,Large Vessel Vasculitis Increases Risk of Acute Myocardial Infarction in Patients Admitted for Congestive Heart Failure : A Nationwide Inpatient Database Study,159
739,Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis,71
740,Clinical Characteristics and Outcomes in Patients Found to Have Clinically Isolated Aortitis After Aortic Aneurysm Repair: A Single-Center Experience,149
741,Sleep Disturbances in Patients with Vasculitis: Results of the Vasculitis Patient-Powered Research Network Sleep Study (SleepVasc),130
742,Aortitis and Periaortitis Spectrum in 135 Patients from a Single Referral Centre,80
743,Prevalence and Distribution of Vascular Calcifications at CT Scan in Patients with Large Vessel Vasculitis and Patients with Lymphoma: A Matched Cross-sectional Study,166
744,NFKB1 and NFKBIA: Relevant Players in the Pathogenesis of IgA Vasculitis?,73
745,Survival of Adults with IgA Vasculitis,38
746,The Association of IgA Vasculitis and Malignancy in Adults: A Systematic Review,79
747,IgA Vasculitis in a Diverse Adult Patient Population,52
748,Clinical and Histologic Prognostic Factors of Renal Progression in Adults with IgA Vasculitis,93
749,IgG4-Related Disease as a Potencial Etiology of Idiopathic Constrictive Pericarditis,84
750,Single Center Experience of Rituximab Treatment for IgG4-RD Disease in a Large Multi-ethnic Cohort,98
751,Glucocorticoid Toxicity in Patients with IgG4-Related Disease Within the First Year of Treatment,96
752,Efficacy of Immunosuppressants for Disease Relapse in Patients with IgG4-related Disease at Our Institution,107
753,Mitochondria-mediated Platelet Activation in Polymyalgia Rheumatica,67
754,Clinical and Economic Burden of Polymyalgia Rheumatica in Patients with an Inadequate Response to Glucocorticoids in a Real-World Setting,137
755,Polymyalgia Rheumatica Following SarsCOV-2 Vaccination: A Single Center Cohort Study,84
756,Cognitive Function and Its Associated Factors in Polymyalgia Rheumatica,71
757,Characterization of Numeric Rating Scales for Symptom Assessment in Polymyalgia Rheumatica,90
758,Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies,71
759,Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension,129
760,Synovial Macrophage Subsets Defined by ScRNAseq Demonstrate Sexually Dimorphic Gene Expression in RA and a Mouse Inflammatory Arthritis Model,141
761,Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis,129
762,Expert Consensus Recommendations for Musculoskeletal Ultrasound Education in Canadian Rheumatology Residency Training Programs,126
763,A Novel Active Pemphigus Vulgaris Mouse Model Induced by Immunization with TLR Ligand Adjuvanted Recombinant Desmoglein 3 Protein Vaccine,137
764,Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype,145
765,ROCK1 Orchestrates B-cell Differentiation Under Stress,54
766,NF-κB Signaling Is Critically Important for Functional Responses of ACPA-producing B Cell Clones from Patients with Rheumatoid Arthritis,136
767,ZEB2 Acts as a Crucial Transcriptional Regulator Governing Age-Associated B Cell Formation and Pathogenicity in Systemic Lupus Erythematosus,140
768,Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?,117
769,Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening,134
770,Immune Isoform Atlas: Landscape of Alternative Splicing in Human Immune Cells and Involvement of Dysregulated Alternative Splicing in Autoimmune Diseases,153
771,Deep Immunophenotyping Reveals Circulating Activated Lymphocytes in Individuals at Risk for Rheumatoid Arthritis,112
772,Deciphering Complement System-dependent Cellular Pathways in Human Rheumatoid Arthritis Synovial Tissue Using Large Single-cell Computational Omics,147
773,Unraveling Pathophysiology and Hematopoiesis of VEXAS Syndrome by Multi-omics Analysis and Targeted Gene Editing,112
774,A Genome-wide Association Study Suggests New Susceptibility Loci for Primary Antiphospholipid Syndrome,102
775,Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis,165
776,Renal Arteriosclerosis in Index Lupus Nephritis Biopsies Predicts Future Cardiovascular Disease,95
777,Adverse Events Among Patients with and Without Autoimmune Rheumatic Disease Prescribed SGLT2 Inhibitors,103
778,Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes,168
779,Risk and Temporal Trends of Heart Failure Subtypes in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study,124
780,Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus,91
781,Artificial Intelligence Models for Computer-Assisted Joint Detection and Sharp-van Der Heijde Score Prediction in Hand Radiographs from Patients with Rheumatoid Arthritis,170
782,The Association Between Sonographic Imaging Phenotype and Response to Treatment in Patients with Psoriatic Arthritis,116
783,Clinical Phenotype of Patients with Subclinical Giant Cell Arteritis in Polymyalgia Rheumatica,94
784,Assessment of Myositis-related Interstitial Lung Disease by ⁶⁸ Ga-DATA.SA.FAPi PET/CT,85
785,Impact of Sprifermin on Denuded Areas of Subchondral Bone (dABs): A Post Hoc Analysis of the FORWARD Study,106
786,Multispectral Optoacoustic Tomography of the Entheses Reveals Common Metabolic and Architectural Tissue Patterns in Psoriasis and Psoriatic Arthritis Independent of Inflammation,177
787,Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023,100
788,Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic DMARD: Gaps in Coverage Overall and Among JAKi Initiators,132
789,Facility Variation in HLA-B*58:01 Allele Testing for Asian and Black Patients Receiving Allopurinol in the Veterans Affairs Healthcare System,141
790,Towards a Guide for Evidence-based Remote Monitoring: Sensitivity of Patient Reported Outcomes to Change in Disease Activity Status in Early and Established Rheumatoid Arthritis,177
791,Changes in Rheumatology Providers’ Perceptions of Telehealth Appropriateness from 2021 to 2022,94
792,Validation of Quantitative Effusion-synovitis Volume Measured by Deep-learning: Data from the Osteoarthritis Initiative,119
793,"Identification of 23 Novel COPA Rare Exonic Non-Synonymous Variants and Their Associated Autoimmune and Inflammatory Clinical Phenotypes Among 53,364 Individuals",161
794,Clinical and Biological Characteristics of Children and Adults Affected with Still’s Disease: A Systematic Review and Meta-analysis Informing the 2023 EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-onset Still’s Disease,284
795,"Derivation and Validation of Four Patient Clusters in Still’s Disease, Results from GIRRCS AOSD-study Group and AIDA Network Still Disease Registry",147
796,Treatment Patterns and Outcomes in Patients with Macrophage Activation Syndrome Secondary to Still’s Disease Treated with Emapalumab: The REAL-HLH Study,152
797,EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still’s Disease (AOSD),149
798,Liver Disease Is a Common Feature of HA20 That Causes Significant Morbidity Associated with Interferon Induction,112
799,Sticking the Landing: A 3-Year Qualitative Longitudinal Study on Navigating Transitions in Pediatric Rheumatology Fellowship,124
800,"An Atypical ClassRheum: RheumMadness, a Collaborative Rheumatology Competition Building Knowledge and Community",111
801,RheumMadness and TheMednet: The Impact of a Collaboration Between Independent Educational Initiatives,101
802,The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis,109
803,Current Musculoskeletal Ultrasound Practices of 12 Years of past Participants of a 10-Months Rheumatology Ultrasound Training Program (Ultrasound School of North American Rheumatologists),187
804,Using Participatory Design-Thinking Process to Create a More Applicant-Centered Rheumatology Fellowship Interview Experience,124
805,"Development and Validation of a Combined Clinical and Genetic Risk Score for Interstitial Lung Disease in a Large, Multicenter, Prospective Rheumatoid Arthritis Cohort",167
806,"Plasma Matrix Metalloproteinases in Rheumatoid Arthritis-Interstitial Lung Disease: Associations with Disease Presence, Severity, and Subtypes",142
807,A Modified Idiopathic Pulmonary Fibrosis-Derived Composite Biomarker Score Is Associated with Interstitial Lung Disease Among U.S. Veterans with Rheumatoid Arthritis,165
808,MUC5B Promoter Variant and Survival in Rheumatoid Arthritis-Associated Interstitial Lung Disease,96
809,Sputum Lautropia Abundance Is Decreased in Rheumatoid Arthritis-Associated Pulmonary Fibrosis and Correlates with Lung Disease Severity,135
810,Deciphering Rheumatoid Arthritis-associated Interstitial Lung Disease Phenotypes Using Unsupervised Hierarchical Clustering Analysis: Results from a Large Collaborative International Study,188
811,Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study,169
812,"Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study",166
813,Characteristics of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis,81
814,The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial,144
815,"Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)",186
816,Assessing Differential Effects of DMARDs on Psoriasis Area and Severity Index and Patient Global Assessment in Subgroups of Patients with Active PsA Treated over 52-weeks with Secukinumab in a Non-Interventional Trial (AQUILA) Using a Multistage Clustering Approach,265
817,Low vs. High Initial Oral Glucocorticoid Dose for Lupus Nephritis Induction Treatment: A Pooled Analysis of Randomized Controlled Clinical Trials,145
818,"Comparison of Dual-immunosuppressive Therapy with a Voclosporin-based, Triple-immunosuppressive Regimen for Lupus Nephritis in the ALMS and AURORA 1 Studies",156
819,Tolerability of CAR T Cell Therapy in Autoimmune Disease,56
820,Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial,157
821,Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity,99
822,A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort,155
823,Understanding Distinct Resident and Migratory Fibroblast Populations in Systemic Sclerosis Skin Through Single-cell RNAseq and Immunohistochemistry,147
824,Whole Exome Sequencing and Evolutionary Action Missense Mutation Analysis Identifies MICB as a New SSc Susceptibility Locus and the Interferon Pathway as Contributors to SSc Pathogenesis,186
825,Telomere Length of Peripheral Blood Cells Predicts More Severe Pulmonary Disease and Worse Survival in Systemic Sclerosis,121
826,Transcriptomic Analyses of Lung Tissues Reveals Potential Key Genes Associated with Progression of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD),153
827,"Expression of TL1A, Inflammatory, and Fibrotic Pathways in Patients with Diffuse Systemic Sclerosis",99
828,Single Cell RNA-seq of Myeloid Cells from Systemic Sclerosis Patients Identifies Circulating Monocyte Population with Interferon Signature Associated with Interstitial Lung Disease,180
829,The Dual Specificity Phosphatase 6 (DUSP6) Regulates Arthritis Severity and IL10 Production,91
830,Microbiota-dependent Indole Production Is Required for the Development of Collagen-induced Arthritis,100
831,The Focal Adhesion Protein Lasp1 Links the Arp2/3 Complex to Cell-to-cell Contact Formation in Arthritic Fibroblast-like Synoviocytes,133
832,Role of Group 2 Innate Lymphoid Cells in the Pathogenesis of Rheumatoid Arthritis,81
833,Innate Lymphoid Cells Enhance Development of CD4+ T-cell Driven Autoimmune Arthritis,84
834,"A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages",117
835,Human Chimeric Antigen Receptor (CAR)-Tregs Targeting OX40L for Treatment of Systemic Lupus Erythematosus,105
836,CD4+ CD96+ T Cells Are Pathogenic Effector Cells in Giant Cell Arteritis,72
837,LncRNA PIGL-217 Regulates Th17 Differentiation by Targeting miR-5008-5p and Suppressing FoxO1 in Behçet’s Disease,113
838,Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells,70
839,IL10 Inhibits Toll-like Receptor-9-induced T Cell Receptor-mediated T Cell Activation in Macrophage Activation Syndrome,119
840,Mutated NOD2 Controls IL-2 Production in Blau Syndrome Patients and Mice,72
841,De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis,68
842,Effectiveness of a Technology-enabled Self-monitoring and Physical Therapist Counselling Program for Improving Self-management Ability in People with Rheumatoid Arthritis: A Randomized Controlled Trial,201
843,Inferring Disease Activity Scores and Low Disease Activity at Registry Visits Based on Structured and Narrative Data from Electronic Health Records,147
844,Real-World Disease Monitoring Patterns in Rheumatoid Arthritis-Associated Interstitial Lung Disease in the Veterans Affairs Health Care System,142
845,Underserved by Rehabilitation: Characteristics Among Adults with Rheumatoid Arthritis,85
846,Telehealth Utilization and Satisfaction Among Patients with Rheumatic Diseases: Trends Since the Onset of the COVID-19 Pandemic,127
847,Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study,197
848,Length of Synovial Fluid Monosodium Urate Crystals According to Sonographic Articular Deposits: Advancing in the Crystallization Process,136
849,Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study Enrolling 115 Participants,153
850,"Treat-to-target Urate-lowering Therapy Reduces Gout Flare Burden: Post-hoc Analysis of a Multicenter, Randomized, Double-blind, Non-inferiority Trial",149
851,Intermittent Fasting Reduces Crystal-induced Inflammation,57
852,"Additive Association of ABCG2 rs4148155 and SLC22A12 rs75786299 Polymorphisms with Hyperuricemia, Gout and Nephrolithiasis, a Hospital-Based, Case-Control Study",160
853,Comparative Effectiveness of Yoga and Strengthening Exercise for Treating Knee OsteoArthritis: A Randomised Controlled Trial (YOGA Trial),137
854,"Efficacy of XT-150, a Novel Non-Viral Gene Therapy Delivering IL-10v, on Moderate to Severe Pain Due to Osteoarthritis of the Knee: Results of a Phase 2 Trial",158
855,Regression to the Mean for Physical Function and Quality of Life in Trials for Symptomatic Knee Osteoarthritis,110
856,Radiographic and Pain Outcomes from a Phase 3 Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects with Severe Osteoarthritis of the Knee (OA-07): 36 Month Single Blind and Placebo Crossover Phase Results,230
857,Effects of Sprifermin on a Novel Outcome of Osteoarthritis Symptom Progression: Post Hoc Analysis of the FORWARD Study,118
858,From Biomarkers to Endotypes: Data-driven Identification of Knee Osteoarthritis Patients Subtypes,97
859,Sleep Disturbance Predicts Pain Interference in Patients with Early Rheumatoid Arthritis in a Prospective Real-World Cohort,123
860,"Defining Poor Global Functioning and Health in Axial Spondyloarthritis, Using the EQ-5D-3L Questionnaire, When the ASAS-Health Index Is Not Available Is Feasible. an Analysis of 2651 Patients from the PERSPA Study",213
861,A Revised Outcome Measure for Dermatomyositis Clinical Trials: The Dermatomyositis Outcomes for Muscle and Skin (DMOMS),119
862,Development of a Decision Aid for Clinical Trial Participation in Systemic Lupus Erythematosus,94
863,Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease,89
864,Item Reduction and Validation of the Cutaneous Lupus Erythematosus Quality of Life Questionnaire,96
865,Decreased History of Breastfeeding During Infancy in Juvenile Spondyloarthritis: A Case-Control Study,101
866,The Upregulation of MAP Kinase Pathway Genes Is Associated with Poor Treatment Response to Tofacitinib in Polyarticular Course Juvenile Idiopathic Arthritis,156
867,Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study,174
868,Cumulative Social Disadvantage Is Associated with Disease Activity and Functional Disability in Juvenile Idiopathic Arthritis: An Analysis of the CARRA Registry,160
869,Machine Learning Detected Healthcare Encounter Patterns Leading to Diagnosis of Juvenile Arthritis in a Population-Based Canadian Cohort,136
870,Characterization of the Youngest Cohort with Non-Systemic Juvenile Idiopathic Arthritis: Demographics and Medication Use of Patients ≤2 Years of Age in the Childhood Arthritis and Rheumatology Research Alliance Registry,219
871,Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial,169
872,Vagotomy and Subsequent Risk of Rheumatoid Arthritis and Osteoarthritis: A Danish Register-Based Cohort Study,109
873,"A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis",145
874,Infusion of Etanercept into the Peripheral Lymphatics Significantly Reduces Disease Activity in Rheumatoid Arthritis Patients with Inadequate Response to Subcutaneous Injections,177
875,"Efficacy and Safety of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): The Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2a IRIS-RA Study",191
876,Head-to-Head Comparison of TLL-018 and Tofacitinib in Patients with Active Rheumatoid Arthritis: Final Results from a Phase IIa Study,133
877,Spondyloarthritis Research and Treatment Network (SPARTAN) Draft Referral Recommendations for Axial Spondyloarthritis,117
878,Low Rate of Switching from Nr-axSpA to r-axSpA After 10 Years of Follow up in Early Axialspondyloarthritis. Data from DESIR Cohort,130
879,Predictive Validity of Data-driven Definitions for Active and Structural Lesions in the SI Joints Typical for Axial SpA: A 2-year Follow-up in the SPondyloArthritis Caught Early Cohort,184
880,"Facet Joint Inflammation Is Rare, but When Present It Is Associated with Facet Joint Ankylosis in Radiographic Axial Spondyloarthritis Patients from the SIAS Cohort",164
881,The Yield of Repeated Assessments in Chronic Back Pain Patients Suspected of Early Axial Spondyloarthritis: Two-year Data from the SPondyloArthritis Caught Early (SPACE) Cohort,176
882,Preosteoclast Plays a Pathogenic Role in Syndesmophyte Formation of Ankylosing Spondylitis Through the Secreted PDGFB – GRB2/ERK/RUNX2 Pathway,142
883,Development of an IFN 5-Gene Signature Score to Identify IFN-high and IFN-low Subsets and as a Pharmacodynamic Biomarker for Deucravacitinib Treatment in a Phase 2 Trial in Patients with Systemic Lupus Erythematosus,215
884,"Performance of Serum MRP8/14, sCD14, IL-6 and Neutrophil CD64 in Isolation and in Combination for Differentiating Flare from Bacterial Infection in Febrile SLE Patients",168
885,Multiplex Profiling and Machine Learning Reveal Distinct Signatures of Circulating Cytokines Associated with Autoantibody Profiles and Disease Severity in Systemic Lupus Erythematosus,183
886,Persistence of Urinary Biomarkers of Intrarenal Inflammation Precedes Loss of Kidney Function in Lupus Nephritis,112
887,Lupus Nephritis Flares Linked to Platelet Activation During Gut Pathobiont Blooms,81
888,Screening for Specific Antinuclear Antibodies Using an Artificial Intelligence-enabled Antinuclear Antibody HEp-2 Substrate by Indirect Immunofluorescence Assay,160
889,Early Experience with Avacopan for ANCA-Associated Vasculitis in a Large Integrated Healthcare System,101
890,Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis,100
891,Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis,100
892,Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study,115
893,Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan,87
894,"Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis",157
895,Single Injection AAV2-hFGF18 Demonstrates Superior Safety and Efficacy over Repeat rhFGF18 Protein Injections in a Model of Induced Osteoarthritis,146
896,Vagus Nerve Stimulation Enhances Bone Morphology in a Rodent Model of Central Nervous System Inflammation,105
897,"The Analgesic Effect of RC-0165, a TRPV1 Antagonist, for Osteoarthritis Pain",76
898,Role of CRTAC1 as a Biomarker of Osteoarthritis,47
899,Phenotype and Energy Metabolism Differ Between Osteoarthritic Chondrocytes from Male Compared to Female Patients,112
900,Proteomic Analysis of Circulating Neutrophils from Osteoarthritis Patients Shows Metabolic Dysregulation That Is Associated with Decreased Physiologic Apoptosis,160
901,Reactive Oxygen Species-scavenging Nanoparticles Target Macrophage Polarization for Osteoarthritis Therapy,106
902,A Novel 3D-Synovium-Immune Microenvironment Mimics Macrophage-Synovial Fibroblast Interactions in Inflammatory Arthropathies,124
903,"Pentosan Polysulfate Sodium, a Glycosaminoglycan Mimetic Demonstrates Durable Effects on Pain, Function and Joint Structure in Canine Naturally Occurring Osteoarthritis",168
904,Enhancing Oxidative Phosphorylation Through PDK2 Depletion Alleviates Cartilage Degradation in Surgically Induced Osteoarthritis,128
905,Clinical Impact of PTEN as a Marker for Diabetes-Associated Osteoarthritis,74
906,Targeting Peroxisome Proliferator-Activated Receptor α Is a Disease-Modifying Therapy for Osteoarthritis,104
907,"Mitochondrial Transfer Functionally Restores the Human Osteoarthritis (OA) Chondrocyte, Is Protective Against Oxidative Stress and Improves OA in a Clinical Model of Disease",173
908,Synovial 5-LOX-Derived Oxylipins Define a B Cell-Enriched Synovium,66
909,FOXO Activators as Drugs for Osteoarthritis,43
910,RNA-Binding Proteins That Are Highly Expressed and Enriched in Healthy Cartilage but Suppressed in Osteoarthritis,113
911,"INV-1498, a Promising Caspase Inhibitor, Exhibits Dose-dependent Therapeutic Efficacy in a Canine Model of Osteoarthritis",121
912,Metabolomic Analysis Reveals Associations Between Calcium Crystals and Metabolites in Osteoarthritic Synovial Tissue,116
913,Loss of Transient Receptor Potential Channel 1 (TRPC1) Links Regulation of Intracellular Calcium to Cellular Senescence and Leads to Development of Osteoarthritis,162
914,Synovial Fibroblasts Undergo a Phenotypic Shift from Early- to Late-stage Knee Osteoarthritis,93
915,Recommendations for a Standardized Approach to Histopathologic Evaluation of Synovial Membrane in Murine Models of Experimental Osteoarthritis,142
916,CD14 Inhibition as a Potential Therapeutic in Post Traumatic OA,63
917,Deficiency of the Pattern-recognition Receptor CD14 Protects Against LPS-induced Inhibition of Osteoclastogenesis in Vitro,122
918,Activation of Ovarian Cancer G-Protein Coupled Receptor (OGR1) Attenuates Chondrocytes Inflammation via ERK1/2 Signaling Pathways in an in Vitro Model of Osteoarthritis,168
919,The Role of Plasmin and Fibrinolysis Pathways in Osteoarthritis,63
920,Identification of a Mast Cell-high Synovial Pathotype of Osteoarthritis,71
921,Mice Fed a Well-formulated Ketogenic Diet After OA Induction Develop Worse OA Outcomes and Increased Pain Sensitivity,117
922,Neonatal Roseolovirus Infection Predisposes to Development of Lupus-like Disease After TLR7 Stimulation,103
923,Dapagliflozin Modulates Inflammation and Germinal Centers in Lupus by Increasing Regulatory T Cells,99
924,Functionally Selective Immunomodulator Shows Robust Efficacy in Spontaneous Lupus Mouse Model,93
925,Axl Receptor Tyrosine Kinase Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice by Regulating Macrophage Polarization,131
926,Specificity of Brain-Intrinsic and Hematopoietic-Derived Mechanisms in Mediating Neuropsychiatric Symptoms of Systemic Lupus Erythematosus,138
927,Selective and Potent Inhibition of Cyclic GMP-AMP Synthase (cGAS) Fully Normalizes Autoinflammation Across Tissues in a Trex1-/- Mouse Model for Type I Interferonopathies,170
928,Single-Cell RNA Sequencing Reveals Keratinocytes and Fibroblasts Drive Hippo and TGFb Dysregulation and Fibrosis in Epidermal Overexpression of VGLL3 in Cutaneous Lupus,168
929,Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model,102
930,The Cellular and Spatial Type I Interferon Response Following Skin Exposure to Ultraviolet Light,96
931,Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus,75
932,"Targeting Toll-Like Receptor 7 with DS-7011a, a Promising Novel Antagonistic Antibody for the Treatment of Systemic Lupus Erythematosus",135
933,"Steroid-sparing Effects of Afimetoran (BMS-986256), an Equipotent Toll-like Receptor (TLR)7 and TLR8 Antagonist, in a Lupus Mouse Model",135
934,The Role of the Endothelin System in the Development of TLR7-accelerated Lupus-Associated Cardiac Dysfunction,109
935,Complement Factor I (CFI) Gene Expression by Kidney Tubular Cells Is Increased in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy,153
936,Complement Deposition on Extracellular Mitochondria Induces Platelet Activation in Vitro,88
937,Scavenging of Isolevuglandins Attenuates Neutrophil Expansion and Aortic NETosis in Systemic Lupus Erythematosus,112
938,Neutrophils in Systemic Lupus Erythematosus Demonstrate Heterogeneity Based on Sex,82
939,Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous,104
940,"KYV-101, a Fully Human Anti-CD19 CAR T Cell Therapy, Demonstrates CAR-Mediated and CD19-Dependent Activity Against Autologous B Cells from Patients with Autoimmune Disease",171
941,Low-Density Granulocytes and Neutrophil Extracellular Traps in Incomplete Systemic Lupus Erythematosus,102
942,Paired Autoantibody Specificities from Serum and Immune Complexes Do Not Fully Explain the Circulating Immune Complex Load in Systemic Lupus Erythematosus: A Study on 530 Patients,179
943,Epstein Barr Virus Reactivation May Associate with Transition from Incomplete to Systemic Lupus Erythematosus,109
944,Association of Biologic Sex with Glycosphingolipids and the N-glycome in Lupus Nephritis and Renal Mesangial Cell Function,122
945,Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus,175
946,17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice,139
947,"Spatial Transcriptomics Reveals Normal-density and Low-density Neutrophils Are More Prevalent Than Macrophages in Lupus Nephritis Glomeruli, and Urine DNA Methylation Analyses Capture Both Myeloid Populations",208
948,Inadequate Screening for Antiphospholipid Syndrome with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus,129
949,Neutrophils in Patients with Systemic Lupus Erythematosus Show Pronounced Inflammatory Signals,94
950,Transcription Factor RFX1 Promotes M1 Macrophage Polarization in Systemic Lupus Erythematosus via Regulating APOBEC3A,117
951,IL-16+ Is Abundantly Expressed by Kidney-infiltrating Myeloid and Lymphoid Cells in Lupus Nephritis: A Spatially Resolved Multiplexed Approach,142
952,Upregulation of the M-CSF Receptor on Non-Classical Monocytes from SLE Patients as an Indicator for Premature Monocyte Aging,124
953,Role of Immunoglobulin Polygenic Risk in Systemic Lupus Erythematosus,69
954,Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus,134
955,Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level,86
956,Proinflammatory Neutrophils and NETs Mediate Skin and Kidney Inflammation During Lupus Flare in Asymptomatic Lupus-prone Mice Triggered by UVB,142
957,SAPhigh T Peripheral Helper Cells Are a Novel Subset Associated with Lupus Nephritis,84
958,The Multi-Omic Landscape of Systemic Lupus Erythematosus Patients Highlights Metabolic and Immune Pathways Associated with Distinctive Clinical Profiles,152
959,Identification of Lupus Nephritis Kidney Immune Populations via Hi-Resolution 20-Plex Immunohistochemistry Single-Cell Spatial Analyses,135
960,Distinct Cell-Bound Complement Activation Products Associate with Disease Activity and Immune Transcriptional Signatures in SLE,127
961,IL-4 Acts Through Aryl Hydrocarbon Receptor to Antagonize TLR7-induced Double Negative 2 B Cells in Lupus,105
962,Single-cell Multi-Omic Evaluation of Differences in Immune Cell Populations in Progression Toward Systemic Lupus Erythematosus,126
963,"A Complex Interplay Among Gut Lachnoclostidium, HLA Haplotype DRB1*07:01, and the TNF Superfamily in Anti-Ro+ Women with a Spectrum of Preclinical and Clinical Autoimmunity Whose Children Have Neonatal Lupus",207
964,Skewing of B Cell Receptor Repertoire in Unswitched Memory B Cells Is Associated with Disease Activity of Systemic Lupus Erythematosus and Targeted by Belimumab,160
965,Persistent Up- or Down-regulation of SOCS1 Exacerbates the Pathogenesis of Systemic Lupus Erythematosus Through Several Mechanisms,130
966,Genetic Risk Profiles of Patients with Lupus Nephritis to Identify Those at Risk for Kidney Deterioration and Eventual Damage,125
967,Down-Regulation of Human NADH-Ubiquinone Oxidoreductase Chain 6 by N6-Methyladenosine Methylation Is Associated with Lupus CD4+ T Cell Activation,145
968,The Landscape of Immune Cells in Systematic Lupus Erythematosus Patients with Epstein-Barr Virus Infection by Single-cell Sequencing,132
969,The ‘Sweet’ in Lupus – IgG Glycosylation in Lupus Nephritis,59
970,"Anti-fibrotic Effects of MT-5562, a Novel Potent Selective Autotaxin Inhibitor, in Preclinical Studies: Roles of Lysophosphatidic Acid in Autoimmune Diseases and Clues to Treat Skin and Lung Fibrosis in Systemic Sclerosis",221
971,Sodium Pyruvate Improves Mitochondrial Fitness in SSc Fibroblasts to Prevent Fibroblast-to-myofibroblast Transition and Fibrotic Remodeling,139
972,Impaired DNA Repair Responses Activate a Novel FOXO1-dependent Metabolic Remodelling in Patients with Progressive Systemic Sclerosis to Promote Fibrosis,152
973,IL-4+ and IFN-α+ Profibrotic T Cells Aggravate Systemic Sclerosis via STIM1/STING Signaling in SKG Mice,103
974,Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum,175
975,HRCT-derived Delta Radiomic Features Classify Response to Anti-Fibrotic Treatment in Experimental and Human Fibrosing Interstitial Lung Disease,143
976,A Novel Therapeutic Opportunity in Systemic Sclerosis: The Fibrolytic Activities of a Specialized Macrophage Secretome,118
977,RUNX1 Expression and Binding Site Accessibility Is Associated with Increased Disease Severity in Systemic Sclerosis,115
978,G Protein-coupled Receptor Kinase 5 in Fibrotic Tissue Remodeling,65
979,Attenuation of Fibroblast Activation and Fibrosis by Adropin in a Hedgehog-Dependent Manner,91
980,Macrophages Regulate Adipocyte Differentiation and Proliferation in Skin Fibrosis,81
981,The Nuclear Receptor TR4 Orchestrates Cytoskeletal Organization in a Gα12/ROCK-dependent Manner to Promote Myofibroblast Differentiation and Tissue Fibrosis in Systemic Sclerosis,178
982,Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts,132
983,Fcγ Receptors Define Pro-Phagocytic Macrophages and Trigger Pro-Inflammatory Responses in Patients with Systemic Sclerosis,122
984,Nintedanib Alters Fibroblast and Macrophage Diversity in a 3D Skin Model of Systemic Sclerosis (SSc),100
985,Development of Interstitial Pneumonia with Autoimmune Features in Conditional Tgfb3 Deletion,92
986,KL-6 and IL-18 Levels Are Negatively Correlated with Respiratory Function Tests and ILD Extent Assessed on HRCT in Patients with Systemic Sclerosis-related Interstitial Lung Disease (SSc-ILD),191
987,Single Cell Analysis of Transitional B Cells in Systemic Sclerosis Highlights Defective Peripheral Tolerance,108
988,Unraveling the Role of MiR-181 in Skin Fibrosis Pathogenesis by Targeting NUDT21,80
989,Flavin-containing Monooxygenase (FMO3) Links the Gut and Fibrosis in Systemic Sclerosis,87
990,Non-canonical WNTA Promotes Cytoskeletal Rearrangement and Integrin Alpha V Clustering via JNK and ROCK to Control the Activation of Latent TGFβ,144
991,GRB2 Serves as a Viable Target Against Skin Fibrosis in Systemic Sclerosis by Regulating Endothelial Cell Apoptosis,115
992,Effects of B Cell Depletion by CD19-targeted CAR-T Cells in a Murine Model of Systemic Sclerosis,96
993,Rationale for Targeting Insulin-like Growth Factor Signalling in Systemic Sclerosis,83
994,Shared Genetic Susceptibility Between Systemic Sclerosis and Primary Biliary Cholangitis: Analyses from Genome-Wide Association Studies,135
995,Redirecting Macrophage Immunophenotype Attenuates Inflammation and Fibrotic Activation in Systemic Sclerosis,108
996,MiR-3606-3p Alleviates Skin Fibrosis by Suppressing Fibroblast Inflammation and Migration via Inhibiting GAB1 and ITGAV,119
997,Transcriptomic Analysis of Scleroderma Monocytes Identifies Distinct Clinically Relevant Clusters and Novel Genes Associated with Disease Complications,151
998,Topological Proteomic Differences in Fibrotic and Unaffected Skin in Scleroderma,80
999,Anti-Topoisomerase Antibody in dcSSc: Unravelling Its Intracellular Effects in Systemic Sclerosis,97
1000,Systemic Sclerosis (SSc) Dermal Fibroblasts Show Shortened Primary Cilia Due to Aberrant Aurora a Kinase Activation Independently of Transforming Growth Factor β Signalling,172
1001,"Comparing Predictors of DAPSA28, DAPSA66/68 and DAS28-CRP Remission at 6 Months in Bio-naive Patients with Psoriatic Arthritis Initiating a TNFi in Clinical Practice – Results from the EuroSpA Collaboration",206
1002,The Burden of Oligoarticular Psoriatic Arthritis in the United States,69
1003,Overall Survival in Patients with versus Without Rheumatoid Arthritis Initiating Immune Checkpoint Inhibitors for Metastatic Non Small Cell Lung Cancer,151
1004,Risk of Incident Heart Failure and Heart Failure Subtypes in Patients with Rheumatoid Arthritis,95
1005,Tumor Necrosis Factor-α Inhibitors Reduces Obstructive Sleep Apnea in Patients with Juvenile Idiopathic Arthritis: A Population-based Cohort Study,146
1006,Comparison of Survival on Treatment and Severe Infection Among New Users of Biosimilar vs. Originator Biologics in Inflammatory Arthritis: Population-based Evidence from a Natural Experiment Due to a Policy Change,213
1007,Network Meta Analyses of the Effectiveness and Safety Profiles of Janus Kinase Inhibitors and Biologic Agents in Treating Children with Non-systemic Juvenile Idiopathic Arthritis (nsJIA),186
1008,Increased Incidence of Inflammatory Arthritis After COVID-19 in a Colombian Population,86
1009,Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis,173
1010,Validation of Boolean 2.0 Criteria for Assessing Remission and Predicting Quality of Life in Korean Patients with Rheumatoid Arthritis Undergoing Targeted Therapy,162
1011,Association of HLA-DRB1 Alleles with Ischemic Events and Mortality in a Multi-ethnic Community-living Population,112
1012,Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis,85
1013,Prevalence of Arthritis in the United States: National Estimates from a Population-based Study,94
1014,Identifying Important Clinical Features for Predicting Remission in Patients with Rheumatoid Arthritis Treated with Biologics Using Machine Learning Model,154
1015,Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases,116
1016,Temporal Trends in Incidence Rates of Seropositive and Seronegative Rheumatoid Arthritis: A Danish Nationwide Population-based Study,132
1017,Time Trends in Overall Infection Risk in Patients with Inflammatory Arthritides Treated with Tumor Necrosis Factor Inhibitors,125
1018,Systemic Autoimmune Rheumatic Diseases (SARD) in the Agricultural Health Study Cohort: Rates of Rheumatoid Arthritis (RA) and Other SARD Among Medicare-linked Participants,171
1019,"Association Between Disease-modifying Anti-rheumatic Drugs and Short-term Outcomes of Dengue: A Population-based, Cohort Study",126
1020,"Factors Associated with 5-year Mortality in Patients with Rheumatoid Arthritis Initiating Their First Biological or Target Synthetic DMARDs: A Nationwide, Population-based Cohort Study of 12,612 Patients",203
1021,Assessing the Value of Comorbidity Clusters in Predicting Clinical Outcomes in Rheumatoid Arthritis: A Machine Learning Approach Using a Very Large US Registry,159
1022,Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea,126
1023,Risk Factors and Predictors of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis: Data from the Mexican Adverse Events Registry (BIOBADAMEX),155
1024,Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX),148
1025,Rheumatoid Arthritis and Risk of Migraine: A Population-based Nationally Representative Cohort,94
1026,Association of Treatment and Disease Activity with Antibiotic Use and Hospitalized Infection Among People Living with Rheumatoid Arthritis: Baseline Data from a Longitudinal Study in the ArthritisPower Registry,210
1027,Trends in Arthroplasty Utilization for Inflammatory Arthritis Including Rheumatoid Arthritis and Spondyloarthritis in China: Analysis of a Large National Database,162
1028,Association Between Metabolic Syndrome and the Presence of Enthesophytes on Musculoskeletal Ultrasound Compared to Joint X-ray,126
1029,Successful Implementation of a New Patient Video Triage Program,63
1030,Narrative Medicine and Pediatric Rheumatology: Addressing Burnout and Bias,74
1031,Rheumatoid Arthritis Early Diagnostic Clinic: A Web-based Referral Tool Serving Ethnic Minority Patients,104
1032,Will Patients Engage with Digital Technologies as Part of Routine Healthcare?,77
1033,"Impact of Depression on Healthcare Utilization in Members with Underlying Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus",148
1034,Barriers and Facilitators for Osteoporosis and Sarcopenia Care for Persons Living with HIV in Peru: HIV Physician and Coordinator Perspectives,142
1035,"Race, Payer, and Hospital Factors Are Associated with Post-primary Total Hip Arthroplasty Healthcare Utilization",112
1036,Incorporation of Social Drivers of Health Screening into a Structured Healthcare Transition Program for Adolescents and Young Adults with Chronic Rheumatic Disease,163
1037,Distance Not Travelled in a Tele-Rheumatology Shared Care Model: Leveraging the Expertise of an Advanced Clinician Practitioner in Arthritis Care (ACPAC)-trained Extended Role Practitioner (ERP) in Rural-remote Ontario,218
1038,Optimizing Rural Rheumatology Access: Collaborative Tele-Health Clinic Between University of North Carolina and Piedmont Health 1 Year Extension and Opportunities for Improvement,178
1039,A Multidisciplinary Obstetric-Medicine/Rheumatology Specialty Clinic in the United States: A Five Year Analysis,111
1040,Telerheumatology Shared-Care Model: Leveraging the Expertise of an ACPAC-Trained Extended Role Practitioner (ERP) in Rural-Remote Ontario,137
1041,"Telemedicine for Rheumatology Care: A Randomized, Single-Blind, Parallel Group, Noninferiority Trial",100
1042,Use of Implementation Strategies to Promote Adherence of Knee Osteoarthritis Guidelines and Improve Patient Outcomes: A Systematic Review,137
1043,Telehealth Conversion: A Strategy for Optimizing Ambulatory Access,66
1044,Identifying Inflammatory Arthritis Ambulatory Care Service Model Enhancements Needed to Reduce Avoidable Emergency Department Use,129
1045,More Implementation Strategies Are Not Associated with Better Implementation Outcomes: Implementing the Lupus Patient Decision Aid,130
1046,Advanced Clinician Practitioners in Arthritis Care: A Workforce Profile,71
1047,A Rheumatology Model of Care Re-design: Integrating the Advanced Practice Provider,82
1048,Leveraging Cues and Rewards to Form Habits to Improve Medication Adherence in Gout: An Adaptive Behavioral Pilot Trial,118
1049,Implementation of a Rheumatology-Based Social Determinants of Health Screening Program to Uncover and Address Needs in a Multihospital Health Care System,153
1050,Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Therapy and Subsequent Referrals to Rheumatologists at a Private vs Public Medical Center in Los Angeles: Ramifications for Health Disparities,220
1051,Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives,135
1052,Cost-related Medication Burden for Patients with and Without Systemic Autoimmune Rheumatic Diseases,99
1053,"Cross Country Differences in b/tsDMARD Prescription Behavior: Associations Between Socioeconomics, Real World b/tsDMARD Use and Disease Outcomes",144
1054,Recognizing Rural Healthcare Disparities in Pain Assessment for Autoimmune Rheumatologic Diseases,97
1055,Association of Historical Redlining and Present-Day Neighborhood Inequities with Missed Outpatient Appointments Among Individuals with Rheumatic Conditions,155
1056,An Increase in Safety Outcome Trials and the Issue of Informed Consent,70
1057,Racial Disparities Between Black and White Patients in Joint Replacement Surgery: A Systematic Review,101
1058,Lower Rates of Statin Therapy Initiation in Dermatomyositis/Polymyositis vs. Rheumatoid Arthritis Patients with Hyperlipidemia: A Multicenter USA-Based Study (2018-2023),169
1059,Characterization of Phenotypic Differences in IgG4-Related Disease Across the Sexes,83
1060,"Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry",150
1061,Embedding Treat to Target Principles in Rheumatoid Arthritis Patient Education in Routine Care of Ethnic Minority Patients,122
1062,Patients’ Barriers to Total Joint Arthroplasty: Associations with the Orthopedic Consultation,93
1063,Single-Payer Health Insurance May Not Mitigate Income-Based Differences in Total Hip Arthroplasty Utilization: A Transnational Analysis,135
1064,Barriers to Total Joint Arthroplasty for Patients Residing in High-Poverty Communities,86
1065,Social Determinants of Health in Children with Rheumatic Disease: A Single Center Cohort,88
1066,"Patterns in the Prescription, the Denials of Coverage, and the Delays in Dispensation of Janus Kinase Inhibitors",112
1067,Geographic Socioeconomic Influences on Disease Activity in Rheumatoid Arthritis in an Academic and Safety-Net Hospital System,125
1068,“Not of Your Ethnicity”: A Qualitative Study Exploring Diverse Patient Experiences in Axial Spondyloarthritis (axSpA),117
1069,The Detection of Subclinical Joint Inflammation by Thermal and Ultrasound Imaging at the Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis,153
1070,The Relationship Between the Extent of Ground Glass to Fibrosis Ratio and Treatment Response to Immunomodulatory Therapy in Three Separate Autoimmune Interstitial Lung Disease Cohorts,183
1071,Diagnostic and Educational Utility of an Ultrasound Protocol for Evaluation of Hand Pain in Systemic Sclerosis,110
1072,The Prevalence of Shoulder and Hip Joints Ultrasound Findings in Polymyalgia Rheumatica: A Multicenter International Study,122
1073,Dual Energy Computed Tomography (DECT) Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Intensive Urate-Lowering Therapy,142
1074,Improved Assessment of Structural Damage in the Spine in Patients with Axial Spondyloarthritis by MRI-based Synthetic CT: A Comparison with Low-dose CT and X-ray,161
1075,Cross-Sectional Associations of Ultrasound Features with Symptom Outcomes at the Knee: A Community-based Study,110
1076,Impact of Ultrasound Limitation to Assess Aortitis in Patients with Giant Cell Arteritis: Comparative Study with FDG-PET/CT,123
1077,Efficacy of Apremilast on Peripheral and Axial Inflammation in Patients with Psoriatic Arthritis Based on Whole-Body Magnetic Resonance Imaging,143
1078,B-line of Lung Ultrasound Reflects Different Morphological Features on Chest HRCT Between Interstitial Lung Disease Associated with Systemic Sclerosis and Myositis,163
1079,Comparison of Optical and Ultrasound Imaging in Lupus Arthritis,63
1080,Prevalence and Distribution of Sonographic Elementary Lesions in PsA – Results of 2 Cohorts,91
1081,Ultrasound Findings in Patients with Difficult to Treat Rheumatoid Arthritis,76
1082,The Level of RF or Anti-CCP Antibody Affect Ultrasound Synovial Findings in Patients with Rheumatoid Arthritis?,111
1083,Infrared Thermography Imaging Discriminates Between Inflamed and Non-inflamed Joints,84
1084,The Prediction of Response to Advanced Therapies on a Joint Level in Rheumatoid Arthritis: The Interpretation of Tenderness and Doppler Ultrasound,146
1085,Enhanced Diagnostic Confidence with High Frequency Temporal Artery Ultrasound in Diagnosis of Cranial Giant Cell Arteritis (GCA),128
1086,Diagnostic Accuracy of Lung Ultrasound for Detecting Interstitial Lung Disease Among Patients with Systemic Sclerosis: A Comparative Study of Two Scanning Protocols,164
1087,Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis,97
1088,Unique Cellular and Autoantibody Signatures in Patients with irAEs Revealed by Longitudinal Immune Tracking,107
1089,Outcomes of Immune Check Point Inhibitor Use in US Veterans with Pre-Existing Inflammatory Muscle Disease,105
1090,Immune Checkpoint Inhibitor Induced Polymyalgia Rheumatica Demonstrates a Similar Scintigraphic Appearance to Classical Polymyalgia Rheumatica on 18F-Fluorodeoxyglucose PET/CT,175
1091,Cancer Outcomes in Cancer Patients with Immune Checkpoint Inhibitor-induced Inflammatory Arthritis Treated with Glucocorticoids: Data from the CanRIO Retrospective Cohort,170
1092,Immune Checkpoint Inhibitor Rechallenge in Patients Who Previously Experienced Immune-Related Inflammatory Arthritis: A Multicenter Observational Study,151
1093,Melanoma and Combination Immune Checkpoint Inhibitors Are More Clearly Associated with the Development of Chronic Inflammatory Arthritis Than Pre-existing Autoimmune Disease: A Cross-Sectional Study of Administrative Health Data,228
1094,Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors,135
1095,Identification of Patients with Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis Using Medicare Claims Data,120
1096,Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors,100
1097,Vasculitis as an Immune-Related Adverse Event: Unraveling the Complexities at the Intersection of Immunology and Vascular Pathology,131
1098,Antiretinal Autoantibodies in Hydroxychloroquine Eye Toxicity,61
1099,Impact of Aging on Rheumatic Immune-related Adverse Events Secondary to Immune Checkpoint Inhibitors: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO),189
1100,Seroconversion Rates in Rituximab-Treated Rheumatic Patients Receiving COVID-19 Vaccination,91
1101,Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs,70
1102,"Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples",163
1103,A Comparison of Joint Involvement Patterns in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Rheumatoid Arthritis,129
1104,Multidisciplinary Prospective Study of Patients Treated with Immune Checkpoint Inhibitors Who Developed Rheumatic Immune-related Adverse Events,143
1105,Exploring the Risk of Demyelination Associated with TNF Alpha Inhibitors: Analysis of the FDA Adverse Event Reporting System (FAERS),132
1106,Safety of DMARDs in Rheumatologic Immune-related Adverse Events Associated with Immune Checkpoint Inhibitors: Data from a Monocentric Cohort in Hospices Civils De Lyon,167
1107,No Increase in Mortality in US Veterans with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors (ICIs),114
1108,Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors,88
1109,Risk of Inflammatory Central Nervous System Diseases Among New Users of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs,141
1110,"Baseline Clinical Features, but Not Shared Epitope or HLA B27, Predict Severe Outcomes for Immune Checkpoint Inhibitor-induced Inflammatory Arthritis",149
1111,Impact of Immunosuppression on the Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Rheumatic Autoimmune Disease: Experience from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO),221
1112,Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study,127
1113,Anti-drug Antibodies Formation During Tapering and Stopping of Methotrexate in Rheumatoid Arthritis Patients with Longstanding Use of Adalimumab,144
1114,Outcomes of COVID-19 Infection in Hospitalized Autoimmune Patients and Transplant Patients on Immunosuppression,111
1115,Identification of Immune Checkpoint Inhibitor-Induced Myositis Patients Using Electronic Health Records Is Most Successful When Employing Multiple Data Elements,160
1116,Prevalence and Incidence of Paradoxical Side-effects of TNF-α Inhibitors: A Cross-sectional Study,97
1117,Clinical Consequences of Infliximab Immunogenicity and the Impact of Proactive Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial,157
1118,Reducing No-shows and Late Cancellations at an Academic Medical Center Subspecialty Clinic,90
1119,A Patient-Centered Approach to Increase Herpes Zoster Vaccination in Patients on Janus Kinase Inhibitors: A Fellowship Quality Improvement Initiative,149
1120,Identifying and Addressing Disparities in Health Literacy in Patients with Rheumatic Diseases Through Point of Care Distribution of Patient Education Materials,159
1121,Utilizing a Maintenance of Certification (MOC) Part 4 Quality Improvement Project to Improve Data Completeness in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry,189
1122,Increase Shingrix Vaccination Rate in Patients on JAK Inhibitors: A Quality Improvement Project at the Rheumatology Practice of an Urban Institution,148
1123,Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach,140
1124,Improving JIA Outcomes Assessments in a Large Pediatric Rheumatology Practice: A Fellow Quality Improvement Project,115
1125,Improving Recombinant Zoster Vaccination Rates Among Immunosuppressed Veterans in an Academic Rheumatology Clinic,113
1126,Improved Patient and Team Satisfaction and Pharmacy Outcomes After Implementing a Rheumatology Clinical Pharmacist in a Large Academic Medical Center,149
1127,Prevalence of Loss to Follow up of Systemic Lupus Erythematosus Patients and Its Effect on Quality of Care,106
1128,Improving Screening of Lupus Nephritis in Patients with Systemic Lupus Erythematous,83
1129,Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases,166
1130,"“Lupus Doesn’t Have Me, I Have Lupus” a Patient Centered Quality Improvement Project to Increase Medication Adherence for Patients with Lupus Nephritis",151
1131,Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures,124
1132,"A Quality Improvement Project About Medication Adherence to Understand What Questions Rheumatology Patients Have About Their Medications, and How They Answer Them",162
1133,Improving Vaccine Uptake of the Pneumococcal 20-valent Conjugate Vaccine (PCV20) in Young Rheumatic Disease Patients Using a Brief Intense Partnership Program,158
1134,Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis,97
1135,Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder,108
1136,A Comparison of Characteristics of Patients with Crystalline and Septic Arthritis Confirmed by Synovial Fluid Analysis: Towards the Development of a Diagnostic Rule,164
1137,Systemic Inflammation Associated with Silent Deposition of Monosodium Urate Crystals in Asymptomatic Hyperuricemia,114
1138,Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME),131
1139,Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy,71
1140,"Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial",241
1141,Effects of Uric Acid Lowering Treatment on Vascular Stiffness in Gout Patients,78
1142,Monosodium Urate and Calcium Pyrophosphate Crystal-induced Inflammation Relies on Cell Volume Regulation and LRRC8/VRAC Channel Activation,138
1143,Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy,104
1144,Minimal Clinically Important Difference (MCID) of Quality of Life Assessments in Patients with Uncontrolled Gout,112
1145,"Genetic Risk Variants in Hyperuricemia and Gout: Common Disease, Multiple Common and Rare Variant Hypothesis",108
1146,Pharmacokinetics and Pharmacodynamics of AR882 Following 12-Week Treatment in Patients with Gout,96
1147,Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis,110
1148,"AR882, a Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses",102
1149,Comparing a Capillary Urate Point-Of-Care Device to Standard Laboratory-based Serum Urate Test for Dose Titration in Gout Patients,130
1150,Role of Dual-energy Computed Tomography (DECT) in Detection of Carotid Artery Monosodium Urate Deposition in Patients with Gout,127
1151,EULAR Recommendations for the Use of Imaging in the Diagnosis and Management of Crystal-induced Arthropathies in Clinical Practice,130
1152,The Current State of Sodium-Glucose Cotransporter Type 2 Inhibitor Use Among Patients with Gout at a Tertiary Academic Healthcare System,136
1153,Serum Urate Change Among Gout Patients Initiating Sodium-Glucose Cotransporter Type 2 Inhibitors (SGLT2i) vs. Sulfonylureas: A Comparative Effectiveness Analysis,161
1154,"The Nomenclature of Calcium Pyrophosphate Deposition (CPPD) Disease – Results of a Systematic Literature Review for the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) CPPD Nomenclature Project",212
1155,Preliminary Descriptive Analysis of the RADIAL Cohort Study About the Prevalence and the Clinical Characteristics of Patients with CPPD in Daily Clinical Practice,162
1156,"Target Serum Urate Levels, Recurrent Gout Flare Rates, and Gout-Primary Hospitalizations: Nationwide Prospective Cohort Study of 3,613 Gout Patients",148
1157,Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials,127
1158,The Tophus Impact Questionnaire (TIQ-20): Responsiveness to Change During Urate-Lowering Therapy,96
1159,Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016,111
1160,"A Double-blind, Placebo-parallel Controlled Phase III Clinical Study of the Efficacy and Safety of Hemay005 Tablets in Patients with Moderate to Severe Chronic Plaque Psoriasis in China",185
1161,A Rheumatologic Clinical Profile of the VEXAS Syndrome: Results from a Survey Conducted Among Rheumatologic Units of 126 Hospitals Across Spain,143
1162,Identification of Clinical Phenotypes in Behçet’s Disease Using a Cluster Analysis,82
1163,Factors Associated with Vision-Related Quality of Life in Patients with Non-infectious Uveitis: A Longitudinal Analysis,119
1164,Refractory Inflammatory Ocular Pathology and Treatment with Janus Kinase Inhibitors. Multicenter Study and Literature Review,124
1165,Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study,146
1166,Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI,109
1167,Clinical Phenotypes of IgG4-related Disease in a Multi-ethnic Singapore Cohort,78
1168,"Preclinical Profiles of FZ007-119, a Highly Potent and Selective Tyk2 Inhibitor, for the Treatment of Immune Mediated Inflammatory Diseases",139
1169,Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center,160
1170,Pilot Study Investigating Adenosine Deaminase-2 as a Disease Activity Biomarker for Cardiac Sarcoidosis,103
1171,The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients,98
1172,"Challenges in Diagnosing VEXAS Syndrome: Delayed Diagnosis, Misdiagnosis, and Associations with Specific Gene Mutations",119
1173,Association Between Nailfold Videocapillaroscopy Findings and sKL-6 Levels in Patients with Idiopathic Inflammatory Myopathies–Related Interstitial Lung Disease,160
1174,Nailfold Capillaroscopy Findings in Patients with Idiopathic Inflammatory Myopathies and Its Association to Autoantibodies,122
1175,From Skin to Bone Lesions: A Pioneer Study Unraveling the Underdiagnosis of SAPHO Syndrome in the Dominican Republic,116
1176,"Inflammation Is More Prominent Than Joint Damage at Initial Visits of Patients with Inflammatory Arthritides, but Organ Damage Is More Prominent and Patient Distress Is as Prominent as Inflammation in Overall Rheumatology Care: Data from a Feasible Physician RheuMetric Checklist",279
1177,COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience,164
1178,A Retrospective Analysis of Radiographic and Serologic Findings in Patients with Scleroderma and Interstitial Lung Disease,122
1179,Nationwide Analysis of Adult-Onset Still’s Disease with and Without Hemophagocytic Lymphohistiocytosis,102
1180,Deucravacitinib in Plaque Psoriasis: Maintenance of Response over 3 Years,73
1181,Human Cardiovascular Disease Model Provides Transcriptomic Evidence of Cardiovascular Risk Associated with Febuxostat,117
1182,Gene X Environment Paradigm: Exemplified by Selected Cases of Autoinflammatory Diseases,87
1183,"Blood-Based Biomarkers of Inflammation and Tissue Remodeling Can Discriminate Between Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis and Are Associated with Hand Function",180
1184,A Comparative Study of Clinical Phenotype in Relation to NOD2 Sub-genotypes in Yao Syndrome,91
1185,Tumor Necrosis Factor Inhibitors as First Line Steroid-Sparing Therapy for Neurosarcoidosis: A Case Series,106
1186,A Comparative Study of Cryofibrinogenemia Before and After COVID-19 Era,71
1187,Revised IWOS Criteria for Ocular Sarcoidosis: A 2019 Review of the 2009 Criteria in a Study of 384 Patients from a Single University Hospital,141
1188,"Relation Between Positive MPO-ANCA Antibodies And: Associated Diseases, Anca-associated Vasculitis Specificty, Severity and Prognosis. Study from a Single University Hospital",174
1189,Unmasking SAPHO: A Case Series Revealing the Clinical Spectrum and Treatment Approaches,87
1190,Clinical Presentation of IgG4-Related Disease. Single Referral Hospital Experience and Literature Review,104
1191,Identification of Serum Biomarkers Associated with Muscle Damage Detected on MRI in Polymyositis/dermatomyositis,112
1192,Presentations and Outcomes of Idiopathic Inflammatory Myopathies in Hong Kong,77
1193,"Experience of Pain in Adults with Idiopathic Inflammatory Myopathies, Myositis",78
1194,Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection,77
1195,Expanded Cytotoxic CD8+ T Cell Clones Characterize the Blood of Inclusion Body Myositis Patients,96
1196,Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease,136
1197,Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models,197
1198,Serial Imaging Changes in Skeletal Muscle Composition and Their Association with Clinical Outcomes in Idiopathic Inflammatory Myopathies,136
1199,Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort,152
1200,Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study,132
1201,Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America,201
1202,Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020,110
1203,"Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)",206
1204,Evaluation of Agreement Between Functional and Radiological Changes in Idiopathic Inflammatory Myositis (IIM) Associated Interstitial Lung Disease (ILD),152
1205,All-cause Mortality and Risk Factors for Death in a Large Multi-center Prospective Registry Cohort of Idiopathic Inflammatory Myositis in China,143
1206,Damage Accrual in Idiopathic Inflammatory Myopathies: Data from a Monocentric Cohort and Impact on Patients’ Quality of Life,124
1207,Cardiac Biomarkers Are a Useful Initial Screening Tool for Myocarditis in Patients with Idiopathic Inflammatory Myopathies,122
1208,Relapse Rate After Glucocorticoid-free Remission in Idiopathic Inflammatory Myopathies with Validation of the International Myositis Assessment & Clinical Studies Group (IMACS) Criteria for Remission and Relapse,211
1209,Prognostic Biomarkers and Radiological Features of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease,120
1210,Anti-HMGCR Immune-mediated Necrotising Myopathy: Calculation of Incidence and Confirmation of Low Malignancy Risk in Two Independent Cohorts. a Retrospective Case Review,169
1211,Inclusion of All Myositis Specific Autoantibodies or Other Rashes Leads to Better Sensitivity but Lower Specificity of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis,186
1212,Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis,161
1213,Anti-HMGCR Autoantibody Levels in the Follow-up of Statin-induced Immune-mediated Necrotizing Myopathy: Multicentric Study of 24 Patients,137
1214,Self-Perceived Knowledge of Myositis Among Social Media Respondents- a Pilot Study on Twitter,93
1215,Rituximab in the Treatment of Interstitial Lung Disease Associated with the Antisynthetase Syndrome,99
1216,Machine Learning Approach for the Prediction of anti-MDA5 Positive Dermatomyositis Mortality,92
1217,Real-World Myositis Antibody Frequency and Patient Awareness,60
1218,Treatment Trajectories and Patient Outcomes in Idiopathic Inflammatory Myopathies,81
1219,"CoLchicine for Treatment of OsteoArthritis of the Knee—Updated Data from a Double-blind, Placebo-controlled Trial",113
1220,A Wearable-Sensor for Assessment of Gait and Chair Stand Patterns in People with Knee Osteoarthritis: Validation and Responsiveness to Treatment of a Potential Digital Biomarker,177
1221,Soluble Buffered Alendronate After Denosumab Discontinuation in Erosive Hand OA Patients,88
1222,Presence of Erosions Is Not a Risk Factor for the Development of Knee OA in a Hand OA Population: The Framingham OA Study,121
1223,"Post-hoc Analysis of Individual Questions from the Australian/Canadian Osteoarthritis Hand Index from a Randomized, Double-blind, Placebo-controlled Trial of Patients with Hand OA",179
1224,Development of a Method to Isolate Functional Mitochondria and Assess Their Functionality and Integration in Joint Tissues: In Vitro and in Vivo Models,151
1225,Evaluating Neuropathic and Nociplastic Pain in Patients with Hip and Knee Osteoarthritis,88
1226,Worsening of Pain as Perceived by Patients Is Not Reflected by an Annual Standardized Questionnaire,99
1227,"A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Ascending-Dose Study Evaluating the Safety, Tolerability and Pharmacokinetics of XG004 Applied Topically in Participants with Osteoarthritis of the Knee",227
1228,Autoimmune Thyroid Disease Associates with Symptomatic Hand Osteoarthritis in Older Persons in the Third National Health and Nutrition Examination Survey,153
1229,The Association of Peak Forces and Loading Rates During Walking with MRI-Based Structural Worsening of the Knee: The Multicenter Osteoarthritis Study,149
1230,Extent of Subregional Involvement of Subchondral Bone Marrow Lesions in Incident Knee OA Is Associated with Weight-Bearing Knee Pain,132
1231,Relationship of Depth-Specific Subchondral Bone Mineral Density to MRI Cartilage Worsening: The Multicenter Osteoarthritis Study,128
1232,Association of Long-Term Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) with Worsening Symptoms and Structural Changes of Knee Osteoarthritis: An Individual Patient Data Meta-Analysis of Cohort Studies,208
1233,"Efficacy and Safety of a Single Intra-Articular Injection of MM-II, a Novel Suspension of Large, Empty, Multilamellar Liposomes, in People with Painful Knee OA: Results of a 26-Week, Phase 2b, Placebo-Controlled, Double-Blind, Randomized Trial",243
1234,Bicycling Is Not Associated with New Knee Pain or Disease Progression over 48 Months in Those with Knee Osteoarthritis: Data from the Osteoarthritis Initiative,159
1235,Association of Dipeptidyl Peptidase-4 Inhibitor Use for Type 2 Diabetes and Incidence of OA in Taiwan,101
1236,Self-Reported Effectiveness of Cannabis for Arthritis-Related Pain,66
1237,Frailty and Its Impact on Patient Reported Outcomes in Polymyalgia Rheumatica,77
1238,Goal Concordant Patient-clinician Dyads Have Higher Odds of Communication Around Rheumatoid Arthritis Goals,107
1239,Vaccination Against SARS-CoV-2 in Inflammatory Arthritis and Factors Determining Its Decision,93
1240,Understanding Community Perspectives on Disease Management: A Social Media Analysis of Gout Care Strategies,107
1241,Universal Social Determinants of Health Screening in a Pediatric Rheumatology Specialty Clinic: A Feasibility Study,115
1242,Self-Perceptions of Aging and Physical Activity in Older Adults with Arthritis: Does General Health Matter?,107
1243,Cardiovascular Mortality of Acute Myocardial Infraction and Acute Heart Failure Hospitalization in Rheumatic Diseases Patients Evaluation from the 2016-2020 National Inpatient Sample (NIS) Database,197
1244,Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study,102
1245,"The Role of Kinesiophobia on Ankylosing Spondylitis Disease Activity, Exercise Habits, and Quality of Life",106
1246,Assessing Patient-Reported Drug Efficacy and Adherence Among IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis,115
1247,Description of Self-Efficacy for Managing Symptoms and Emotions in a Large Rheumatology Clinic Population,105
1248,Racial Disparities in Comorbidities and Perception of Physical Health in Systemic Lupus Erythematosus,101
1249,Using Patient-Reported Disease Activity in a Population-Based Cohort to Predict Systemic Lupus Erythematous Hospitalization and Emergency Room Visits,149
1250,Using Patient Self-Reported Measures to Predict All-Cause Hospitalization in a Population-Based Lupus Cohort,108
1251,Efficacy of Pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases,200
1252,"“I Call It Zombie Hands and Feet, That’s Actually How I Found out I Had This Disease”: Disease Symptoms and Treatment Side Effects in a Diverse Sample of Patients with Early Limited Cutaneous and Diffuse Cutaneous Systemic Sclerosis",232
1253,"Sex Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey",146
1254,"Discovering the Potential Application of Digital Biomarkers for Inflammatory Arthritis Patients, a Design Thinking Approach; Preliminary Results of the Patients’ Perspective",173
1255,Patient Experience of Brain Fog to Inform the Development of a De Novo Patient Reported Outcome (PRO) in Patients with Sjögren’s Disease,136
1256,Sjögren’s Patients’ Experiences and Content Validity of the Dry Eye Disease Symptom Questionnaire (DED-SQ),106
1257,Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis (JDM),93
1258,The Association Between Gingival Inflammation and Clinical Signs of Active Juvenile Dermatomyositis (JDM),105
1259,Extracorporeal Life Support for Childhood-Onset Systemic Lupus Erythematosus: An ELSO Registry Analysis,103
1260,Mental Health Screening Follow-Up in the Childhood-Onset Systemic Lupus Clinic,78
1261,Nailfold Video Capillaroscopy and Its Association with Autoantibodies and Rheumatic Diseases in Pediatric Patients,114
1262,Examining the Relationship Between Socioenvironmental Factors and Cognitive Functioning in Youth with Childhood-Onset Systemic Lupus Erythematosus,146
1263,Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus,99
1264,Validation of the PEDiatric Behçet’s Disease Classification Criteria (PEDBD): An International Consensus-based Approach,119
1265,Longitudinal Assessment of Self-reported Executive Function in Youth with Childhood-Onset Lupus,95
1266,Differences in Nailfold Capillary Morphology Distinguish Juvenile Dermatomyositis Patients That Are Myositis-Specific Autoantibody Positive,139
1267,Successful Implementation of a Mental Health Screening Program for Youth with Juvenile Dermatomyositis,102
1268,"Improvement Across Organ System, Physician and Patient Reported Outcome Measures over a 36-time Period in the Juvenile Systemic Scleroderma Inception Cohort",156
1269,The Pattern of Medication Use Significantly Changed over 36 Months Observation Period. Result from the Juvenile Scleroderma Inception Cohort,140
1270,Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity,165
1271,Apparent Diffusion Coefficient (ADC) from Diffusion Weighted Imaging (DWI) as an Objective Tool to Differentiate Normal Maturational Subchondral Signal from Inflammation at the Sacroiliac Joint in Youth,202
1272,Melanoma Differentiation-Associated Protein-5 in Juvenile Dermatomyositis: A Single Center Cohort,97
1273,The Associations Between Depressive Symptoms and Executive Function and Academic Outcomes in Children with SLE,110
1274,Prevalence of Celiac Disease Among Children and Adolescents with Systemic Lupus Erythematosus (SLE),99
1275,Clinical Manifestations and Management of Takayasu Arteritis: A Multicenter Pediatric Cohort,92
1276,Obvious Only in Retrospect: A Cohort of STING Associated Vasculopathy in Infancy (SAVI) Without Typical Rash,108
1277,Adverse Childhood Experiences in a Paediatric Systemic Lupus Erythematosus Cohort,81
1278,Agreement Between Parent- and Self-Report of Executive Function in Adolescents with Childhood-Onset Systemic Lupus Erythematosus,128
1279,Tubulointerstitial Inflammation Is Associated with End-Stage Renal Disease in Pediatric Lupus Nephritis: A Single Center Retrospective Cohort Study,147
1280,Characterizing Lupus in African American Children in Southern United States,75
1281,Evaluating a Diagnostic Algorithm for Childhood Sjögren’s Disease,65
1282,Assessment and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis,85
1283,"Pharmacokinetic, Pharmacodynamic, and Safety Profile of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: Analysis of Data from a Multicenter, Open-Label Trial",189
1284,Thrombotic Manifestations in Pediatric Behçet Disease Patients: A Multicentre Comparative Study from EUROFEVER Registry,119
1285,Cross-Sectional Associations of Emotional Distress and Cardiovascular Health in Juvenile Lupus and Dermatomyositis,114
1286,Local Inflammatory Response Mediated by the Homing of Tfh17 Cells Is Involved in Tissue Injury of Immunoglobulin a Vasculitis,125
1287,Neurologic Manifestations of Pediatric Sjogren’s Disease Patients: Case Series from an Academic Children’s Hospital,115
1288,Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?,123
1289,The Novel Florida Scoring System: A Machine Learning-Based Stratification of Clinical and Laboratory Features in Children with Suspected Sjögren’s Disease,154
1290,Outcome of Pediatric Lupus in South Asia: Data from Indian SLE Inception Cohort for Research (INSPIRE),102
1291,Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort,116
1292,Self-esteem and Body Image of Young People with Rheumatic Diseases: A Systematic Review,87
1293,The Psychological Experience of Work for People with Inflammatory Arthritis (IA),80
1294,“What Is My Risk Really?”: A Qualitative Exploration and Ideal-Type Analysis of Preventive Interventions Among Individuals at Risk of Rheumatoid Arthritis,154
1295,Voices Unheard: Unmasking the Hidden Challenges of Youth with Rheumatic Diseases,80
1296,Optimal Approaches for Reducing Depressive Symptoms in Rheumatoid Arthritis Patients Based on Psychological Interventions: A Systematic Review and Network Meta-analysis,168
1297,Network Analysis of Depression and Anxiety Symptoms in Chinese Rheumatoid Arthritis Patients,92
1298,“Somebody Who’s Been There and Can Understand the Challenges That You’re Going Through”: Participant Perspectives of a Resilience-Based Energy Management Online Intervention for Systemic Sclerosis with Peer Health Coaches,221
1299,Depression and Anxiety Risk Assessment in Patients with Rheumatic Diseases,74
1300,Nomination of Biomarkers for Self-testing Disease Activity in Rheumatoid Arthritis Using Patient Similarity Networks: A Pilot Study,131
1301,Changes in the Endocannabinoid Tone in Rheumatoid Arthritis and Osteoarthritis – Discovery of a Novel Target for the Treatment of Pain and Inflammation?,152
1302,The Anti-inflammatory Effect of High-density Lipoprotein Is Blunted by Delivery of Altered MicroRNA Cargo to Macrophages in Patients with Rheumatoid Arthritis,158
1303,Lower Herpes Zoster Rate of Tocilizumab and Tofacitinib in Patients Undergoing Treatment for Rheumatoid Arthritis,113
1304,Clinical Characteristics of Patients with Rheumatoid Arthritis (RA) Who Rate Their Global Assessment of Disease Activity Substantially Lower Than Their Physicians (Negative Discordance) Based on a Large RA Database in Japan: A Rare but Important Subgroup,254
1305,"The Impact of Sex, Serostatus, and Smoking on Risk for Rheumatoid Arthritis-associated Interstitial Lung Disease Subtypes",121
1306,Identification of Subclinical Atherosclerosis by Six Cardiovascular Risk Calculators in Rheumatoid Arthritis Patients,117
1307,Upregulation of IFNγ-Response Genes in Monocytes and T Cells Identified by Single-Cell Transcriptomics in Patients with Anti-CCP Antibody-Positive Rheumatoid Arthritis (RA),172
1308,Immunomodulators and Risk for Breakthrough COVID-19 After a Third SARS-CoV-2 mRNA Vaccine Among Patients with Rheumatoid Arthritis: A Cohort Study,146
1309,Long-term Follow-up of Treated-to-target RA and UA: Results of the BeSt and IMPROVED Studies,92
1310,"Rheumatoid Arthritis Patients, Achieving Low Disease Activity State or Remission, Still Demonstrate Significant Hand Disability, as Assessed by Functional Dexterity Test: A Disconnection Between CDAI and Functional Hand Assessment",230
1311,Prevalence of Frailty Among Individuals Living with Rheumatoid Arthritis: A Population-based Cohort Study,105
1312,Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis,98
1313,Relationship Between Quality of Life and the Region of the Affected Joints in Japanese Patients with Rheumatoid Arthritis: A Cross-sectional Study,146
1314,Nature and Severity of Activity Limitations According to the Health Assessment Questionnaire Disability Index in Patients with Rheumatoid Arthritis and Functional Disability,173
1315,"What Is the Nature of Functional Problems in People with Rheumatoid Arthritis and Severe Disability; An Analysis Using the International Classification of Functioning, Disability and Health as a Reference",204
1316,"Systemic Inflammation Is Associated with Incident Valvular Heart Disease in Patients with Rheumatoid Arthritis: A Multicenter, Prospective Cohort Study",151
1317,Risk of Cancer in Patients with Rheumatoid Arthritis Under Tocilizumab: Data from the French National Registry REGATE,117
1318,Proteomic Signature in Peripheral Blood and Sputum in Rheumatoid Arthritis Patients with and Without Lung Involvement,117
1319,Atherogenic Index of Plasma Identifies Patients with Rheumatoid Arthritis and Increased Carotid Intima-Media Thickness,118
1320,Baseline Data’s Role in Predicting All-cause Mortality in Chinese Rheumatoid Arthritis Patients: Findings from the China Registry of Rheumatoid Arthritis (CREDIT) Study,168
1321,PROMIS Symptom Clusters Predict Disease Activity in the First 6 Months in Newly Diagnosed RA Patients Starting MTX Therapy: Data from the Canadian Early Arthritis Cohort,169
1322,Impact of Body Mass Index (BMI) on Upper versus Lower Extremity Joints Assessed Using Clinical and Musculoskeletal Ultrasound Measures in Rheumatoid Arthritis Patients,167
1323,Impact of Body Mass Index (BMI) on Rheumatoid Arthritis Disease Activity and Musculoskeletal Ultrasound Measures,112
1324,Frailty Is Associated with Higher Risk of Readmission in Patients with Rheumatoid Arthritis,91
1325,Increases in Serum Levels of Tartrate-Resistant Acid Phosphatase 5b Reflected Radiographic Progression of Joint Damage in Treated Rheumatoid Arthritis,150
1326,Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis,68
1327,Risk Factors for Major Adverse Cardiovascular Events and Malignancies in Patients with Rheumatoid Arthritis in a Real-World Setting in Japan,140
1328,"Active Rheumatoid Arthritis Patients Exhibit an Altered Serum Lipidomic Profile Directly Linked to Disease Activity, Which Is Reversed by Biologic and Targeted Synthetic DMARD",175
1329,Single Camera Hand Motion Capturing as a Digital Biomarker for Disease Activity in Rheumatoid Arthritis Using Computer Vision: The Proof-of-Concept MeFisto Study,161
1330,Patient Reported Outcome Measures for Rheumatoid Arthritis Disease Activity: Using Rasch Measurement Theory and Cognitive Interviewing to Achieve More Meaningful Measurement,173
1331,Having More Tender Than Swollen Joints Is Associated with Worse Functional Outcomes in Patients with Early RA in a Prospective Real-World Cohort,144
1332,Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study,110
1333,COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Rheumatoid Arthritis: Results from the COVAD Study,122
1334,Risk Factors Associated with Venous Thromboembolism in Rheumatoid Arthritis in Clinical Practice,96
1335,Rheumatoid Arthritis Patients Who Never Use a Biological During Their Disease Course Represent a Subgroup of Patients Likely to Achieve Sustained DMARD-free Remission,166
1336,Bone Marrow Edema in MRI Is More Associated with Rapid Radiographic Progression Than Clinically Relevant Radiographic Progression,129
1337,The Relationship Between Socioeconomic Factors and Persistent Active Rheumatoid Arthritis: Results from (NEIAA) a Large UK Cohort of Early Inflammatory Arthritis,161
1338,Biomarkers of Cardiovascular Risk in Patients with Rheumatoid Arthritis: Results from the TARGET Trial Biomarker Study,118
1339,Patient’s and Physician’s Evaluation of Global Assessment of Disease Activity over Follow up and Across Disease Activity Levels in Recent-Onset Rheumatoid Arthritis,164
1340,Window of Opportunity to Achieve Better Functional Outcomes in Patients with RA: Effectiveness of an Early Treatment Strategy,125
1341,Variations in Macrophage Cholesterol Loading over Time Are Linked to Dynamic Changes in Coronary Atherosclerotic Plaque in Rheumatoid Arthritis,143
1342,Statin Use Attenuates the Impact of Systemic Inflammation on Ischemic Cardiovascular Risk in Patients with Rheumatoid Arthritis,127
1343,Impact of Comorbidities on the First bDMARD Effectiveness and Retention Rate After 2 Years of Follow-up in Patients with Rheumatoid Arthritis. Data from the Spanish Registry BIOBADASER,184
1344,Certolizumab Pegol Shows Longer Retention Rate in Comparison with Other TNF Inhibitors in Patients with Rheumatoid Arthritis and High Rheumatoid Factor Titers at Baseline. a Multicentre and Retrospective Study,209
1345,Refractory RA Patients for Targeted Therapies in Real Life,58
1346,Comparison of Two Methotrexate Initiation Strategies in Rheumatoid Arthritis in Current Practice,96
1347,T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis,123
1348,Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry,216
1349,Remotely Supervised Weight Loss and Exercise Training Improves Disease Activity and Patient Reported Outcomes in Older Patients with Rheumatoid Arthritis,153
1350,Safety Results from a Phase 1 Double-blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early RA,117
1351,"Elevated Serum Adiponectin Levels During Olokizumab Treatment in Patients with Rheumatoid Arthritis Correlate with High-density Lipoprotein Lipid Profile Independently of Body Mass Index: Results from the Double-blind, Randomized Controlled Phase III Studies",258
1352,Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis,119
1353,Discontinuation of Biological Disease Modifying Drugs Due to Adverse Drug Reactions in an Inception Rheumatoid Arthritis Cohort,127
1354,Abatacept Modulates Both Global and Citrulline Specific T Cell Signatures: Results from Inhibition of Co-Simulation in Rheumatoid Arthritis Phase IV Trial,154
1355,Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients,125
1356,Evaluation of Circulating Levels of Helper T and Innate Lymphoid Cells Subsets in a Cohort of bDMARDs-naïve Patients with Rheumatoid Arthritis Treated with Abatacept,165
1357,"Effect of Subcutaneous Local Anaesthesia Prior to Intra-Articular Injection: An Open Label, Paired-group, Randomized Controlled Trial",133
1358,"Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models",145
1359,Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1,141
1360,"Previous History of Serious Infection Is Associated with the Use of IL-6 Inhibitors in Rheumatoid Arthritis in Wales, UK",120
1361,Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis with a Maximum Exposure of 8.3 Years,141
1362,Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 from the SELECT-CHOICE Study,158
1363,Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials,187
1364,"Switching Biologics or Janus Kinase Inhibitors Is Effective in Difficult-to-treat Rheumatoid Arthritis, Regardless of Inflammation",130
1365,"R851, a Potent Second Generation IRAK1 and IRAK4 Inhibitor Suppresses IL-6 in Vitro and in Vivo for the Treatment of Rheumatoid Arthritis",137
1366,"Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial",161
1367,Long-term Effectiveness of a Lifestyle Program for Rheumatoid Arthritis: One-year Follow-up of the “Plants for Joints” Randomized Clinical Trial,144
1368,"Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)",183
1369,Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset,162
1370,Comparison of Malignancies and Serious Infections Between Etanercept Biosimilar and Bio-Originator Initiators: Population-Based Analyses,136
1371,Effectiveness of Longstanding Exercise Therapy versus Usual Care in People with Rheumatoid Arthritis and Severe Functional Limitations: A Randomized Controlled Trial (L-EXTRA),175
1372,Adalimumab and Etanercept Serum Levels in Rheumatoid Arthritis Patients with and Without a Disease Flare During Tapering,120
1373,Effect of Tofacitinib Therapy on Angiotensin Converting Enzyme Activity in Rheumatoid Arthritis,95
1374,The Advantage of Tight Control and Treat-to-Target in New-onset Rheumatoid Arthritis Patients in Daily Rheumatology Practice: Results from a Contemporary University Clinic Inception Cohort,188
1375,Neutrophil Activation and Formation of Neutrophil Extracellular Traps Are Associated with Response to Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis,168
1376,Recent Trends in Treatment Patterns for Rheumatoid Arthritis in Response to Emerging Data,89
1377,Impact of Ultrasound on Physician Assessments of Patients with RA with Elevated Clinical Disease Activity Scores,112
1378,The Delivery of the Super-repressor IκBα by Exosomes Has the Potential to Alleviate Inflammation Associated with Rheumatoid Arthritis,133
1379,Cardiovascular (CV) and Malignancy Events in the Filgotinib Rheumatoid Arthritis (RA) Clinical Development Program up to 8.3 Years,130
1380,Efficacy and Safety of JAK Inhibitors in Difficult to Treat Rheumatoid Arthritis in Clinical Practice,101
1381,Maternal and Infant Outcomes Following Abatacept Exposure During Pregnancy,74
1382,"Semen Analysis of Patients with Psoriatic Arthritis, Axial Spondyloarthritis and Healthy Controls",97
1383,"Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination",196
1384,Reproductive Outcomes for Women with Vasculitis,47
1385,Paternal Effects of Anti-TNFs in Inflammatory Arthritis,55
1386,Identification of ACR Guidelines for SLE Pregnancy Care in the Electronic Health Record,87
1387,HPV Vaccination in Adolescent and Young Adult Patients Seen in an Academic Rheumatology Center,94
1388,Similar Delivery Outcomes in Pregnant Patients with and Without Takayasu Arteritis – A Nationwide Inpatient Database Study,122
1389,Sexual Dysfunction in Women with Systemic Lupus Erythematosus: A Cross-Sectional Multicentre Study,98
1390,The Impact of Pregnancy Intention on Depression and Quality of Life in Women with Lupus,87
1391,Delivering Care for Pregnant Women with Rheumatic and Musculoskeletal Diseases in Ireland: Current Challenges and Practices,123
1392,Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis,121
1393,Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review,113
1394,Experiences and Attitudes Related to Assisted Reproductive Technologies Among Women with Systemic Rheumatic Disease,115
1395,Association of Menstrual Cycles and Disease Flare Activity in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis,126
1396,Factors Associated with Medication-related Concerns in Women with Inflammatory Rheumatic Diseases – an Analysis of a Nationwide Pregnancy Cohort,144
1397,Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers,150
1398,Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs,103
1399,Plasma Neutrophil Extracellular Trap Remnant Levels Are Lower in Premenopausal Healthy Women Using Oral Contraceptive Pills,123
1400,Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus,109
1401,Extraglandular Involvement and Autoantibody Status as Risk Factors for Cardiovascular Disease in Primary Sjogren’s Syndrome (pSS): A 20 Year-follow up Study,156
1402,A Unique Cluster of Inflammatory Monocytes and Functionally Intact Regulatory T Cells in Rare Childhood Sjögren’s Disease,121
1403,Novel Autoantibodies Might Circumvent the Need for Labial Biopsy in a Subset of Seronegative Sjögren’s Disease Patients,119
1404,Development of the Sjögren’s-related Quality of Life (SRQoL) to Assess Health-related Quality of Life (HRQoL) in Sjögren’s,122
1405,"Treatment Patterns and Drivers of Biologic Prescriptions in Patients with Primary Sjögren’s Disease: Results from a Multinational, Real-World Survey",148
1406,Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration,122
1407,Are Ultrasound Salivary Parenchymal Abnormalities More Severe in Primary Sjögren Patients with a Higher Disease Duration ? A Cross-sectional International Study,160
1408,Obinutuzumab Efficacy and Tolerance in Patients with Auto-Immune Diseases Immunized Against Rituximab,101
1409,Deltex1 May Involve the Function of T Regulatory Cells and Regulate the Disease Activity of Sjögren’s Syndrome,110
1410,Interstitial Lung Disease Is Frequent in Primary Sjögren’s Syndrome and Is Associated with Reduced Survival,107
1411,The Relative Burden of Fatigue Is Associated with High TSH/fT4 Ratio in Korean Patients with Primary Sjogren’s Syndrome,119
1412,SJOGRENSER Registry: Prospective Evaluation of a Cohort of Patients with Primary Sjögren’s Syndrome After 8 Years of Follow-up,126
1413,Characterization of Pulmonary Manifestations of Sjögren Syndrome: A Multicenter Retrospective Study,99
1414,The UCSD Shortness of Breath Questionnaire Is a Useful Tool for the Assessment of Dyspnea in Primary Sjögren’s Syndrome Patients with Interstitial Lung Disease: A Monocentric Cross-Sectional Study,197
1415,"Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome",171
1416,Synergistic Dose Effects of Extra X Chromosome in Development of Sjogren’s Syndrome in Klinefelter and Triple X Syndromes,121
1417,Fatigue and Associated Factors in Patients with Primary Sjogren’s Syndrome Compared to Secondary Sjogren’s Syndrome,115
1418,Efficacy of Tofacitinib Immunotherapy Suppresses Tfh and Tph Cells in Patients with Primary Sjögren’s Syndrome,110
1419,Long-term Association Between Physical Activity and Global Functioning in Patients with axSpA: Results of a 2 Year Prospective Study,132
1420,Functional Status by Sex and Socioeconomic Status in Axial Spondyloarthritis,76
1421,Where Are We with Implementing Axial Spondyloarthritis Treatment Recommendations and Disease Activity Monitoring in Clinical Practice – Results of an Online Survey Amongst Rheumatology Care Providers,199
1422,Opioid Prescription Rates in Patients with Ankylosing Spondylitis in the UK Between 2001-2020: An Electronic Health Records (EHR) Analysis,138
1423,Power Doppler Musculoskeletal Abnormalities in Patients with Psoriasis at High Risk of Progression to Psoriatic Arthritis,121
1424,"Pain Mechanisms in Psoriatic Arthritis: Differentiating Inflammation Related Pain in Enthesitis Using Ultrasound, in Comparison to Functional MRI",145
1425,Low Spinal Radiographic Progression After a Mean of 15 Years of Follow-up in a Cohort of Patients with Axial Spondyloarthritis,126
1426,Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated with Secukinumab in Real World – Data from a German Observational Study,154
1427,Rates of Remission in Patients with Axial Spondyloarthritis Treated in Tertiary Care,84
1428,Improving the Diagnostic Accuracy in Axial Spondyloarthritis: Interim Results of a Nationwide Telemedicine Project,114
1429,Fully Automated Detection of Active Sacroiliitis in Patients with Axial Spondyloarthritis: A Machine Learning-Based Analysis Magnetic Resonance Image,149
1430,"Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study",196
1431,Aerobic Capacity and Its Relation to Disease Characteristics and Lifestyle Habits in Patients with Axial Spondyloarthritis,122
1432,Comprehensive Evaluation of the Digital Annular Pulleys: From Ultrasonographical to Anatomical and Histological Evaluation with Special Focus on the Entheses,157
1433,Sustainability of Clinical Response at Week 52 to Upadacitinib Among Patients with Axial SpA: Data from the SELECT-AXIS 1 and SELECT-AXIS 2 Trials,146
1434,A Deep Learning Algorithm for MRI Spinal Inflammation in Axial Spondyloarthritis,80
1435,Trends in Proportionate Cardiovascular Mortality in Patients with Ankylosing Spondylitis in the Era of Biologic Therapies: Analysis of US Death Certificate Data,160
1436,Achieving ASDAS Inactive Disease Status in Axial Spondyloarthritis: A Systematic Review and Meta-analysis,105
1437,The Association of 3VAS/4VAS and DAPSA with Radiographic Progression in Early PsA,81
1438,Exceeding Activity Targets but Missing the Mark with Sleep: Mapping 24-Hour Movement Guidelines in Axial Spondyloarthritis,122
1439,MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients,85
1440,Factor H-related protein-5 Exacerbates Pathological Bone Formation of Ankylosing Spondylitis,92
1441,Diagnostic Delay of Axial Spondyloarthritis in African American Patients,72
1442,Temporal Trends in Cardiovascular Events in Axial Spondyloarthritis Patients with Medicare Insurance versus Commercial Insurance: An Analysis Using Claims Data,159
1443,Defining Thresholds of Presenteeism Measures for Unacceptable Work Participation in axSpA,89
1444,Impact of Disease Activity on Functional Impairment in Patients with Spondyloarthritis Is Different According to the Degree of Radiographic Progression: Result from SNUH-AS Cohort,179
1445,Analysis of Soluble Biomarkers in Axial Spondyloarthritis,57
1446,The Use of the ASAS Referral Criteria Together with Increased Education and Training of Its Use Improves Delay to Diagnosis of Axial Spondyloarthritis,150
1447,Prevalence of Early Axial Spondyloarthritis in the Be-GIANT Cohort Based on the ASAS Consensus Definition of Early Axial Spondyloarthritis,138
1448,Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry,219
1449,Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST,148
1450,Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis,130
1451,Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD‑Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies,173
1452,Improvement of Work Absenteeism Following Start of Methotrexate Monotherapy in Newly-Diagnosed Psoriatic Arthritis,114
1453,Do Long-term Patient-reported Outcomes Improve Similarly in Psoriatic Arthritis and Axial Spondyloarthritis Patients Treated with Secukinumab? Results from the EuroSpA Collaboration,181
1454,"Efficacy of the Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active PsA: Results from a Phase 2 Trial",160
1455,"Impact of Psoriatic Arthritis Manifestations on Perception of Pain Improvement: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies with Guselkumab",180
1456,Changes in Serum Cytokines and Collagen Proteins Correlate with Durability of Guselkumab Efficacy and Continued Disease Improvement Through 2 Years in Patients with Active Psoriatic Arthritis,191
1457,Domains Impacting Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors Receiving Guselkumab (COSMOS),167
1458,Long-Term Safety of Risankizumab in Patients with Psoriatic Disease: Integrated Analysis of Psoriasis and Psoriatic Arthritis Clinical Trial Data,145
1459,Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial,174
1460,"Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients",282
1461,"Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis",216
1462,Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib,99
1463,"Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials",214
1464,"Guselkumab Provides Clinically Meaningful Improvents in Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Who Are Inadequate Responders to Tumour Necrosis Factor Inhibitors: Results Through One Year of a Phase 3b, Randomized, Controlled Study (COSMOS)",271
1465,"Longitudinal Evaluation of the Novel Psoriatic Arthritis 5-Thermometer Scale (PsA-5Ts) Domains During Treatment with Guselkumab: Pooled Analysis of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies",215
1466,A Proof-of-concept Study Evaluating the Use of Functional Brain Magnetic Resonance Imaging in Assessing Treatment Response in Psoriatic Arthritis Patients,154
1467,"Izokibep, a Unique IL-17A Inhibitor, Improves Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis up to Week 46 – Phase 2 RCT Results",151
1468,Experiences and Perspectives of Patients with Psoriatic Arthritis Participating in a Randomized Controlled Trial of Dietary Interventions,137
1469,Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies,195
1470,Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial,120
1471,Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients with Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 1 Trial,145
1472,"Secukinumab Demonstrates a Consistent Safety Profile in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Updated Pooled Safety Analysis from Clinical Trials",181
1473,"Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from a Phase 3, Active-Reference Study",226
1474,Efficacy of Guselkumab in Early-Onset and Late-Onset Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials in Patients with Active PsA,170
1475,Better Drug Retention on anti-IL17A Compared to Anti-TNF Therapy Despite Its Inferior Effect on Composite Joint Indexes and Quality of Life in Patients with PsA–analysis from the Czech Biologics Registry ATTRA,209
1476,Removal of Methotrexate in Patients with Active Psoriatic Arthritis with Newly Induced Ustekinumab Treatment Leads to a Delayed Response in DAPSA and DAS28 Within the First 16 Weeks,181
1477,Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial,193
1478,Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus,114
1479,Vasculitis Associations Among Patients with Systemic Lupus Erythematous,71
1480,Identifying Determinants of Favourable and Poor Physical Function in Systemic Lupus Erythematosus: Results from an International Collaborative Study,148
1481,SLESIS-R: An Improved Score for Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus Based on the RELESSER Prospective Cohort,150
1482,"Glucocorticoids Use Is a Major Driver of Self-perceived Depression in Systemic Lupus Erythematosus: Insights from a Large, Prospective and Multicenter Study Using RELESSERPROS Register’s Database",195
1483,Increased Left Ventricular Mass Index in Systemic Lupus Erythematosus Patients with Lupus Nephritis Compared to Those Without Nephritis,135
1484,Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients,153
1485,Evaluation of Progression from Preclinical to Systemic Autoimmune Rheumatic Disease,83
1486,Clinical Manifestations and Outcomes in Systemic Lupus Erythematosus Patients Who Received Antiviral Therapy During the COVID-19 Omicron Variant Wave: Results from a Single Center Cohort of Puerto Rico,201
1487,"Evaluation of Changes in SLE Patients’ Phenotype at Disease Onset, and Assessment of Disease Activity, Damage and Therapy at Diagnosis and During Follow up in the Last Forty Years: Preliminary Data of a Single Center Experience",227
1488,Inflammatory Markers and Left Ventricular Dysfunction in Systemic Lupus Erythematosus (SLE),91
1489,Musculoskeletal Involvement in Systemic Lupus Erythematosus: Insights from a Survey of Lupus Experts,100
1490,Neuropsychiatric Systemic Lupus Erythematosus in Children: A Scoping Review,75
1491,Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus,102
1492,Systematic Review of Effects of Systemic Lupus Erythematosus on Brain Structure and Structural Connectivity and Its Relationship with Cognitive Dysfunction Through an Advanced Neuroimaging Lens,193
1493,Obesity Is an Independent Poor Prognostic Factor in Lupus Nephritis,67
1494,Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity,115
1495,Unveiling the Impact of Neuropsychiatric Involvement in Systemic Lupus Erythematosus on Damage Accrual,102
1496,Impact of Neuropsychiatric Involvement on Health-related Quality of Life in Patients with Systemic Lupus Erythematosus,118
1497,"Association of Serum Analytes with SLE Cognitive Impairment Phenotypes Formed by Machine Learning: MMP-9, S100A8/A9, IL-6, IL-10, and NGAL",138
1498,Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER),218
1499,Predictors of Cognitive Impairment in Individuals with Systemic Lupus Erythematosus,83
1500,Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis,122
1501,Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis,82
1502,Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020,129
1503,Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis,156
1504,Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest,168
1505,Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus,114
1506,SARS-CoV-2 Antibody Formation After COVID-19 Vaccination in SLE Patients Treated with Belimumab: Single-Center Prospective Observational Study,142
1507,A Comparative Study of Lupus Nephritis Class II and IgA Nephropathy: Renal Disease Other Than Lupus Nephritis in Systemic Lupus Erythematosus Patients,150
1508,Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience,110
1509,Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades,92
1510,Associations and Outcomes of Critical Peripheral Ischemia in Systemic Lupus Erythematosus (SLE): Data from Indian SLE Inception Cohort for Research (INSPIRE),157
1511,Retrospective Study of Obesity on Clinical and Immunological Features in Systemic Lupus Erythematosus Using AI Software Deep 6 and EPIC Slicer Dicer,148
1512,"Discriminating Disease Flare from Infection in Febrile Patients with Systemic Lupus Erythematosus Admitted to a Safety-Net Hospital System: A Retrospective, Multicenter Study",174
1513,Clinical and Economic Burden of Herpes Zoster in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study,121
1514,Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review,162
1515,Risk Factors for Human Papillomavirus Cervical Infection and Clearance in Patients with Systemic Lupus Erythematosus: The PAPILUP Study,135
1516,Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region,102
1517,Racial Disparities in Lupus Nephritis: A Nationwide Analysis,60
1518,Change in the SLE Mortality Rate and Prevalence of Lupus Nephritis Overtime: Single Center Retrospective Study in Japan,119
1519,High Chronicity Index of the Modified NIH (National Institute of Health) Scoring System of Lupus Nephritis Is Associated with Increased Risk of End-stage Kidney Disease: A Retrospective Single-center Study,205
1520,Ruminococcus Implicated in the Clinical Development of Lupus Nephritis: A Systematic Review of the Literature,109
1521,Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis,94
1522,Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018),187
1523,Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE),90
1524,Association of Glucocorticoid Use with Patient-Reported Outcomes Among Persons with Systemic Lupus Erythematosus,112
1525,Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study,175
1526,Early Experience with SGLT2i in Systemic Lupus Erythematosus,60
1527,Targeting the Mevalonate Pathway-dependent Protein Geranylgeranylation to Restrict Follicular Helper T Cell Differentiation for the Treatment of Systemic Lupus Erythematosus,173
1528,Pre-treatment Differentially Expressed Metagenes Characterize Systemic Lupus Patients Who Subsequently Achieve Clinical Response to Belimumab,141
1529,"Novel BCMA-CD19 Compound CAR-T (cCAR) Targets B Cells and Plasma Cells Achieving Immune Reset and Eliminates All Autoantibodies in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients Resulting in Long-Term, Medication-Free Remission",249
1530,The Effect of Belimumab on Steroid Use in Patients with SLE: Results from a Retrospective Observational Study of Real-World Data from a US Rheumatology Provider Network,168
1531,Deep Serological Profiling of SLE Patients Treated with anti-CD19 CAR T Cells,77
1532,"Clinical Safety and Efficacy Results from EQUALISE Type B: A Phase 1b Open-label Clinical Study of Itolizumab, a Novel anti-CD6 Therapy, in Subjects with Active Proliferative Lupus Nephritis",190
1533,Eltrombopag in SLE-Associated Thrombocytopenia: Treatment Response and Thrombotic Complications,95
1534,"First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus",190
1535,"Year-5 Follow-up of Belimumab Safety (mortality and Malignancies) in Patients with Systemic Lupus Erythematosus (SLE) Who Completed a Phase 4, 52-week, Randomized, Double-blind Placebo-controlled Safety Study",208
1536,Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies,117
1537,"Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE",160
1538,Introduction of Belimumab Within Five Years of the Onset of Systemic Lupus Erythematosus (SLE) Contributes to the Better Therapeutic Response; A Multi-center Retrospective Cohort Study,184
1539,Disease Course and Complement as Predictors of Response to Standard of Care Plus Placebo in Patients with SLE: A Post Hoc Analysis of Dapirolizumab Pegol and Epratuzumab Clinical Trial Data,189
1540,Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S,193
1541,Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis: Results from the AURORA 1 and AURORA 2 Studies,131
1542,Prescribing Patterns in Lupus Nephritis: Analyzing Time from Proteinuria to Prescription of ACE/ARB,99
1543,Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial,132
1544,Predicting in Virtual Patients the Efficacy of an Anti IFNa Mab in Cutaneous Lupus Erythematosus,96
1545,Calcineurin Inhibitors for Treatment of Lupus Nephritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,126
1546,Efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in Women with Systemic Lupus Erythematosus (SLE) Receiving Cyclophosphamide (CYC),164
1547,B-Cell Recovery in a Randomized Controlled Trial of B-Cell Depletion with Obinutuzumab for the Treatment of Proliferative Lupus Nephritis,137
1548,Rituximab Objective Outcome Measures Trial in SLE (ROOTS): Randomised and Rescue Therapy Outcomes from a Randomised Controlled Trial,132
1549,"Trends in Systemic Sclerosis- related Mortality by Age, Sex and Race in the United States, 1999-2019",100
1550,Phase I Study to Evaluate the Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for Interstitial Lung Disease in Patients with Connective Tissue Disorders,168
1551,Performance of the Revised CRISS in a Phase 3 Trial of Early Systemic Sclerosis,79
1552,Systemic Sclerosis Gastrointestinal Tract Vascular Biomarkers of Symptomatic Disease Activity,93
1553,Comparing Deep Neural Network to Modified Rodnan Skin Score in a Trial for Belumosudil in Systemic Sclerosis Patients,117
1554,Efficacy and Safety of Prostaglandins Analogues in Systemic Sclerosis-associated Raynaud’s Phenomenon. a Systematic Review and Meta-Analysis,140
1555,Renal Complications Following Autologous Stem Cell Transplantation for Systemic Sclerosis,89
1556,Identifying Core Domains for Clinical Trials in Systemic Sclerosis-Associated Raynaud’s Phenomenon and Digital Ulcers Using the Delphi Consensus Method,151
1557,Microvascular Remodeling After Autologous Stem Cell Transplant for Systemic Sclerosis,85
1558,Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis,105
1559,The Risk of Scleroderma Renal Crisis from Intraarticular Corticosteroid Injection in Systemic Sclerosis,103
1560,The Effectiveness of Nintedanib in Treating Fibrosing Interstitial Lung Disease in Both Scleroderma and Non-scleroderma Patients: A Systematic Review and Meta-analysis,167
1561,Chelation Therapy in the Management of Calcinosis Associated with Systemic Sclerosis,84
1562,Evusheld Efficacy and Safety in Autoimmune Rheumatic Diseases (AIRD) Treated by B Cell Depeting Therapy or Autologous Stem Cell Transplantation: A Prospective Observational Study,178
1563,Acute Effects of Intravenous Iloprost on Finger Power Doppler Ultrasound in Scleroderma Patients,96
1564,"Intravenous or Subcutaneous Immunoglobulins as Potential Treatment for Gastrointestinal, Cutaneous and Vascular Involvement in Systemic Sclerosis: Data from an Italian Cohort of 65 Patients",189
1565,Mycophenolate Mofetil Use in Clinical Practice: Persistence on Therapy and Long-term Adverse Events in a Multicentric Cohort of Scleroderma Patients,148
1566,Outcomes in Patients with Systemic Sclerosis Following Lung Transplantation: An Italian Multicentre Experience,110
1567,A Retrospective Analysis of the Efficacy of Nintedanib in Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD): A TriNetX Database Study,156
1568,Safety and Microvascular Effects of Long-term Treatment with Aminaphtone in Systemic Sclerosis Patients: A Retrospective Analysis,129
1569,Long-term Use of Rituximab in Systemic Sclerosis: A Real-life Italian Multicentre Study,87
1570,ANCA-associated Vasculitis Incidence in a Norther Spanish Health Region,71
1571,"Epidemiology and Treatment Outcome of ANCA-associated Vasculitis in South Korea: A Nationwide, Population-based Cohort Study",124
1572,The Impact of COVID-19 Vaccination on ANCA Vasculitis Hospitalisations: A Perspective from Sydney Australia,107
1573,Long-term Observational Study of Interstitial Lung Disease in ANCA-associated Vasculitis,88
1574,Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades,131
1575,"Digital Ischemia, a Rare Manifestation in Anti-neutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)",113
1576,Evaluation of the Validity of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Antineutrophil Cytoplasmic Antibody-associated Vasculitis for an Asian Population on the Basis of the Patterns of Organ Involvement,282
1577,Neurologic Involvement Does Not Affect Cumulative Survival Rates in Patients with ANCA-associated Vasculitis and Is Less Commonly Associated with Rapidly Progressive Glomerulonephritis in Patients with GPA,205
1578,The Burden of Multimorbidity in ANCA-Associated Vasculitis: A Cohort Study,74
1579,The Association of Frailty with Outcomes in Patients with Vasculitis,68
1580,Increased Risk of Severe Infection in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitides: A Population-based Trend Analysis,146
1581,Validation of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA-associated Vasculitis,174
1582,Eosinophilic Granulomatosis with Polyangiitis: Clinical Suspicion Red Flags Identification by a Systematic Literature Review and Multidisciplinary Expert Consensus,163
1583,Disease Burden of Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data,131
1584,Diagnosis Pathways in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data,149
1585,Treatment Patterns for Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Retrospective Analysis of US Health Insurance Claims Data,136
1586,Importance of Shared Decision-Making for Patients with ANCA-Associated Vasculitis,81
1587,Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis,77
1588,Epidemiology and Outcome of Eosinophilic Granulomatosis with Polyangiitis in France,83
1589,Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis,78
1590,Therapeutic Approaches and Predictive Factors of Relapse in Severe Ocular Involvement in Behçet’s Disease: A Multicentre Retrospective Study,140
1591,Axial Spondyloarthritis in Patients with Gastrointestinal Involvement of Behçet Syndrome,88
1592,Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behçet Syndrome,100
1593,De Novo Manifestations During Adalimumab Treatment in Behçet Syndrome,69
1594,Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement,122
1595,"Comparison of Treatment with Adalimumab, Infliximab and Certolizumab in Refractory Cystoid Macular Edema Due to Behçet Disease",126
1596,Decreased Level of Peripheral CLA+ Treg Is a Protective Factor of Nervous System Involvement in Behcet’s Syndrome: A Real-World Study in China,142
1597,Clinical Features and Quality of Life of Japanese Bechet’s Disease Patients with Arthritis: A Japanese Monocentric Study,120
1598,Behcet’s Disease Coagulopathy in a Racially Diverse Patient Population,70
1599,Methotrexate: A Safe and Effective Therapeutic Alternative in Behçet´s Disease,78
1600,Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Suspected Behçet’s Disease,97
1601,Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months,123
1602,Exposure-Response Analysis of Sarilumab in Patients with Polymyalgia Rheumatica,79
1603,Assessment of the Extent and Accrual of Damage in Takayasu’s Arteritis,70
1604,Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu’s Arteritis,134
1605,Efficacy and Safety of Tofacitinib and Tocilizumab in 84 Patients with Takayasu Arteritis: Single-Center Post-Hoc Analysis of a Prospective Study,145
1606,Prognostic Assessment of the 2022 ACR/EULAR Classification Criteria for Takayasu Arteritis: A Multi-centre International Study,126
1607,Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis,139
1608,Long-term Efficacy and Retention Rate of Molecular Targeted Drugs in Takayasu Arteritis,87
1609,Inpatient Prevalence and Comorbidity of Takayasu’s Arteritis: Nationwide Inpatient Sample 2016-2020,99
1610,The Role of 18F-FDG PET/CT Scans in Takayasu Arteritis,54
1611,Takayasu Arteritis Is Associated with Worse Fatigue Than Healthy Controls Which Persists over Time – A Longitudinal Cohort Study,128
1612,Application of the 2022 ACR/EULAR Criteria for Takayasu Arteritis to Previously Diagnosed Patients Based on the 1990 ACR Criteria,129
1613,Analysis of Takayasu’s Arteritis as Risk Factor for Acute Coronary Syndrome,75
1614,Impact of Anxiety or Depression Status and Fibromyalgia on Adherence to Treatment of Patients with Takayasu Arteritis,117
1615,Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus,117
1616,CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon,147
1617,Microbiome Transplantation Prevents Osteoarthritis in Mice and Is Associated with Immunophenotype Changes,105
1618,"Non-TNFi b/tsDMARDs vs. TNFi in Rheumatoid Arthritis-Interstitial Lung Disease: An Active-Comparator, New-User, Propensity Score Matched Study Using National Veterans Affairs Data",179
1619,"Comparison of Two Dosing Schedules for Oral Methotrexate (Split-Dose versus Single-Dose) Once Weekly in Patients with Active Rheumatoid Arthritis: A Multicenter, Open Label, Parallel Group, Randomized Controlled Trial (SMART Study)",231
1620,Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study,159
1621,Defining Neutrophil-Mediated Renal Damage Triggered by Ultraviolet (UV) Skin Exposure,85
1622,Keratinocyte VISTA Suppresses Skin IFN-I Production by Regulating DNA Damage Repair and Cytosolic DNA Sensing,109
1623,Mitochondrial Z-DNA and ZBP1 Drive Autoimmune Photosensitivity,62
1624,Monocyte-derived Macrophages Accumulate in the Lungs in anti-MDA5+ Dermatomyositis with RP-ILD: Proinflammatory and Profibrotic Phenotype Revealed by Single-cell RNA Sequencing,176
1625,Epigenetic Regulation of DNMT3A by TFEB and DOT1L Through AMPK Signalling Orchestrates the Lysosomal Response of Macrophages During Gout and Clonal Hematopoiesis,161
1626,Autoimmune Pathway Blockade by a Potent Orally Bioavailable STING Antagonist,76
1627,Complement Factor D/Adipsin Knockout Mice Demonstrate Disparate Pain and Structural Damage Phenotypes in Obesity-induced Post Traumatic Osteoarthritis,150
1628,Memantine Attenuates the Development of Osteoarthritis by Blocking NMDA Receptor Mediated Calcium Overload and Chondrocyte Senescence,133
1629,Combining Single-cell RNA Sequencing and Population-based Studies Reveals Hand Osteoarthritis-associated Chondrocyte Subpopulations and Pathways,144
1630,Oral Delivery of Δ9-Tetrahydrocannabinol Provides Symptom and Disease Modification in a Mouse Model of Knee Osteoarthritis,122
1631,Pharmacological Modulation of Krüppel-like Factor 4 Reduces the Severity of Experimental Osteoarthritis via Tissue Protection and Regeneration,142
1632,A Cell and Transcriptomic Atlas of the Infrapatellar Fat Pad from Patients with Knee Osteoarthritis: Identification of an Obesity-Associated Transcriptomic Signature,165
1633,"Staphylococcus Aureus Peptidoglycan Induces Pathogenic Autoantibody Production via Autoreactive B Cell Receptor Clonal Selection, Implications in Systemic Lupus Erythematosus",174
1634,Single-cell Spatial Proteomics Identifies Intraglomerular Myeloid Cells in Membranous Lupus Nephritis,101
1635,Single-Cell RNA Sequencing Reveals Cellular Drivers of UV-mediated Skin Injury in Cutaneous Lupus,97
1636,Transcriptomic Characterization of Class II Lupus Nephritis and Outcomes,72
1637,Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus,102
1638,NADPH Oxidase Exerts a B Cell-intrinsic Contribution to Lupus Risk by Modulating Endosomal Toll-like Receptor (TLR) Signals,123
1639,Infection-Associated Antiphospholipid Antibodies and Their Potential Role in Sepsis Outcomes,92
1640,"First and Recurrent Thrombosis Risk After 4,454 Patient-Years of Follow-Up: Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)",247
1641,Complement Activation as a Marker of Thrombosis Risk in Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”),268
1642,Purinergic Signaling as a Potential Therapeutic Target for APS Thromboinflammation,82
1643,Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus,126
1644,Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry,232
1645,Associations Between SARS-Cov-2 Infection and Neuropathic Pain in Fibromyalgia Patients: A Cohort Study,103
1646,"Digital Acceptance and Commitment Therapy Improves Fibromyalgia Outcomes: Results from a Pivotal, Multi-center, Randomized Controlled Trial",139
1647,Mitochondrial Structural Alterations in Fibromyalgia – A Pilot Electron Microscopy Study,88
1648,Design and Validation of a Comparator for Randomized Controlled Trials of a Digital Cognitive Behavioral Therapy,112
1649,Tetrodotoxin Sensitive Nav1.7 Sodium Channel SCN9A Gene Polymorphism rs6754031(T >G) Is Associated with Fibromyalgia,116
1650,"Therapy Combining Millimeter Wave-based Neuromodulation with Coaching for the Improvement in Quality of Life of Patients with Fibromyalgia: A Prospective, Multicenter, Randomized, Controlled Trial",196
1651,Therapeutic Hydroxychloroquine Blood Levels Are Cost Effective and May Reduce Health Disparities by Reducing Lupus Hospitalizations,131
1652,"Geographic and Demographic Representation in Industry-sponsored, US-based Clinical Trials of Systemic Lupus Erythematosus Therapies",131
1653,"Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022",143
1654,Intervention to Improve Medication Adherence Among Patients with SLE,68
1655,Receipt of Antimicrobial Prophylaxis in U.S. Medicare Beneficiaries Initiating Immunosuppressive Medications for ANCA Vasculitis,128
1656,Cardiovascular Risk and Fracture Risk Among Women Initiating Treatment with Romosozumab or Denosumab,100
1657,Maxillofacial MRI Augments Detection of Non-CNS Abnormalities in Pediatric Craniofacial Scleroderma,99
1658,Myositis-associated Autoantibodies in Juvenile Myositis Are Associated with Severe Disease Features and Mortality,113
1659,"Diffuse Juvenile Systemic Sclerosis Patients Show Distinct Organ Involvement, Antibody Pattern and Have More Severe Disease in the Largest jSSc Cohort of the World. Results from the Juvenile Scleroderma Inception Cohort",219
1660,Racial Disparities Impact Achieving LLDAS and Glucocorticoid Use in Pediatric Lupus: A CARRA Registry Study,107
1661,Identifying Potential Neuroimaging Biomarkers of Neuropsychiatric Lupus in Children Using Deep Learning,103
1662,"Clinical Presentation, Disease Course and 12-month Outcomes in Childhood Polyarteritis Nodosa: A PedVas Study",109
1663,Methotrexate Use Associates with Ischemic Cardiovascular Risk Reduction in Males but Not Females with Rheumatoid Arthritis,122
1664,The Impact of Cardiovascular and Cerebrovascular Disease on the Risk of Dementia in Rheumatoid Arthritis. a Mediation Analysis,126
1665,"Persons with Rheumatoid Arthritis and Long COVID Had Worse Pre-COVID RA Symptoms and Worse Non-RA Symptoms, as Well as Higher Rates of Fibromyalgia Compared with COVID Infected Long COVID Negative",196
1666,Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis,85
1667,Comparison of Peripheral Biomarker Profiles Across Unique Multimorbidity Patterns in Rheumatoid Arthritis,105
1668,Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care,89
1669,Dose Dependent Modulation of a B Cell Protein Signature by Ianalumab in Patients with Sjögren’s Disease,103
1670,"Iscalimab (CFZ533) in Patients with Sjögren’s Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study",155
1671,Deep Learning Accurately Predicts Focus Score and Diagnosis of Primary Sjögren Syndrome Using Labial Salivary Gland Biopsies,125
1672,"Dazodalibep, a CD40L Antagonist, in Subjects with Sjögren’s Having Moderate-to-Severe Systemic Disease Activity: Full Crossover Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study",220
1673,IgG-Fc-N-Sialylation and -Galactosylation in Primary Sjögren’s Syndrome (Pss) in Its Potential as Marker of Disease State and Disease Activity,142
1674,CD40L Inhibition with Dazodalibep Rapidly Reduces Blood Biomarkers of T and B Cell Costimulation in Subjects with Sjögren’s Having High Disease Activity or High Symptom Burden,175
1675,"PsA Patients of Diverse Ethnic and Racial Backgrounds Experience More Skin Psoriasis, Increased Pain, and Higher Rates of Radiographic Axial Disease",148
1676,Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network,91
1677,The Window of Opportunity in Psoriatic Arthritis: Similar to Rheumatoid Arthritis?,82
1678,Identifying Distinct Phenotypes in Psoriatic Arthritis: A Study from the Psoriatic Arthritis Research Consortium (PARC) Cohort,126
1679,Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis,86
1680,The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients,121
1681,Aortic Dilatation and PET/CT Vascular Activity at Diagnosis and 5 Years in an Inception Giant Cell Arteritis (GCA) Cohort,121
1682,The Real-World Experience of Combined Cranial and Large Vessel FDG-PET/CT in the Investigation of Giant Cell Arteritis,118
1683,Association Between Vascular FDG Uptake at Diagnosis and Evolution in Aortic Dimensions in Giant Cell Arteritis: A Prospective Study,132
1684,EULAR Recommendations for the Use of Imaging in Large Vessel Vasculitis in Clinical Practice: 2023 Update,105
1685,Follow-up Ultrasound Examination in Patients with Newly Diagnosed Giant Cell Arteritis,86
1686,Optic Nerve Sheath Measurement as a Disease Activity Biomarker in Giant Cell Arteritis,86
1687,Beneficial Effect of Temporary Methotrexate Interruption on B and T Cell Responses upon SARSCoV-2 Vaccination in Patients with Rheumatoid Arthritis or Psoriatic Arthritis,170
1688,Lupus Research Action Network: Increasing Minority Clinical Trial Participation Through Peer Leaders,100
1689,Up or Down: Does Direction of Stair Climbing Difficulty Matter for Incident Functional Limitation and Knee Replacement in Knee Osteoarthritis?,142
1690,A Peer Health Coached Resilience-Based Energy Management Program Was Effective in Improving Fatigue and Other Outcomes in People with Systemic Sclerosis: Results of a Randomized Controlled Trial,194
1691,"Usability Testing of JIActiv, an Instagram-Based Program Promoting Engagement in Physical Activity Among Young People Living with Juvenile Idiopathic Arthritis",159
1692,Nothing About Us Without Us: Top 10 Research Priorities from Patients – A James Lind Alliance Project for Public and Patient Involvement (PPI),142
1693,Mapping the Network of Coordinated Immune Dysregulation in Juvenile Dermatomyositis at Single-cell Resolution,109
1694,Title: Inflammatory Arthritis Across the Age-Spectrum: Single-Cell Profiling of the Inflamed Synovium in Children with Juvenile Idiopathic Arthritis,148
1695,Cellular Deconstruction of Stromal and Myeloid Cell Compartments in the Inflamed Synovium of Juvenile Idiopathic Arthritis,122
1696,"Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways",171
1697,Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin,91
1698,"Chronic Excess IL-18 Induces NK Deficiency, but Drives Hyperinflammation via CD8 T-cell Cytokine Overproduction and Selective Immunodeficiency",142
1699,Clinically Severe Systemic Sclerosis Skin Harbors Inflammatory Fibroblasts Associated with Lymphocytes and Plasmacytoid Dendritic Cells,135
1700,Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis,191
1701,Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis,137
1702,TNF-mediated Pulmonary Hypertension Is Marked by Aberrant Bone Morphogenic Protein (BMP) and Integrin/Basement Membrane Ligand-Receptor Signaling,145
1703,Characterization of the Vascular Niches in Systemic Sclerosis (SSc) as a Prototypical Immune-mediated Fibrotic Disease with Prominent Vasculopathy Using Imaging Mass Cytometry,175
1704,Cell Specific Molecular Profiling of Scleroderma Associated Interstitial Lung Disease Subtypes,94
1705,High Incidence of Immune-mediated Inflammatory Diseases in Sepsis Survivors: A Nationwide Exposed-non-exposed Epidemiological Study,131
1706,Exacerbation of Immune-mediated Inflammatory Diseases in COVID19 Sequelae,73
1707,Use of Metagenomic Microbial Plasma Cell-Free DNA Next-Generation Sequencing Assay in Outpatient Rheumatology Practice,118
1708,Association of COVID-19 Vaccinations with Flares of Systemic Rheumatic Disease: A Case-Crossover Study,102
1709,Immunomodulatory Treatment and Autoimmune Patient Responses to COVID-19 Booster Shots: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study,168
1710,Severe Infections in Patients with VEXAS Syndrome: A Study from the French VEXAS Group,86
1711,Survival in Patients with Rheumatoid Arthritis and Early Breast Cancer Treated with Tumor Necrosis Factor Inhibitors,116
1712,Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology,214
1713,"Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial",245
1714,Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis,127
1715,Effects of Janus Kinase Inhibitor on TNF-a and IL-6-Induced Osteoclasts and RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis,171
1716,What Trade-offs Are Acceptable to Rheumatoid Arthritis Patients During Treatment Selection?,91
1717,Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers,131
1718,Prospective Evaluation of Anti-SSA/Ro Pregnancies Supports the Utility of High Titer Antibodies and Fetal Home Monitoring for the Detection of Fetal Atrioventricular Block,171
1719,Moving the ACR’s Reproductive Health Guidelines into Practice: Assessment of a Novel Reproductive Rheumatology ECHO,115
1720,The Impact of Pregnancy Timing on Outcomes in SLE,49
1721,SLE Disease Activity Is a More Important Risk Factor Than Immunosuppression for Acquiring Human Papillomavirus (HPV) Infection in Systemic Lupus Erythematosus Patients,167
1722,Adolescent and Young Adult Rheumatology Patient Reports of Reproductive Health Screening and Counseling in the Clinical Setting,127
1723,Sex of the Patient Affects Response to Advanced Therapies in Psoriatic Arthritis: Meta-analysis of Data from Randomized Controlled Trials,137
1724,"Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks",156
1725,Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy,130
1726,Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study,146
1727,"16-Week Results from FOREMOST, a Placebo-Controlled Study Involving Oligoarticular Psoriatic Arthritis Treated with Apremilast",126
1728,Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study),143
1729,Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures,140
1730,Transcriptomic Analysis of the Impact of Iberdomide on Patients with SLE,72
1731,Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis,213
1732,Multi-Omic Profiling Reveals Immune Cell Priming Signature Linked to Systemic Lupus Erythematosus Prognosis,107
1733,Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort,182
1734,High-throughput Proteomics Identities a Spectrum of Novel Serum Biomarkers of Lupus Nephritis,93
1735,Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis,167
1736,Incidence and Risk Factors for New Onset of Interstitial Lung Disease in Systemic Sclerosis: A EUSTAR Analysis,110
1737,Treatment Regimens and Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in Light of the 2022 ESC/ERS Guidelines,137
1738,Outcomes in Systemic Sclerosis Patients Treated with Rituximab and Mycophenolate Mofetil Combination Therapy Compared to Autologous Hematological Stem Cell Transplantation,171
1739,Increased Mortality and Cardiovascular Events in Male Patients with Systemic Sclerosis: Left Ventricular Global Longitudinal Strain as Possible Screening Tool,158
1740,Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma,203
1741,Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients,158
1742,Autoreactive B Cell Responses Are Enriched in Early-onset Oligoarticular Juvenile Idiopathic Arthritis,102
1743,PD1-Expressing Regulatory T Cells Found in Inflamed Joints Suppress Tph Cell-B Cell Interactions,96
1744,In Cis SOCS1 Variants Illustrate the Precise Regulation of Interferon Signaling Needed to Prevent Autoimmunity,110
1745,Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction,160
1746,Genetic Associations in Juvenile Idiopathic Arthritis Determined with an Electronic Health Record Based Approach,112
1747,"CD14+ Monocytes Demonstrate a Unique Transcriptional Signature in Macrophage Activation Syndrome, Highlighting a Role for Interferons and Identifying Putative Hemophagocytes in Circulation",188
1748,Identification and Functional Characterization of Eight CANDLE/PRAAS Causing Proteasome Variants in Five Unrelated Patients,123
1749,Prevention of Arthritis Development by Mechanical Unloading Through Inhibition of CCL2 and YAP-mediated Inflammation in the Rat Adjuvant-induced Arthritis Model,160
1750,Aberrant Myeloid Populations in the TNF-Transgenic Model of Pulmonary Hypertension Overexpress Interferon Pathways and Are Driven by TNFR1 Signaling,148
1751,Androgen Treatment Exhibits a Protective Role Against Focal Erosions in TNF-Induced Inflammatory Arthritis in Mice,114
1752,High-Throughput Semi-Automated Micro-CT Analysis Identifies the Cuboid Bone as a Sex-Dependent Biomarker of Inflammatory-Erosive Arthritis in TNF-Tg Mice,153
1753,Endothelial Cell Sphingosine 1-Phophate Receptor 1 Restrains VE-cadherin Cleavage and Attenuates Experimental Inflammatory Arthritis,132
1754,"Longitudinal Quantification of Bone Erosions, Pulmonary Disease, Pain, Gait and Sarcopenia to Holistically Assess Decreased Ad Libitum Physical Activity and Effects of Exercise in the TNF-Transgenic Murine Model of Rheumatoid Arthritis",235
1755,Exploring the Link Between Osteitis and Bone Microstructure Changes in Rheumatoid Arthritis: Role of JAK-STAT Signaling Pathway,127
1756,"Successful Treatment of Rheumatoid Arthritis in Mice Using Cenerimod, a Selective Modulator of the S1P1 Receptor, Demonstrates the Potential Benefits of S1P1 Receptor Immunomodulation for Rheumatic Diseases",206
1757,The Therapeutic Effects of Gingival Mesenchymal Stem Cells and Their Exosomes in a Chimeric Model of Rheumatoid Arthritis,121
1758,Fate-mapping of Synovial Monocytes and Macrophages,50
1759,"3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity",141
1760,Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Attenuates Experimental Pulmonary Fibrosis Through Mitochondria Transfer Mediated Anti-apoptotic and Immunomodulatory Effects,182
1761,"Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model",181
1762,Therapeutic Effect of ICAM-1 Mimic on Experimental Axial Spondyloarthritis,74
1763,Arthritogenicity of Homocitrullinated Peptides in HLA-DRB1 Transgenic Mice,74
1764,A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis,80
1765,An Antibody-drug Conjugate of Anti-TNFα Antibody and a Novel Glucocorticoid Molecule Exerts Synergistic Anti-inflammatory Effects for Treatment of Autoimmune Diseases,166
1766,Gut Microbiota Dysbiosis Impact Autonomic Function in Rheumatoid Arthritis Patients,83
1767,A Competitive Inhibitor of MOART Showed Potent Therapeutic Effects in a Mouse Model of Collagen-induced Arthritis,113
1768,Immunopathogenesis and Preclinical Trials in a Humanized Mouse Model of Rheumatoid Arthritis(RA),96
1769,Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease,125
1770,Serum PDGF-BB Levels Correlate with Lung Fibrosis in Mice Injected with Malondialdehyde-Acetaldehyde and/or Citrulline Modified Vimentin,136
1771,An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry,110
1772,The Effect of Resolvin E1 and Resolvin D1 Specialised Pro-resolving Mediators on the Inhibition of Osteoclastogenesis,117
1773,"ACPA, Anti-CarP and AAPA Can Be Detected in Saliva, but Not in Feces of Seropositive Rheumatoid Arthritis Patients – Support for Mucosal Involvement in Specific Locations in RA",176
1774,Identification of Homeostatic and Inflammatory Synovial Fibroblast Signatures in Synovial Tissue Biopsies of Healthy Controls and Patients with Rheumatoid Arthritis,164
1775,Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies,136
1776,Exploring Disease-Associated DNA Methylome Alterations in Rheumatoid Arthritis: Potential Diagnostic and Prognostic Biomarkers,126
1777,The Occurrence and Phenotype of Autoreactive T Cells in the At-Risk Phase of Rheumatoid Arthritis,97
1778,Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA,148
1779,Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies,165
1780,Histological and Molecular Comparison in the Synovial Tissue of Patients with Active Rheumatoid Arthritis to Remission,118
1781,Chronic Inflammation and Collagen IV Fragment Canstatin Influence Rheumatoid Arthritis Synovial Fibroblast and Endothelial Cell Interactions in Vitro and in Vivo,161
1782,Smoking as a Risk Factor for Rheumatoid Arthritis: Exclusive Association with IgA Autoantibodies,96
1783,A Newly Described Cytokine interleukin-40 Is Increased in the Serum of Individuals At-risk of Rheumatoid Arthritis and Induces an Inflammatory Response in Mononuclear Cells,172
1784,Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies,161
1785,Fatty Acid Synthase Is a Critical Repressor of Ferroptosis in Rheumatoid Arthritis,82
1786,Dysregulated NUB1 and Neddylation Enhances Rheumatoid Arthritis Fibroblast-Like Synoviocyte Inflammatory Responses,114
1787,Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls,153
1788,Fibroblast Expression of Neurotransmitter Receptor HTR2A Associates with Inflammation in Rheumatoid Arthritis Joint,115
1789,Acylcarnitine Enrichment Is a Characteristic of Rheumatoid Arthritis Fibroblast-Like Synoviocyte Metabolic Fingerprint,118
1790,Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19,79
1791,Unique Pattern of Cadherin 6 Localization in Fibroblast-Like Synoviocytes,73
1792,Circulating CD4+CD25+CD127-FoxP3+CD39+ T Cells Predict the Response to Methotrexate Across Basal Disease Activity Strata in Early Rheumatoid Arthritis,150
1793,Quantitative Assessment of Synovial Vascularity Using Power Doppler Index in Rheumatoid Arthritis and Psoriatic Arthritis Patients with High Disease Activity,157
1794,Identification of Circulating Autoantibodies Associated with ACPA Status in Early Rheumatoid Arthritis,102
1795,Runx1 Is a Key Transcription Factor That Drives Synovial Fibroblast Pathogenicity in Rheumatoid Arthritis,105
1796,Methotrexate Augments the Release of Granulocyte-macrophage Colony-stimulating Factor from Activated Rheumatoid Arthritis Fibroblast-like Synoviocytes – Possible Consequences for Persistence of Joint Inflammation,212
1797,JAK/STAT Inhibition Modifies the Innate Lymphoid Cells 1 Immune Response in Patients with Rheumatoid Arthritis,110
1798,Single-cell RNA Sequencing Analysis and Immune Profiling of Antigen-specific T Cells in Patients with Rheumatoid Arthritis and Healthy Controls,143
1799,Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up,130
1800,Antibody Responses to Citrullinated Type II Collagen and Vimentin Modified with Malondialdehyde-Acetaldehyde Differ in Rheumatoid Arthritis and Rheumatoid Arthritis-Interstitial Lung Disease,190
1801,Persistent Cigarette Smoking Is Associated with Rheumatoid Arthritis Onset and Neutrophil Activation in a Prospective Study of At-risk First-Degree Relatives,157
1802,Inflammatory Priming of the Joints via Pre-activation of Macrophages by Anti-MAA Antibodies in Rheumatoid Arthritis,115
1803,TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts to Induce Inflammation,109
1804,The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study,129
1805,TNF-Stimulated Production of IL-15 by Fibroblast-Like Synoviocytes Mediates Human Resident Memory T Cells Development in Synovial Organoid Model,144
1806,Dual Inhibition of TNF-α and OX40L on Synovial Inflammation and Osteoclastogenesis in Rheumatoid Arthritis,106
1807,Role of Periostin in the Pathophysiology and Accurate Diagnosis of Interstitial Lung Disease Associated with Autoimmune Diseases,128
1808,Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients,82
1809,Integrated Analysis of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) Transcriptome and Chromatin Accessibility Identifies Mechanisms Associated with Location-specific Disease Severity,198
1810,Gut Microbiota and Permeability Biomarkers for Diagnosis and Prognosis in Rheumatoid Arthritis Associated Interstitial Lung Disease,131
1811,The Peptidyl Arginine Deiminase Inhibitor BB-CLA Decreases the Inflammatory and Fibrotic Responses in Macrophages and Rheumatoid Arthritis Synovial Fibroblasts Exposed to Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct and Citrulline,246
1812,Macrophage Migration Inhibitory Factor May Help Maintain Tight Junctions in the Gut by Enhancing Occludin Expression,116
1813,The Effect of the Inflamed Joint Microenvironment on Endothelial Cell Function,78
1814,"Role of GITR/GITRL Interaction in Modulating T Helper 9, T Helper 17 and T Regulatory Response in Psoriatic Arthritis",117
1815,A Novel Inhibitory Pathway of Synovial Inflammation Exerted by Glucocorticoids and TNF Inhibitors Through LAG-3 Up-Regulation,125
1816,Biomarkers Predicting Structural Progression of Axial Spondyloarthritis: A Pilot Study,86
1817,TNF Induces Neutrophil Elastase/Gasdermin D-mediated Neutrophil Extracellular Traps in Axial Spondyloarthritis,110
1818,The Stromal-cell Derived Cytokine interleukin-17D Attenuates Joint Inflammation,79
1819,Integrative Functional Genomics Points to Natural Killer Cells as Key Drivers in the Pathogenesis of Ankylosing Spondylitis,123
1820,Dendritic Cell-specific TNFR2 Depletion Reduces Psoriatic Arthritis-like Disease in a Mouse Model,97
1821,Machine Learning Models Identify Gut Microbiota That Predict Chronicity in Reactive Arthritis,93
1822,Newly Identified Gut Commensal Clostridium Fessum AM100 for Treating Ankylosing Spondylitis,91
1823,Regulatory Role of JAK-1/TYK2 Signaling on the Pannus Formation: Novel Mechanisms for JAK Inhibitors in Psoriatic Disease,121
1824,The Emerging Mechanism of TNF&IL-17A/WNT5a/ROR2 Axis in Pathological Bone Formation of Ankylosing Spondylitis,109
1825,Microtrauma Exacerbates Arthritis and Enthesitis in Curdlan-administered SKG Mice by Inducing FGF16 Expresssion,111
1826,Expansion of CD8+ TCRVβ9+ T Cells in the Peripheral Blood of HLA-B27+ Patients with Axial Spondyloarthritis,107
1827,Exploring the Mechanism of Anti-TNFα Therapy Non-response in Psoriatic Arthritis: The Role of TNF Receptor 2 Polymorphisms rs1061622,132
1828,Identifying Synovial Fluid Micro-RNA Signature That Distinguishes Psoriatic Arthritis from Osteoarthritis,105
1829,Goblet Cell Specific Anti-Apoptotic Role of Interleukin-24 in Spondyloarthritis-Associated Ileitis,98
1830,The Role of the Deubiquitinase ZRANB1/TRABID in Inflammation and Bone Formation in Spondyloarthritis,100
1831,Multi-Omics Analyses Identify Metabolic Pathways That Differentiate Psoriatic Arthritis from Psoriasis,102
1832,Safety & ImmUnogenicity of COVID-19 VaCcines in SystEmic immunE Mediated Inflammatory Diseases (SUCCEED),104
1833,Factors Associated with Distress Related to Perceived Dignity in Patients with Rheumatic Diseases,97
1834,Association Between Knee Osteoarthritis and Mortality: A Serial Propensity Score-matched Cohort Study,101
1835,Association of Pregabalin vs Gabapentin with Incident Congestive Heart Failure in Patients with Non-Cancer Pain,111
1836,Factors Associated with an Electronic Health Record-Based Definition of Post-Acute Sequelae of COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases,159
1837,Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study,137
1838,Rheumatologic Disorder Diagnostic Testing Patterns:Real World Evidence from a National Laboratory Database,106
1839,Perceived Dignity in Patients with Rheumatic Diseases: An Unrecognized Source of Emotional Distress,99
1840,Plant-based Diet Quality and the Risk of Gout: Results from Two Prospective Cohort Studies of US Men and Women,110
1841,Longitudinal Changes in Serum Urate Associate Minimally with Changes in Daily Alcohol Intake,92
1842,The Prevalence of Cardiac Sarcoidosis – A Systemic Review and Meta-Analysis,75
1843,Hypothyroidism Impacts Clinical and Healthcare Utilization Outcomes After Primary Total Hip Arthroplasty,104
1844,Tobacco Smoking Reduces the Incidence and Delays the Progression of Knee Osteoarthritis: 10-year Retrospective Cohort Study Based on Korea National Health Insurance Service-Health Screening Database,198
1845,Clinical Outcome and Antibody Responses Following the Surge of SARS-CoV-2 Omicron Infection Among Patients with Systemic Autoimmune Diseases,140
1846,"Alcohol Consumption Amount, Type of Beverage, and Gender, All Matters to Serum Uric Acid Levels",95
1847,Strong Relationships Between Body Component Changes and Serum Uric Acid Variability,83
1848,Duloxetine and the Risk for Cardiovascular Events in US Veterans with Non-Cancer Pain,85
1849,Assessing Immunogenicity of SARS-CoV-2 Vaccine Neoantigen S1 in Autoimmune Rheumatic Disease Patients: A Study on Cellular and Humoral Responses,144
1850,Silica and Other Exposures from Jobs and Hobbies Are Associated with Myositis Phenotype in a National Myositis Registry,119
1851,The Association of Body Mass Index with SARS-CoV-2 Infection (COVID-19) in Patients with Inflammatory Arthritis on Biologic Disease Modifying Anti-Rheumatic Drugs: Results from the Singapore National Biologics Register,218
1852,Hyperuricemia – Especially “Metabolic Hyperuricemia” – Is Independently Associated with Higher Risk of Fatty Liver,114
1853,"Geographic Variability of Inflammatory Bowel Disease Related Mortality, 1999-2019; CDC WONDER",93
1854,Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S,83
1855,Clinical Indications Associated with New Opioid Use for Pain Management in the United Kingdom Using National Primary Care Data,126
1856,Statewide Burden of Osteoarthritis in United States Between 1990-2019: A Systematic and Comparative Benchmarking Study,118
1857,The “Weekend Effect” and Rheumatological Association in Patients with Diffuse Alveolar Haemorrhage,98
1858,The Food and Drug Administration’s (FDA’s) Safety Surveillance of Baricitinib and Tocilizumab for COVID-19 (Disclaimer: This Abstract Reflects the Views of the Authors and Not Necessarily Those of the US FDA),208
1859,"Higher Body Mass Index and Older Age, Both of Which Are Linked to Immunothrombosis Are Associated with Improved Survival with Baricitinib Therapy in COVID-19 Pneumonia",167
1860,Breakthrough COVID-19 and Severity After Vaccination Among Pregnant Persons with Rheumatic Diseases,99
1861,"Exploring the Health and Cannabis Use Among Young and Middle-Aged Adults with Rheumatologic Conditions in Alberta, Canada",121
1862,"Investigating the Health Profiles and the Prevalence and Correlates of Cannabis Use Among Patients Accessing Rheumatologic Care in Alberta, Canada",146
1863,Revolutionizing Fibromyalgia Treatment: Exploring the Efficacy of a New FDA Cleared Photoceutical Device,104
1864,"Positive Screening for Fibromyalgia or Depression on Validated MDHAQ Indices Is Seen in 56-71% of Rheumatoid Arthritis Patients with High DAS28 or CDAI, 40-47% with Moderate, 2-42% with Low, and 0-21% with DAS28 or CDAI Remission",229
1865,Blood-derived Extracellular Vesicles as Potential Diagnostic Biomarker in Fibromyalgia Syndrome,95
1866,Exploring Psychosocial Characteristics of Youth with Chronic Pain Across Gender Identities,90
1867,Effect of the COVID-19 Pandemic on Health Status of Fibromyalgia,64
1868,Prevalence of Musculoskeletal Manifestations in Post-acute COVID 19 Patients and Their Quality of Life at Kenyatta National Hospital,132
1869,Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores,199
1870,"Evaluation of Fibromyalgia, Clinical/Serologic Activity, and Patient Reported Outcomes in a Racially/Ethnically Diverse SLE Patient Cohort",138
1871,A Survey on Fibromyalgia-Related Knowledge Among Internal Medicine Residents,76
1872,Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium,126
1873,Depression and Suicide Attempt in Systemic Lupus Erythematosus with and Without Fibromyalgia,92
1874,The Burden of Dysautonomia in Patients Suffering from Pathologies Associated with Generalized Joint Hypermobility,113
1875,Value of Small Fiber Neuropathy in Fibromyalgia Patients in a Rheumatological Setting,85
1876,Value of Various Intra-Articular Injections for Knee Osteoarthritis Management,78
1877,Clinical Trial Perceptions Among Male Patients with Systemic Lupus Erythematosus (SLE): Georgians Organized Against Lupus (GOAL) Cohort,135
1878,Reduction in the Concomitant Ordering of Erythrocyte Sedimentation Rate and C-Reactive Protein Within the Rheumatology Clinics at an Academic Medical Center,156
1879,Detection of Clinically Relevant Subgroups in Patients Undergoing Knee Replacement Using Machine Learning,105
1880,Are Patients with Inflammatory Rheumatic Diseases Ready for Studies with Medical Cannabis? – Results from a Digital Survey,122
1881,Development of a Scoring System for Accurate Lupus Nephritis Case Identification in Real-World Databases,104
1882,"A Longitudinal Study: The Benefits of Non-Pharmacological Approaches to Improve Self-Reported Pain, Stiffness, and Fatigue in Individuals with Musculoskeletal Disorders",168
1883,Influence of Seasonal Changes on Adherence in Rheumatoid Arthritis Patients,75
1884,Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease,103
1885,Impact of the First Three Waves of the Covid-19 Pandemic on Everyday Restrictions and Clinical Care of Patients with Spondyloarthritis Across Europe – Results from the EuroSpA Collaboration,189
1886,Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data,187
1887,Healthcare Providers’ Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar,98
1888,Human Papillomavirus Vaccine Uptakes in Ethnically Diverse Women Living with Systemic Lupus Erythematosus,105
1889,Each Joint in a 28 Joint Count Is More Likely to Be Affected by Deformity/Limited Motion Than by Swelling in Rheumatoid Arthritis Patients with Long Disease Duration: Deformity/Limited Motion Should Be Included in Joint Counts Performed in Routine Care,252
1890,What Is Our Regional Delay to Diagnosis in Patients with Axial Spondyloarthropathy – Are We Hitting the Target? Data from a Multi-centre UK Patient Cohort,154
1891,Using a Whole-population Approach to Help Design More Effective and Efficient Healthcare Services for People with Fibromyalgia,126
1892,Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project,189
1893,More Than 50% of Rheumatoid Arthritis (RA) Patients with High or Moderate CDAI (clinical Disease Activity Index) Screen Positive on MDHAQ (multidimensional Health Assessment Questionnaire) Indices for FAST4 (fibromyalgia Assessment Screening Tool) And/or MDS2 (MDHAQ Depression Screen),285
1894,How Did a Mandatory Switch Policy Influence the Uptake of Adalimumab Biosimilar and Other TNF Inhibitors?,105
1895,Examining Hydroxychloroquine Prescribing and SLE Damage in a Statewide Lupus Cohort,83
1896,Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis,167
1897,Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases,204
1898,"Significant Overlap of Inflammatory and Degenerative Features on Spinal Imaging Among Patients with Degenerative Spinal Disease, Diffuse Idiopathic Skeletal Hyperostosis and Radiographic Axial Spondyloarthritis",210
1899,Immune-mediated Hypertrophic Pachymeningitis: Focusing on the Localization and Volume of Thickened Dura Mater Lesion,116
1900,Quantifying Inflammation: A Novel In-Vivo Total Body PET Imaging Tool to Determine the Kinetics of the Degree of Changes in Inflammation in Different Time Points,161
1901,Is Flexion Contracture in Knee Osteoarthritis Associated with MRI Pathologies over Time? Data from the Osteoarthritis Initiative,128
1902,MRI Confirms MRE Evidence of Sacroiliitis in Many with Crohn’s Disease: A Prospective Study for the Screening of axSpA in High-risk Populations,143
1903,Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography,203
1904,Long-term Efficacy of a 2-year MRI Treat-to-target Strategy on Radiographic Joint Damage Progression in Rheumatoid Arthritis Patients in Clinical Remission – Five Year Follow-up of the IMAGINE-RA Randomized Clinical Trial,221
1905,"FDG-PET/CT for Diagnosing Polymyalgia Rheumatica Before, During and After a Short-term Prednisolone Cessation – a Prospective Study of 101 Patients",147
1906,Assessing the Appropriateness of Imaging Modalities in Primary Care for Low Back Pain and Their Impact on Outcomes: A Retrospective Observational Study in a Single Center in Trenton,181
1907,Utility of Infrared Thermography in Patients with Digital Gangrene,66
1908,Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients,127
1909,Cervical Spine Involvement in Axial Spondyloarthritis. Radiographic Characteristics and Associated Factors,106
1910,Cartilage Thickness Measures Are More Responsive Than Cartilage Area Loss Measures: A Comparison of Quantitative and Semi-quantitative Cartilage Assessments from the Osteoarthritis Initiative,191
1911,Inter and Intra-observer Reliability of Assessment for Nailfold Capillary Abnormalities in Rheumatic Patients with Raynaud’s Phenomenon,135
1912,A Deep Learning System for Automated Assessing Microcirculation Abnormalities in Nailfold Capillaroscopy Images of Systemic Sclerosis,133
1913,Diagnostic Yield of 18F-FDG PET-CT for Large Vessel Involvement in Patients with Suspected Giant Cell Arteritis and Negative Temporal Artery Biopsy,147
1914,MRI-determined Intramuscular Fat Changes During Oral Glucocorticoid Treatment: Findings from a Feasibility Study,112
1915,Artificial Intelligence for the Detection of Sacroiliitis on Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis,128
1916,Performance of Machine Learning Algorithms in Discriminating Spondyloarthritis Features on Magnetic Resonance Imaging: A Systematic Review and Meta-analysis,156
1917,Deep Learning Approaches to Rheumatoid Arthritis Severity Prognosis,67
1918,"Imaging in Diagnosis, Monitoring and Outcome Prediction of Large Vessel Vasculitis: A Systematic Literature Review Informing the 2023 Update of the EULAR Recommendations",169
1919,Thalamocortical Mechanisms of a Remote Mind-body Intervention for Knee Osteoarthritis Pain,90
1920,Which Cell Pattern in Immunological Bronchoalveolar Lavage (BAL) Is Associated with a High-resolution Computer Tomography (HRCT) Pattern at the Onset of Inflammatory Rheumatic Disease with Interstitial Lung Disease?,215
1921,The Frequency and Importance of Subchondral Radius Cysts in Rheumatoid Arthritis Patients Under B/tsDMARDs,106
1922,Costotransverse Joint Ankylosis and Association with Syndesmophyte Progression in Patients with Radiographic Axial Spondyloarthritis,132
1923,Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients,127
1924,Solving the Final Puzzle of Gout Detection in DECT via Machine Learning-Based Mitigation of Pseudolesion-Related Challenges: Enhancing Diagnostic Accuracy,154
1925,Utility of a Diagnostic Algorithm in the Assessment of Large Vessel Vasculitis,78
1926,Use of Artificial Intelligence to Diagnose Polymyalgia Rheumatica on 18F-FDG Whole Body PET/CT in Patients with Atypical Clinical Features,138
1927,Effect of Apremilast on Disease Interception in Patients with Psoriasis at Increased Risk of Developing PsA – Results of the Prospective Interventional Epos Trial,162
1928,Sacroiliac Bone Marrow Oedema on Postpartum MRI Does Not Result in Significant SpA-like Structural Lesions: Results of a 5-year Follow-up Study,143
1929,Abnormalities Detected with [18F]-FDG-PET/CT Imaging in VEXAS Syndrome,70
1930,3-Dimensional Regional Variation in Inter-rater Reliability of Bone Marrow Lesion Scoring in the Knee,101
1931,Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies,137
1932,Systematic Review and Analysis of Mobile Apps for Rheumatoid Arthritis Using the Mobile Application Rating Scale,112
1933,In Pursuit of Excellence: Improving Systemic Sclerosis Quality of Care,70
1934,Patient After Visit Instructions at a University Rheumatology Outpatient Clinic: Do They Make a Difference?,107
1935,Healthy People with Lupus 2030: Goals to Improve the Quality of Care and Health of All People with Lupus in the United States,125
1936,Assessment of Hospitalist Confidence Levels in Management of Rheumatic Conditions to Identify Potential Knowledge Gaps,118
1937,Which ASDAS-ESR Cut-offs for Disease Activity Correspond to ASDAS-CRP Cut-offs in Axial Spondyloarthritis? – Results from the EuroSpA Collaboration,147
1938,Improving the Sharing of Information from Reviews of Measurement Properties: The OMERACT Summary of Measurement Properties (SOMP) Table,135
1939,Assessing Disparities Through Missing Race and Ethnicity Data: Results from a Juvenile Arthritis Registry,105
1940,Treat-to-Target in RA Clinical Practice: Global Evidence of Practice Gaps and Educational Needs,95
1941,Implementation of the Clinical Disease Activity Index to Optimize Treat-to-Target Management of Rheumatoid Arthritis at the University of North Carolina Hospitals Rheumatology Specialty Clinic,192
1942,"Implementation Practices for the 2022 American College of Rheumatology Guidelines for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis",183
1943,Selection of a Candidate Instrument to Assess Flare in Osteoarthritis with Content Matching with Endorsed Domains,113
1944,Clinic Protocol Boosts Blood Pressure Confirmatory Readings and Accuracy in an Academic Medical Center,102
1945,Identifying and Addressing Suboptimal Urate Lowering Therapy in Gout Patients with Chronic Kidney Disease,105
1946,Development of the American College of Rheumatology Toolkit for Implementation of Rheumatoid Arthritis Outcome Measures in Clinical Practice,140
1947,Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study,173
1948,Impact of Pharmacist-Led Specialty Medication Management Service on Time-to-Dispense for Specialty Rheumatologic Medications in a University Health System,154
1949,Neurosarcoidosis Disease Epidemiology. University Hospital in Northern Spain 1999-2019,86
1950,Intravenous Immunoglobulins in the Treatment of Idiopathic Inflammatory Myopathies in a Region of Northern Spain: Analysis by Subtypes,134
1951,Scleritis and Development of Autoimmune Disease: A Case Series,62
1952,Clinical Features of the Patients with NLRP1 Gene Variants and a Systemic Autoinflammatory Phenotype,100
1953,Reducing Inadvertent Antifilarial Antibody Testing at an Academic Medical Center: A Quality Improvement Project,111
1954,Nationwide Analysis of Predictors of Sarcoid Inpatient Mortality,64
1955,Arthroplasty Outcomes in Immune Checkpoint Inhibitor-Treated Patients: A Single Center Series,93
1956,"A Phase Ib/II Randomized, Double-blind, Placebo-controlled Study of Novel anti-IL-17A Monoclonal Antibody JS005 in Patients with Moderate to Severe Psoriasis",157
1957,Clinical Spectrum of VEXAS Syndrome in a Rheumatology Department,64
1958,Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol,207
1959,Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre,113
1960,Impact of the COVID-19 Pandemic on Clinical and Psychosocial Features of Patients with UCTD,91
1961,Importance of the Patient Pain Experience in Disease Activity Assessment in the Adult SAPHO and Chronic Nonbacterial Osteomyelitis Study,136
1962,Use of 18F-FDG PET in Assessing Response to Treatment in Adults with Pulmonary Sarcoidosis: A Systematic Literature Review,122
1963,"Manifestations, Management and Outcomes of Interstitial Lung Disease Associated with Anti-synthetase Syndrome: A Systematic Literature Review",141
1964,Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies,123
1965,Anakinra Treatment in Idiopathic Recurrent Pericarditis: A Single-center Experience,83
1966,Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series,82
1967,Anti-Ku Antibodies: A Case Series,33
1968,The Association Between Initial Ferritin and Complications from Adults Onset Stills Disease and Intensive Care Unit Admission,125
1969,Analysis of IgG4-Related Disease in a Diverse Long Island Population: Insights from the Rheumatology Clinic,107
1970,"Pooled Safety Analysis from the VOLTAIRE Trials in Patients with Rheumatoid Arthritis, Crohn’s Disease, and Chronic Plaque Psoriasis",132
1971,Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19,201
1972,Higher Rates of Disease Control During the Coronavirus Pandemic in Pediatric Patients with Autoinflammatory Periodic Diseases on Canakinumab Treatment – Interim Data from the RELIANCE Registry,192
1973,Efficacy of Different Treatment Approaches for Cardiac Sarcoidosis,66
1974,"Cranial Nerve Manifestations in Sarcoidosis Associated with Lymphoma, Non-facial Paralysis, and Other Neurologic Disorders",122
1975,"Sinonasal Sarcoidosis Associated with Chronic Pulmonary Disease, Deficiency Anemias, and Obesity",96
1976,"A Single-center, Observational, Retrospective, Case Control Study of Rituximab for the Treatment of Interstitial Pneumonia Associated with Autoimmune Features",158
1977,Identification of VEXAS Syndrome in Mexican Patients with Inflammatory and Hematologic Manifestations,101
1978,Prevalence and Screening Strategy for Latent Tuberculosis Infection in Patients with Rheumatic Immune-Mediated Diseases,119
1979,IgG4-related Disease: 2010-2022 Case Review and Comparative Evaluation of Diagnostic Criteria,93
1980,Characterization of Interstitial Pneumonia with Autoimmune Features (IPAF) in a National Referral Centre,104
1981,Case Series of 6 Patients Exhibiting Myositis as a Rheumatologic Adverse Events Related to Cancer Immunotherapy in Two Spanish Hospitals,136
1982,Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis,230
1983,"National Incidence, Prevalence & Mortality in Idiopathic Inflammatory Myopathies & Associated Interstitial Lung Disease in England",130
1984,The Influence of Specific Myositis Antibodies on the Development of Interstitial Lung Disease,93
1985,Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis,159
1986,Thromboembolic Risk Associated with Intravenous Immune Globulin Use in Patients with Idiopathic Inflammatory Myopathy: A Large Database Study,141
1987,Valid and Reliable Physical Function Tests in Idiopathic Inflammatory Myositis,78
1988,Anti-MDA5 Associated Dermatomyositis: Clinical Features and Outcomes in a Predominantly African-American Case Series,116
1989,Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019,114
1990,Evaluation of Cancer Screening Methods in Patients Diagnosed with Inflammatory Muscle Disease at Kansas University Medical Center,129
1991,"Responsiveness and Minimal Important Difference of PROMIS Pain Interference, Fatigue, and Physical Function Forms in Adults with Idiopathic Inflammatory Myopathies",163
1992,Rituximab Treatment in Adult Patients with Idiopathic Inflammatory Myositis (IIM): A Systematic Review and Meta-analysis,120
1993,Non-Linear Mendelian Randomization Analyses Support a Role for Low Vitamin D Status in Sarcopenia Risk,102
1994,"Validity, Responsiveness and Minimal Clinically Important Difference of EQ-5D-5L in Inflammatory Myositis: A Longitudinal Study",127
1995,Quantitative Scoring of High Resolution Chest Computed Tomography (HRCT) Images in Myositis and Antisynthetase Syndrome Related Interstitial Lung Disease in Comparison to Scleroderma Related Interstitial Lung Disease,216
1996,From Clinical Amyopathy to Severe Oropharyngeal Dysphagia in Pure Dermatomyositis: A Greater Extent of Muscle Weakness Is Associated with a Higher Cancer Prevalence,164
1997,Anti-PM/Scl Autoantibodies in Juvenile Myositis Are Associated with a Distinct Phenotype Resembling Anti-synthetase Syndrome,124
1998,Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis,173
1999,Effect of JAK-STAT Inhibition by Baricitinib and Tofacitinib on Disease Phenotype in a Mouse Model of Myositis,110
2000,Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization,133
2001,Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Idiopathic Inflammatory Myopathies: Results from the COVAD Study,157
2002,Investigating Esophageal Involvement in Anti-Synthetase Syndrome: How to Discover the Submerged?,96
2003,Infectious Myopathies in an Urban Inflammatory Idiopathic Myopathy Cohort: Frequency and Impact on Disease Course and Treatment,127
2004,Pregnancy Outcomes in Idiopathic Inflammatory Myopathies: A Comparison to the General American Population,105
2005,Multimorbidity and PROMIS Health Outcomes in Patients with Idiopathic Inflammatory Myopathies: Analysis from the COVAD Study,124
2006,Impaired Health-Related Quality of Life in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Analysis from the COVAD Dataset,142
2007,Muscle Pathology in Patients with Primary Biliary Cholangitis,61
2008,"Evaluation of Myositis Autoantibodies as Predictors of Response to IVIG: Post-hoc Analysis of a Large Randomized, Double-Blind, Placebo-Controlled Phase III Trial",162
2009,Work-related Impact in Young Patients with Chronic Back Pain Awaiting a Magnetic Resonance Imaging,98
2010,Comparison of Gait Spatiotemporal Measures Between Patients with Insertional Achilles Tendinopathy or Midportion Achilles Tendinopathy,134
2011,Do You Believe in Exercise for Osteoarthritis? Exploring Differences in Participant Characteristics with Treatment Beliefs in Exercise for Knee Osteoarthritis,158
2012,Distribution and Validity of Proposed Disability Categories from the Short-Valued Life Activities Questionnaire,111
2013,"Combined Datasets for CNTX-4975 Osteoarthritis Knee Pain (OAKP) Phase 3 Trials (OAKP 301 and 304) to Assess Overall Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP)",275
2014,Infrapatellar Fat Pad Size and Subcutaneous Fat in Knee Osteoarthritis Radiographic Progression: Data from the Osteoarthritis Initiative,136
2015,Weight Loss Induced by Anti-obesity Medications and All-cause Mortality Among Patients with Knee or Hip Osteoarthritis,118
2016,Movement Evoked Pain as an Outcome Measure in Patients with Knee Osteoarthritis,79
2017,The Association Between X-ray Progression and Clinical Outcomes in Patients with Hand Osteoarthritis with 5-year Follow-up,122
2018,Effect of Denosumab on Knee Pain and Bone Marrow Lesions in Symptomatic Knee Osteoarthritis,91
2019,Heated Mittens for Patients with Hand Osteoarthritis: A Randomized Trial,72
2020,Therapeutic Effects of Pentosan Polysulfate Sodium on Clinical and Disease Modifying Outcomes in Subjects with Knee Osteoarthritis,130
2021,"Preliminary Results for the Total Knee Replacement Coaching Program for Patients Preparing to Undergo Total Knee Arthroplasty, a Pilot Randomized Trial",151
2022,"Deep Immunophenotyping of Osteoarthritis Patients Demonstrates Baseline Alterations in Monocyte Populations in OA, Dendritic Cell Subpopulations Among Radiographic Progressors, and Th17 Cells Among Pain Progressors",214
2023,Clinical and Imaging Characteristics of Individuals Who Underwent Knee Replacement During Years 3 to 5 in the FORWARD Study: A Post Hoc Analysis,144
2024,Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis,165
2025,Shared Variation Among Cartilage Thickness Change Maps and Baseline Clinical Features at the Initiation of Structural Knee Osteoarthritis,137
2026,Effects of Exercise on Movement-Evoked Pain in People with Knee Osteoarthritis,78
2027,"Therapeutic Efficacy of Intra Articular Injection of Human Bone Marrow Derived Mesenchymal Stem Cells in Knee Osteoarthritis; Randomized, Double-blind, Placebo-controlled Clinical Trial",185
2028,Association Between Knee Osteoarthritis Pain and Concomitant Drug Use: A Post-hoc Analysis of Two Phase 3 Clinical Trials,121
2029,Impact of Metabolic Syndrome on Ultrasonographic Findings and Quality of Life in Patients with Early Osteoarthritis,115
2030,How Is Paracetamol Prescribed in Low Back Pain and Osteoarthritis in France? Paracetamol Prescription Patterns in the Real-World General Practice,145
2031,"Cross-cultural Adaptation, Reduction, and Validation of the Turkish Versions of the Flare-OA Questionnaire for Hip and Knee Osteoarthritis",138
2032,Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics,116
2033,"A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis",159
2034,How to Tailor Osteoporosis Therapies in Patients with Advanced Liver Disease? Variations of Renal Function by Creatinine and Cystatin C,135
2035,One-year Incidence of Clinical Fragility Fractures After Implementing an Osteoporosis Care Protocol in Patients Eligible for Liver Transplantation,146
2036,Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study,120
2037,Burden of Metabolic Bone Disease in Patients with IgG4-Related Disease with and Without Autoimmune Pancreatitis,111
2038,Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures,147
2039,Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis,99
2040,Bone Health Following Bariatric Surgery: A Single Center Quality Improvement Study,82
2041,Secondary Prevention of Osteoporosis in Hip Fracture Care for Elderly Patients. Clinical and Functional Profile of Users,120
2042,Improvement of Care: Osteoporosis Screening in a Resident-led Primary Care Clinic,81
2043,Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study,114
2044,Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program,131
2045,Screening and Treatment of Low Bone Mineral Density in Allogeneic Hematopoietic Cell Transplant Patients,104
2046,B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort,123
2047,Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis,121
2048,Incidence of Hyperparathyroidism in Patients with Osteoporosis Treated with Zoledronic Acid or Denosumab,104
2049,Clinical Characteristics and Risk Factors Associated with Fragility Fractures in Patients with Primary and Idiopathic Mast Cell Activation Syndromes,148
2050,The Role of Orosomucoid 2 in the Regulation of Bone Remodeling by Inhibiting Osteoclastogenesis and Promoting Osteogenesis,122
2051,Synergistic Effect Between Denosumab and Immune Checkpoint Inhibitors : A Retrospective Study of 268 Patients with Bone Metastases,130
2052,Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis,92
2053,Lupus Nephritis Is Strongly Associated with Low Bone Mineral Density and Osteoporosis in Patients with Systemic Lupus Erythematosus,131
2054,Development of an Osteoporosis Treatment Gap Dashboard,54
2055,2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases,123
2056,Exploring Experiences and Perspectives of Canadian Patients with Lupus Nephritis Through Photovoice,99
2057,"Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy",128
2058,Development of an mHealth App for Lupus: Insights from a Human-Centered Design Approach,87
2059,Transition Readiness over Time in a Rheumatology Transition Clinic,66
2060,Patient-Reported Outcomes in Patients with Lupus Nephritis: A Post Hoc Analysis of Control Arm Data from Two Completed Phase III Randomized Clinical Trials,155
2061,Osteoporosis Treatment Attributes and Levels for an Online Decision-Making Tool for Patients: Findings from Adaptive Choice-Based Conjoint Analysis,147
2062,Developing a Guided Joint Self-Exam for Rheumatoid Arthritis Patients to Use in Telehealth-Delivered Care,105
2063,Developing and Implementing a Pilot Educational Intervention to Improve Readiness for Self-Management Among Patients with Rheumatic Diseases in Uganda,150
2064,Endorsement of Core Domain Definitions to Measure the Impact of Glucocorticoids in Patients with Rheumatic Diseases: A Report from the OMERACT Working Group on Glucocorticoid Impact,181
2065,Health-Related Quality of Life in Idiopathic Inflammatory Myopathies: How to Act for Improving the Disease Burden of Patients?,126
2066,Positive Psychosocial Factors May Protect Against Perceived Stress in a Multiethnic Cohort of People with SLE with and Without Trauma History,141
2067,Involving Patients Research Partners in Research in Rheumatology: Where Do We Stand? A Scoping Review of Recent Randomized Controlled Trials and Translational Science Studies,174
2068,Goal Concordance in Rheumatoid Arthritis Patients with Depression – What Do Patients Prioritize?,96
2069,Sex Differences in Patient-Reported Outcomes in Patients with Rheumatoid Arthritis After Starting a New Disease-Modifying Antirheumatic Medication,146
2070,Assessment of the Immediate and Short-term Impact of an Information Course on Patients’ Knowledge About Rheumatoid Arthritis: Evaluation Using a Self-prepared and Validated Assessment Questionnaire,197
2071,Intimate Partner Violence Is Associated with a Poorer Health-Related Quality of Life (HR-QoL) in Women with Systemic Lupus Erythematous,135
2072,Switch or Stay the Same? Preferences of People with Autoimmune Disease on Rituximab for Different Types of COVID-19 Vaccine Boosters,132
2073,"Assessing Risk of Depression in Common Rheumatologic Disorders Using Diagnostic Codes, Survey Scores, and Propensity Score Matching Methodology",143
2074,Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients,89
2075,"Clinical, Immunologic, and Genetic Characteristics in Patients with Syndrome of Undifferentiated Recurrent Fevers (SURF)",120
2076,Distinguishing Multisystem Inflammatory Syndrome in Children from Typhus Using Artificial Intelligence: MISC vs. Endemic Typhus (AI-MET),136
2077,An Analysis of Recurrent Parotitis Patients Referred to Rheumatology Clinic,75
2078,Intraocular Cytokine Profiling of Autoimmune Uveitis,52
2079,Phenotype of Musculoskeletal Manifestations in a Canadian Inception Cohort of Pediatric Patients with Inflammatory Bowel Disease,128
2080,Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population,106
2081,Treatment Response in a Cohort of Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV),127
2082,Implementation of an Automated Transition Readiness Assessment in a Pediatric Rheumatology Clinic,97
2083,Safety of Baricitinib for COVID-19 Related Hyperinflammation in Pediatric Patients: A Large Tertiary Care Center Experience,123
2084,Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO),162
2085,Vaccination Coverage and Caregiver Perspectives for Children with Rheumatic Diseases Compared to Healthy Controls,113
2086,Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey,183
2087,Screening Multisystem Inflammatory Syndrome in Children: Accuracy of SickKids Screening Pathway Compared to ACR Algorithm,121
2088,Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis,132
2089,Predictive Factors Associated with Treatment Response in Chronic Nonbacterial Osteomyelitis,91
2090,Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience,114
2091,A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study,179
2092,Pediatric Acute-onset Neuropsychiatric Syndrome: Markers of Inflammation/autoimmunity at Clinical Presentation and Eventual Development of Arthritis and Other Autoimmune Diseases,178
2093,Medical Trauma and Its Association with Pain and Disability Risk in Children with Inflammatory Arthritis,104
2094,IL-1 Blocking Treatment Slows the Progression of Sensorineural Hearing Loss in Patients with NOMID,98
2095,"Management of Iatrogenic, Recombinant Interleukin-1 Receptor Antagonist-type Amyloidosis on NOMID in Patients on Anakinra",121
2096,Creation of a Standardized and Collaborative Transfer Process from Pediatric to Adult Rheumatology,98
2097,Evaluation of a Tool to Enhance Training of the Physical Examination of the Temporomandibular Joint (TM Joint) in Juvenile Idiopathic Arthritis (JIA),149
2098,A Mental Health Workshop for Pediatric Rheumatology Fellows,59
2099,Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers,188
2100,Perceptions of Rheumatology Fellows on Mentorship Quality After Implementation of a Formalized Mentorship Program,113
2101,Exploring the Power of Ultrasound in Rheumatology: Insights from Young Rheumatologists in Mexico,96
2102,Ultrasound Guided Synovial Biopsy Course: Achievement of Learner Self Efficacy,78
2103,A New Tool Assessing Trainees’ Interventional Musculoskeletal Ultrasound Skills,79
2104,Integration of Basic Science into Virtual Patient Cases to Enhance Clinical Reasoning Skills,92
2105,Navigating the Residency-to-Fellowship Transition in Rheumatology,65
2106,Augmenting Medical Education: An Evaluation of GPT-4 and ChatGPT in Answering Rheumatology Questions from the Spanish Medical Licensing Examination,147
2107,A Consensus Based Shoulder Examination for Rheumatology Training,64
2108,Utility of a Novel Pediatric Rheumatology Interactive Teleconference Series: Rheum2Play,87
2109,Outcomes of the First Year of a Rheumatology Curriculum at Two Internal Medicine Residency Programs,99
2110,Creation and Dissemination of a Near-Peer Rheumatology Fellowship Bootcamp,74
2111,The Impact of Rheumatology Fellow Initiated Curriculum Design on Resident Education,83
2112,Piloting a Rheumatology and Sports Medicine Case-Based Collaborative Learning Curriculum for Medical Students,109
2113,"A Curriculum of Online Education Significantly Improved Rheumatologists’ Knowledge, Competence and Confidence in Managing Patients with Spondyloarthritis",153
2114,Interim Evaluation of a 6 Year Remote Online Adaptive Learning Platform Module for Rheumatology Fellows: Applied Rheumatology on the Go,135
2115,Comparative Analysis of Teledidactic and On-Campus Training in Musculoskeletal Ultrasound – the TELMUS Study,108
2116,Implementation of a Clinically-Focused Online Journal Club in Rheumatology: Experience from TheMednet,101
2117,Harnessing the Power of Social Media for Good: Using Instagram as a Formative Assessment Tool,93
2118,Delivery of Rheumatology Education to Internal Medicine Residents in Rwanda: Evaluation of a New Virtual Rheumatology Course Supplemented by On-site Clinical Teaching,166
2119,Compiled Verbal Feedback as a Novel Mechanism for Faculty Feedback from Rheumatology Fellows-in-Training,104
2120,Enhancing Internal Medicine Curriculum: Key Rheumatology Themes in Inpatient Setting,84
2121,A Survey on Giant Cell Arteritis-Related Knowledge Among Internal Medicine Residents,84
2122,From Fellow to Fellowship Director: Gender Equity in Pediatric Rheumatology Pipeline,84
2123,Racial and Ethnic Diversity in Pediatric Fellowships: Fortifying the Pipeline,77
2124,Room for Racial and Ethnic Diversity in Adult Rheumatology Fellowship Pipeline,78
2125,Social Listening Analysis of IgG4-Related Disease Social Media Discussions,74
2126,Adaptation of the Making it WorkTM for People with Systemic Sclerosis,69
2127,"Reach and Representativeness of Participants in an Evidence-Based, Community-Delivered Physical Activity Intervention in Adults with Arthritis",142
2128,Feasibility and Efficacy of Culturally Appropriate Spanish Language-First Patient Education for Rheumatoid Arthritis,116
2129,Meeting the Educational and Language Needs of the Lupus Community: A Snapshot of 2022 Lupus Inquiries,101
2130,"Increasing Collaboration, Education, and Awareness of Scleroderma Through an Interprofessional Education Program: Emphasizing the Importance of a Multidisciplinary Team and the Patient as the Primary Educator",208
2131,Integrated Analysis of Gene Expression and Methylation Identifies Biomarkers Associated with Mode of Action of Upadacitinib Treatment in Rheumatoid Arthritis,157
2132,Association of Left Ventricular Mass with Interleukin-17 in Rheumatoid Arthritis Patients Without Clinical Heart Failure,120
2133,Comparing the World Health Organization and the American College of Cardiology/American Heart Association Algorithms for Detection of Carotid Plaque,148
2134,Contribution of Rare Deleterious Exonic Variants in Telomere Related Genes to Interstitial Lung Disease Risk in Patients with Rheumatoid Arthritis,146
2135,Lesser Impact of Lower-Small Joint Involvement on Pain Than Upper-Small Joint in Rheumatoid Arthritis: Analysis Based on a Large Rheumatoid Arthritis Database in Japan,167
2136,Paradoxical Antagonistic Association of Visceral and Subcutaneous Adipose Tissue with Circulating C-Reactive Protein in Rheumatoid Arthritis,140
2137,Diagnosis of Mental Disorder Complicated by Rheumatoid Arthritis: A Study of the Validity of a Psychiatrist’s Diagnosis and Questionnaire Method,144
2138,Is This Prosthetic Joint Infected or Flaring?,45
2139,Inflammation and Immunomodulatory Therapies Influence the Relationship Between ATP-binding Cassette Transporter A1 (ABCA1)-mediated Cholesterol Efflux and Coronary Atherosclerosis in Rheumatoid Arthritis,203
2140,Relationship Between Frailty and Large Joint Symptoms in Rheumatoid Arthritis Patients,86
2141,Cohort-wide Immuno-phenotype Deconvolute Immunological and Clinical Heterogeneity Across Autoimmune Rheumatic Diseases,118
2142,Evaluation of the Construct of Constitutional Stiffness (CS) in Anti-CCP-Antibody-Positive Rheumatoid Arthritis (ACPA+RA) and Controls,134
2143,Social Determinants of Health and Clinical Outcomes in Rheumatoid Arthritis: A Single Center Study,98
2144,Specific Symptom Clusters at Diagnosis Signal a Poorer Early RA Prognosis: Data from the Canadian Early Arthritis Cohort (CATCH),128
2145,Real-world Positivity of 14-3-3η Protein in Rheumatoid Arthritis,64
2146,Rheumatoid Arthritis and Changes in Pulmonary Function Measures on Spirometry in a Prospective Longitudinal Cohort of Smokers,125
2147,Self-reported Methotrexate Adherence Underestimates Biochemical Adherence: Results from the Methotrexate Use Improvement in Rheumatoid Arthritis Using Biomarker Feedback Trial,175
2148,Physical Activity in a Cohort of Patients with Rheumatoid Arthritis,67
2149,Impact of Sociodemographic Factors on Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 2/3/3b/4 Studies,157
2150,The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function,85
2151,Genetic Risk Load as a Predictor of Radiographic Damage and Mortality in Female Patients with Rheumatoid Arthritis,114
2152,Risk of Tuberculosis in Patients with Rheumatoid Arthritis: A Nationwide Population-based Cohort Study,102
2153,Frailty Is Associated with Mortality in Veterans with Rheumatoid Arthritis,74
2154,New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry,152
2155,"Serum Alarmin Concentrations and Risk of Incident Major Adverse Cardiovascular Events and Heart Failure in a Multicenter, Prospective Rheumatoid Arthritis Cohort",161
2156,Independent and Combined Impact of Interstitial Lung Disease and Airway Disease on Rheumatoid Arthritis Disease Activity and Infections,135
2157,Clinical Significance of Negative Seroconversion of Anti-CCP and Anti-Mutated Citrullinated Vimentin Antibodies in Patients with Rheumatoid Arthritis,149
2158,Coronary Calcium and Carotid Artery Stiffness as Predictors of Cardiovascular Events and Mortality in Patients with Rheumatoid Arthritis: A 10-year Prospective Follow-up Study,175
2159,Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?,113
2160,Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals,117
2161,Comparing the ITIS Diet and the Mediterranean Diet in Rheumatoid Arthritis: Preliminary Findings on Clinical and Microbiome Outcomes,132
2162,Performance of the Rheumatoid Arthritis Impact of Disease (RAID) Score in Relation to Flares in Disease Activity,112
2163,"Associations Between Rheumatoid Arthritis, Frailty Status and Mortality in Older Adults with Bladder Cancer",107
2164,Higher Vitamin D Levels Before Methotrexate Start Are Associated with Lower Subsequent Mortality in Rheumatoid Arthritis,120
2165,SCORE and SCORE2 Comparison in Cardiovascular Risk Estimation in Rheumatoid Arthritis Patients: A Cross-sectional Study Including Carotid Ultrasound,148
2166,Prevalence and Risk Factors of Pneumocystis Jirovecii Colonization in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors and Tocilizumab,166
2167,Time-course Analysis from the First Wave to Early 2023 in Critically Ill Patients with Novel Coronavirus Infection in Rheumatoid Arthritis,138
2168,Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates,137
2169,Cardiovascular Risk Factors Are Associated with Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results from the OBRI,157
2170,Autoantibodies to Joint-related Proteins Predict Remission with High Specificity in New Onset RA,96
2171,Synovial Fluid High-density Lipoprotein (HDL)-miR-1246 Is Enriched in Patients with Inflammatory Arthritis Compared to Osteoarthritis and Increases Synovial Fibroblast IL-6 Expression,183
2172,Arthritogenic Cells Found in the Peripheral Blood of Rheumatoid Arthritis Patients Transfer the Disease to NSG-DR4 Mice,119
2173,"Line of Therapy of Biologics and JAK Inhibitors in RA, PsA and AxSpA: Implications for Design and Uptake of New Drugs and Diagnostics",133
2174,Frailty Is a Predictor of Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis,95
2175,Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort,97
2176,Serum Alarmins and the Risk of Interstitial Lung Disease in Patients with Rheumatoid Arthritis,94
2177,Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR),210
2178,Adherence Patterns in Rheumatoid Arthritis Patients Receiving a Janus Kinase (JAK) Inhibitor or a Tumor Necrosis Factor α Inhibitor (TNFi) After the Addition of a Black Box Warning to JAK Inhibitors,198
2179,Efficacy of Filgotinib in Patients with Rheumatoid Arthritis: Week 156 Results from a Long-term Extension Study,111
2180,"Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study",208
2181,"Patterns of Use, Effectiveness, Persistence and Cardiovascular Risk in Patients with Rheumatic Diseases Treated with Upadacitinib in a Real-world Setting. UPAREAL Study",168
2182,"After JAK Inhibitor Failure, “Switching” or “Cycling”?",54
2183,Safety and Effectiveness in Cycling Between Non-Selective and Selective JAKi in a Multi-Center Registry of Rheumatoid Arthritis in the Middle East,146
2184,Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial,182
2185,Biologic IRL201805 Drives Differential Cell-contact and Metabolism Transcriptional Profiles in Monocytes from RA Patients Compared to Healthy Donors,148
2186,Novel Biologic IRL201805 Inhibits Osteoclastogenesis in Monocytic Cells from RA Patients,88
2187,Effects of Methotrexate on Blood Pressure in Rheumatoid Arthritis: A Randomized Controlled Trial,96
2188,Survival Benefits of Knee and Hip Arthroplasty in Patients with Rheumatoid Arthritis: A General Population-based Cohort Study,125
2189,Effects of One-year Tofacitinib Therapy on Angiogenic Biomarkers in Rheumatoid Arthritis,88
2190,Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs,176
2191,The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies,112
2192,Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study,124
2193,Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis,205
2194,Continued Nintedanib Treatment in Patients with Progressive Pulmonary Fibrosis Related to Autoimmune Disease: Data from INBUILD-ON,130
2195,"Results of a 24-week Open-label, Non-interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis After Switching from Anti-B-cell Therapy During the SARS-COV-2 Pandemic",216
2196,Poly-Refractory Rheumatoid Arthritis: All B/tsDMARD Classes Exhausted – An Uncommon Disease Subset with Distinct Inflammatory and Non-inflammatory Phenotypes,157
2197,Pharmacokinetic and Safety Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501,114
2198,Safety and Efficacy of Filgotinib: An Update from the DARWIN 3 Phase 2 Long-term Extension with a Maximum of 8.2 Years of Exposure,130
2199,Omnipresent Poor Prognostic Factors in Early Rheumatoid Arthritis in the IMPROVED Trial; Is Earlier bDMARD Treatment Escalation for All Necessary?,146
2200,"Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis",188
2201,Efficacy of Abatacept in Rheumatoid Arthritis- associated Usual Interstitial Pneumonia. National Multicenter Study of 233 Patients During a Long-Term Follow Up,159
2202,"Long-Term Effects of Abatacept on Arthritis and Atherosclerosis in Older vs Younger Patients with Rheumatoid Arthritis: 3-year Results of a Prospective, Multicenter, Observational Study",185
2203,"24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis (Encore1)",118
2204,The Potential of Autologous Patient-derived Circulating Extracellular Vesicles to Improve Drug Delivery in Rheumatoid Arthritis,127
2205,Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial,203
2206,Systemic Glucocorticoids Are Associated with a Time and Dose-dependent Risk of Major Adverse Cardiovascular Event in Patients with Rheumatoid Arthritis: A Population-based Study,177
2207,"Common IL-6 Signaling Is Inhibited by IL-6 Inhibitors and JAK Inhibitors, but Which Is Better at Preventing Bone Destruction in RA?",131
2208,Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients,130
2209,Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients,147
2210,"JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib",126
2211,"Real-World Drug Persistence of GP2015, an Etanercept Biosimilar, in Patients with Rheumatoid Arthritis: Results from the Multi-Country COMPACT Study",148
2212,"Cellular and Proteomic Changes Following Administration of Peresolimab, in a Phase 2a Trial in Rheumatoid Arthritis",115
2213,Characterization of Crevicular Fluid Microbiota in Primary Sjögren’s Syndrome,77
2214,Increased Risk of Dementia in Patients with Primary Sjogren’s Syndrome: A Nationwide Population-based Cohort Study,114
2215,Disease Burden of Patients with Primary Sjögren’s Disease: Results from a Multinational Real-World Survey,105
2216,Salivary and Plasma Mitochondrial Double-strand RNAs as a Diagnostic Biomarker for Sjӧgren Syndrome,99
2217,Secretagogue Effect of PDE4 Inhibitor Apremilast on Human Salivary Gland Organoids Obtained from Primary Sjögren’s Syndrome Patients,132
2218,Mitochondrial Alterations in Primary Sjögren´s Syndrome,55
2219,Evolution of Lymphoma Predictors in Primary Sjogren’s Syndrome by Data Driven Analysis in Harmonized Patients,109
2220,Development of Salivary Gland Organoids to Study Sjögren Syndrome,65
2221,35 Years Follow-up of Primary Sjögren’s Disease: A Single Center Study,70
2222,Neurological Complications in Sjögren’s: Occurrence & Impact on Patient Quality of Life,87
2223,"Association Between Illness Perception, Anxiety and Depression State, Disease Activity and Glucocorticoid Therapy in Patients with Sjӧgren’s Syndrome",149
2224,Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis,74
2225,Lymphopenia Fluctuation Patterns Determine the Trajectory of the Disease in Sjogren’s Patients with Hematological Involvement,125
2226,Saliclick: A Novel Technology for Minimal Invasive Salivary Gland Biopsy in Suspected Sjögren’s Syndrome,104
2227,Efficacy of anti-CD38 Treatment with Daratumumab in Two Cases of Refractory and Severe Sjogren Disease,102
2228,New Inducible Mouse Model of Sjögren’s Syndrome Represents a Valuable Tool to Assess the Impact of Gene Knockout on the Disease’s Physiopathology,145
2229,Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement,160
2230,Association of Self-perceived Oral Health Status with ESSPRI Reported by Sjögren’s Syndrome Patients,100
2231,Regional Differences in Clinical Phenotype of Axial Spondyloarthritis. Results from the International Map of Axial Spondyloarthritis (IMAS),139
2232,Females with Axial Spondyloarthritis Report Higher Burden of Disease and Worse Patient-reported Outcomes. Results from the International Map of Axial Spondyloarthritis (IMAS),174
2233,"Diagnostic Delay in Patients Included in the International Map of Axial Spondyloarthrtis: Associations with Geographic, Socio-demographic and Disease-related Factors",165
2234,Which Factors Are Associated with Clinically High Disease Activity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS),163
2235,Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration,164
2236,Sensitivity to Change of Structural Outcomes in Early Axial Spondyloarthritis After 10 Years of Follow Up. Data from DESIR Cohort,129
2237,When Usual Care Is Not so Usual: Facing the Challenges of Protocol Violations and Generalisability When Running a Strategy Trial. the Example of the Cluster-Randomized TICOSPA Trial,181
2238,"Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Moderate to Severe Psoriasis: Long-Term Efficacy in Placebo Crossovers",164
2239,Self-Reported and Physician´s Assessment of Inflammatory Back Pain According to ASAS Criteria: Is It the Same?,110
2240,Residual Disease Activity in Canadian Patients with Axial Spondyloarthritis: Results from a Multi-registry Analysis (UNISON-Axial SpA),134
2241,"Disease Activity and Widespread Pain Are the 2 Key Drivers of Global Health in Axial Spondyloarthritis, with Similar Findings in Different Patient Populations: An Analysis of 4 Databases and 6064 Patients",204
2242,Increased Frequency of Activated MAIT Cells Expressing the Gut Homing Receptor CCR9 in Patients with Radiographic Axial Spondyloarthritis,137
2243,"Knowledge, Awareness, and Attitudes Regarding Inflammatory Back Pain Among Non-Rheumatology Physicians in the United States",123
2244,Awareness and Attitudes Regarding Axial Spondyloarthritis Among Non-Rheumatology Physicians in the United States,112
2245,Prevalence and Clinical Characteristics of Late Onset Axial Spondyloarthritis: Results from a Multicentre Nationwide Study,122
2246,Antibodies to Four Novel Peptides in New Onset Axial Spondyloarthritis,70
2247,A Two-year Comparison of Back Pain and Morning Stiffness in Axial Spondyloarthritis and Non-axial Spondyloarthritis Chronic Back Pain Patients in the Spondyloarthritis Caught Early (SPACE) Cohort,195
2248,"Interpretation of Disease-specific Questionnaires on Disease Activity, Functional Capacity and Quality of Life in Daily Practice in Axial Spondyloarthritis",155
2249,Identification of a Diagnostic Model for Axial Spondyloarthritis in Daily Clinical Practice Using a Random Forest Machine Learning Approach,139
2250,Systematic Literature Review and Meta-analysis Informing the Development of 2023 Spondyloarthritis Research and Treatment Network (SPARTAN) Referral Recommendations for Axial Spondyloarthritis,192
2251,Can Axial Spondyloarthritis Unequivocally Be Diagnosed by Rheumatologists in Patients with Chronic Back Pain of Less Than Two Years Duration? The Primary Outcome of the Two-year SPondyloArthritis Caught Early (SPACE) Cohort,223
2252,Hierarchy of Determinants of Work Impairment in Spondyloarthritis: Data from the Assessment of Spondyloarthritis International Society Health Index (ASAS-HI) International Validation Study,188
2253,Gender Disparities in Disease Activity Scores and Treatment Response Among Patients with Axial Spondyloarthritis,112
2254,Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients,145
2255,Comparing the Construct Validity Among Measures of Pain and Stiffness in Patients with Axial Spondyloarthritis,110
2256,Factors Associated with Achieving Remission in Patients with Early Peripheral Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort,163
2257,Clinical and Molecular Patterns Associated with Persistence of Inflammation in Spondyloarthritis Patients: Unveiling Potential Biomarkers,137
2258,"Association Spondyloarthritis and Inflammatory Bowel Disease, More Severe Diseases on Both Sides",96
2259,"Relationship Between Sleep Quality, Disease Activity, and Psychological Factors in Patients with Axial Spondyloarthritis: A Cross Sectional Study",145
2260,Difficult to Treat Axial Spondyloarthritis. Predictors of Poor Outcomes,71
2261,"Long-term Evolution of Spondyloarthritis Patients Included in REGISPONSER, 17 Years Later (REGISPON-3 Study)",108
2262,How Do Spondyloarthritis Start? Identification of the First Signs or Symptoms According to Diagnosis and HLA-B27. Data from REGISPONSER and RESPONDIA Registries,160
2263,"The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration",145
2264,Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS Predicts Reduced Rates of Radiographic Change in Bio-naive Active Psoriatic Arthritis Patients Receiving Guselkumab Treatment,182
2265,"Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies",240
2266,Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label Extension up to 1 Year,199
2267,Ixekizumab Significantly Improves Nail Disease and Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis,112
2268,"Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23",186
2269,Neutrophil Levels Associate with Early Improvement in Spinal Pain and Week 24 Multi-Domain Disease Control During Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials,234
2270,Disagreement Between Patient and Physician Global Assessment over Time in Psoriatic Arthritis: Insight into Treatment Priorities,128
2271,Identifying Differentially Expressed Genes to Predict TNF-Alpha and IL-17A Inhibitor Response in Psoriatic Arthritis,116
2272,Guselkumab Provides Rapid Clinically Meaningful Improvements in Clinical and Patient Reported Outcomes and Sustained Disease Control of Psoriatic Arthritis,155
2273,Upadacitinib in Refractory Psoriatic Arthritis. Multicenter Study of 134 Patients in Clinical Practice,102
2274,"Longitudinal Effect of Guselkumab on Biomarkers of Inflammation and Cardiovascular Risk in Bionaive Patients with Active Psoriatic Arthritis and High Systemic Inflammatory Burden: Post-hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-Controlled Study",262
2275,Achievement of Disease Control in PsA Patients Treated with Upadacitinib at Week 152: Post Hoc Analysis of the Long-term Extensions of Two Phase 3 Trials,153
2276,Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi),119
2277,"Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies",176
2278,"Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes",141
2279,Ultrasound Enthesitis Responsiveness versus Clinical Enthesitis Responsiveness: Week 52 Results of an Exploratory Analysis from a Phase 3b Study in Patients with Psoriatic Arthritis,181
2280,Switching Between Biologics and Targeted Synthetic Therapies Due to Inefficacy in Psoriatic Arthritis,101
2281,Drug Survival of Risankizumab vs Other Biologics After 13 Months of Treatment Among Patients with PsA in the Multicountry Postmarketing Observational VALUE Study,161
2282,Real-World Switching and Discontinuation Patterns for Biologic Disease-Modifying Antirheumatic Drugs in Patients with Active Psoriatic Arthritis in Japan,153
2283,Gender Differences in Switching Biological and Targeted Synthetic Therapies in Psoriatic Arthritis,98
2284,Primary Non-response in Psoriatic Arthritis Treated with Biologics and Targeted Synthetic Therapies in Daily Clinical Practice,126
2285,Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies,206
2286,"Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis Who Were Biologic DMARD‑Naïve or Had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized Studies",263
2287,Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study,129
2288,"Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors Who Were Responders at Week 16: Results from a Phase 3, Randomized Study",227
2289,"Deucravacitinib, an Oral, Allosteric, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis in POETYK PSO-1 and POETYK PSO-2: Effect on Joint Pain and Peripheral Joint Disease vs Placebo and Apremilast",266
2290,The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials,225
2291,Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial,163
2292,The Impact of Clinical Trial Metrics in Psoriatic Arthritis,59
2293,Outcomes and Clinical Features of Acute Coronary Syndrome in Patients with SLE: A 14-Year Real-World Study (2006-2019),118
2294,Brain Activity Patterns and Behavioural Performance in SLE Patients During a Spatial Working Memory and Sustained Attention Task,128
2295,The Effects of Systematic Lupus Erythematosus Related Cognitive Impairments on Activities of Daily Living and Life Role Participation: A Qualitative Framework Study,164
2296,Right Insular Cortex-Thalamic Functional Connectivity as a Potential Marker for Fatigue in Systemic Lupus Erythematosus and Primary Sjögren’s Syndrome,150
2297,Burden of Flare and Organ Damage in Systemic Lupus Erythematosus (SLE) in the Asia Pacific Region: A Multicenter Cohort Study,125
2298,Identifying Important Domains for Inclusion in a Novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): Results of a Modified Delphi Study,160
2299,Disease Activity Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS),131
2300,Proposal for Defining Moderate and Severe Activity States in Systemic Lupus Erythematosus. Impact on Flares and Other Outcomes,126
2301,Lupus Damage Index Revision – Item Generation and Reduction Phase,65
2302,Direct Health Care Costs Differ by SLE Autoantibody Machine Learning Clusters in an International Inception,107
2303,Explainable Machine Learning to Predict Hospitalized Infection in Patients with Systemic Lupus Erythematosus,108
2304,Mental Illness and Outcomes of COVID-19 in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study,120
2305,Evaluating Global Patterns in Treatment and Prevalence of Glucocorticoid Related Comorbidities in Systemic Lupus Erythematosus: An International Study,150
2306,Factors Associated with Discordance Between Patient and Physician Perception of Disease Activity Among Patients with Systemic Lupus Erythematosus: An International Collaborative Study,183
2307,Longitudinal Changes in Type 1 & Type 2 SLE Activity,52
2308,Age and Race-Based Differences in Emergency Department Utilization for Systemic Lupus Erythematosus in the United States,120
2309,Predicting SLE Disease Activity with Blood Biomarkers: A Step Towards Precision Medicine,88
2310,Lupus Low Disease Activity State as an Attainable Target in Lupus Nephritis Associated with Reduced Risk of Relapse,115
2311,Lupus Low Disease Activity State Ameliorates the Poor Prognosis in Lupus Nephritis Patients with anti-Sm Autoantibody,117
2312,Patient Reported Impact of Lupus on Quality of Life,51
2313,"Patients with Systemic Lupus Erythematosus: A Comparative Study Between Two Large, Multi-centric, Spanish and Argentinian Registers, Focused on Outcomes Differences",164
2314,Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry,121
2315,"Sociodemographic Features, Health-Related Quality of Life (HRQoL), Previous General Self-Efficacy and Corticosteroids (CS) Are Associated with General Self-Efficacy in Systemic Lupus Erythematosus (SLE) Patients. Data from a Prevalent Latin American Lupus Cohort",262
2316,The LFA-REAL Clinician Reported Outcome Predicts Damage in Patients with Systemic Lupus Erythematosus (SLE). Data from a Prevalent Latin American Lupus Cohort,158
2317,Epidemiology and Risk of Brain Abscess in Patients with Systemic Lupus Erythematosus in Taiwan: A Nationwide Population-based Study,131
2318,Increased Risk of Systemic Lupus Erythematosus Flare After COVID-19,67
2319,Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness,130
2320,Effect of Air Pollutant Exposure on Disease Activity of Systemic Lupus Erythematous: A Prospective Longitudinal Study from Korea,128
2321,Vaccine Uptake in Women with Systemic Lupus Erythematosus (SLE) – Study Update,78
2322,Systemic Lupus Erythematosus and Functional Work Disability: A Qualitative Perspective Using a Work Disability Prevention Approach,130
2323,Mental Health of Lupus Erythematosus Patients Managed in an Academic Safety-Net Clinic,86
2324,Scoping Literature Review and Focus Groups Interviews to Identify Candidate Domains for the SLE OMERACT Core Domain Set,119
2325,Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease,125
2326,Association of Mycophenolate and Azathioprine Use with Cognitive Function in Systemic Lupus Using a Bayesian Longitudinal Item-response Theory Model,148
2327,"Therapeutic Drug Monitoring (TDM) of Hydroxychloroquine in Whole Blood: Analysis of over 10,000 Patient Results Using Lab Developed Liquid Chromatography Tandem Mass Spectrometry",178
2328,Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus?,93
2329,Recurrent Intracellular Infections Cluster Together in Patients of SLE with Lymphopenia and Active Disease,106
2330,Organ Damage Progression in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS),127
2331,Predictors of Adherence to Cervical Cancer Screening Guidelines Among Patients with Systemic Lupus Erythematosus,112
2332,Association Between EQ-5D-5L and SLEDAI Scores in Patients with Systemic Lupus Erythematosus in the United States and Europe: A Real-world Survey,145
2333,Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis,64
2334,SLE Patients Are at High Risk for Tuberculosis Infection: Data from a Lupus Center of an Endemic Country,104
2335,Medication-related Hospitalizations in Systemic Lupus Erythematosus,67
2336,Outcomes of COVID-19 Before and During the Omicron Variant Period in Patients with Systemic Lupus Erythematosus: A Global Multicenter Cohort Study Using the TriNetX Network,172
2337,Relapse in Japanese Patients with Newly Diagnosed SLE and Its Clinical Characteristics in Daily Clinical Practice: A Single Center Experience in Recent 10 Years,160
2338,Persistently Active Disease in Adult Patients with Childhood Onset Systemic Lupus Erythematosus,95
2339,Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?,182
2340,Disparity in Healthcare in Systemic Lupus Erythematosus: A Single-Center Study,78
2341,Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus,87
2342,Changes in Rheumatology Disease Measures After Initiation of Belimumab Treatment in Patients with Systemic Lupus Erythematosus,126
2343,Comparing Social Vulnerability Index to Area Deprivation Index to Patient Outcomes in SLE and Glucocorticoid Utilization,120
2344,The Association Between Poverty and SLE Disease Burden: Experiences from a Saint Lucian Cohort,94
2345,Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus,80
2346,Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models,147
2347,Effect on Lupus Outcomes of the Protective Allele at rs1876453 in the Complement Receptor 2 Gene,96
2348,Fungal Infections in Hospitalized Patients of Systemic Lupus Erythematosus: A Nationwide Cohort Analysis,104
2349,Utilization of Palliative Care in Hospitalized Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Analysis,119
2350,Comparison of Disease Severity and Outcomes in Adolescent-Onset and Young Adult-Onset Systemic Lupus Erythematosus,114
2351,Assessing Lupus Disease Activity Following the Onset of End-Stage Kidney Disease Within a Single Tertiary Centre in South London,128
2352,Effect of SARS-CoV2 Infection on Disease Flares in Patients with Systemic Lupus Erythematosus: A Case-control Study,115
2353,Effect of SLE-DAS Remission on Quality of Life in Patients with Systemic Lupus Erythematosus: A Cross-sectional Validation Study,128
2354,The Association Between Systemic Lupus Erythematosus (SLE) and Bone Mineral Density (BMD) Polygenic Risk Scores with Lumbar Spine BMD Z-score: A Retrospective Cohort Study,171
2355,Changes in the Causes and Predictors of Lupus Mortality in Spain Through the Last Decades: Data from the RELESSER Registry,122
2356,Predicting Remission and Low Disease Activity Attainment in Patients with Systemic Lupus Erythematosus,102
2357,Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort,193
2358,Identifying SLE Patients with Depression Using a Zero-Inflated Hidden Markov Model and Predicting Factors Associated with Transition from a Non-depressed State to a Depressed State,180
2359,An Electronic Health Record-Based Algorithm for Predicting Systemic Lupus Erythematosus Flares: Integrating Clinical Factors and Social Determinants of Health,158
2360,Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study,130
2361,Longitudinal ANA Titers in SLE and ANA-associated Rheumatic Diseases,68
2362,Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g,71
2363,Hydroxychloroquine Improves Low Complement Levels,49
2364,"Deucravacitinib, an Oral, Allosteric, Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Patient-Reported Outcomes in a Phase 2 Trial",172
2365,"AMTX-100, a Nuclear Transport Inhibitor, Attenuates Inflammatory Cytokine Production in vitro and Following UV Mediated Skin Inflammation in a Mouse Model of Cutaneous Lupus Erythematosus in vivo",195
2366,Disease-Related Outcomes of Cognitive Behavioral Therapy in Randomized Control Trial for Youth with Childhood-onset SLE: A Secondary Analysis,141
2367,Molecular Predictors of Treatment Response in Two Trials of Abatacept in Systemic Lupus Erythematosus,101
2368,Dapirolizumab Pegol Efficacy by Subgroups in Patients with SLE: A Post Hoc Analysis of Phase 2b Clinical Trial Data,115
2369,Dapirolizumab Pegol Impacts Important Immunologic Pathways in SLE: Pharmacodynamic Analysis of B Cell and Type I Interferon Pathways from a Phase 2b Trial,154
2370,Remission Attainment in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab Compared with Placebo over a 4-Year Period,134
2371,Defining a Basket Population for ANA+ Arthritis Trials,54
2372,Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis,157
2373,"Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers",165
2374,"Results of Single-Arm, Phase 1b Study of Anti-C1q Treatment (ANX009) Show That the Classical Pathway Is a Key Driver of Complement Activation and Consumption in Patients with Active Lupus Nephritis",197
2375,Fragility of Randomized Clinical Trials of Systemic Lupus Erythematosus and Lupus Nephritis Therapies,101
2376,Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis,118
2377,Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus,84
2378,Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial,143
2379,"Hydroxychloroquine Discontinuation in the Real World: Reasons, Predictive Factors and Clinical Implications",107
2380,"Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study",145
2381,Paired Kidney Biopsies from the AURORA 2 Study of Voclosporin in Active Lupus Nephritis,87
2382,SLE Medication Usage and Organ Damage Among Adult SLE Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years,168
2383,Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials,151
2384,Incidence of Infections Among Adult Patients with SLE Treated with Belimumab (BEL): Pooled Data from Three Open-Label Extension Studies over 11+ Years,150
2385,"Selection of the Dose for Subcutaneous Administration to Non-Japanese Subjects and Intravenous Administration to Japanese Subjects in the First-in-Human Study of DS-7011a, an Anti-TLR7 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus",254
2386,"Upregulation of Both APRIL and BAFF in Systemic Lupus Erythematosus Suggests Non-Redundant Roles, Further Revealed by Dual Inhibition with Povetacicept (ALPN-303; TACI vTD-Fc)",175
2387,Health Outcomes Among Patients (Pts) with SLE Initiating Belimumab (BEL) with and Without the Use of Immunosuppressants in the Previous 2 Years,143
2388,High Serum C-X-C Motif Chemokine Ligand 10 (CXCL10) Potentially Predicts New Onset of Systemic Sclerosis-Interstitial Lung Disease,130
2389,Role of Insulin-like Growth Factor Binding Protein-7 (IGFBP7) in Pulmonary Hypertension Pathogenesis and as a Biomarker Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH),191
2390,Is Midkine a Novel Biomarker for Acro-osteolysis in Systemic Sclerosis?,71
2391,Proteome-based Stratification of Therapeutic Target Population for MT-6194 in Systemic Sclerosis with Pulmonary Arterial Hypertension,133
2392,A Macrophage-Specific Mechanism for Mycophenolate Mofetil in the Treatment of Systemic Sclerosis,96
2393,The Involvement of CCR3-CCL24 Axis in Endothelial to Mesenchymal Transition Process and Pulmonary Arterial Hypertension in Systemic Sclerosis Patients,150
2394,Neutrophil Extracellular Traps Induce Endothelial-to-Mesenchymal Transition and Associate with Vascular Complications in Scleroderma,132
2395,Reversal of the Activation State of Pro-fibrotic CD206 Positive Macrophages by Therapeutic Peptide AUR300 in Systemic Sclerosis,127
2396,Systemic Sclerosis Macrophages Stimulate Calcinosis in Adipose Derived Mesenchymal Stem Cells via the Activin a Pathway,119
2397,Optimal Combination of Circulating Biomarkers for Predicting the Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis,141
2398,Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients,172
2399,Increase in Macrophage Infiltration in Scleroderma Esophageal Mucosa Is Associated with Motility and Mucosal Complications,122
2400,Circulating CTHRC1 Levels Are Associated with Disease Severity and Predict Survival in Systemic Sclerosis,105
2401,Decoding the Peripheral Immune Landscape of Systemic Sclerosis to Investigate Disease Stages and Interstitial Lung Disease Progression,134
2402,Spatial Frequency Domain Imaging as a Novel Method to Quantify Longitudinal Skin Changes in Scleroderma,103
2403,Characterization of the SFRP4+ PRG4+ Fibroblast Subpopulation in the Dermis of Healthy Skin and Its Relationship to SFRP4+ PRG4- Myofibroblasts in the Skin of Patients with Systemic Sclerosis,191
2404,Is Skin Disease a Local Manifestation of Systemic Tissue Turnover? Serological Collagen Biomarkers Provide Important Information on Skin Diseases Arising from Mutations in Collagen Genes,186
2405,Investigating Macrophage Heterogeneity in the Esophagus of SSc Patients,71
2406,C5 as a Genetic Marker for Discriminating Between IgA Vasculitis and IgA Nephropathy?,85
2407,Plasma and Urine Cytokine Profiles in Active ANCA-Associated Vasculitis,71
2408,Soluble Triggering Receptor Expressed on Myeloid Cell-1 Reflects the Cross-sectional Activity of Microscopic Polyangiitis and Granulomatosis with Polyangiitis,158
2409,SIRPα Expression in Systemic Vasculitis,39
2410,Torque Teno Virus as a Potential Biomarker for Assessment of Immunocompetence in Patients with ANCA-associated Vasculitis,121
2411,Clinical Characteristics of ANCA-associated Vasculitis with High Levels of Serum Interleukin 7,94
2412,Eosinophil Activation as a Biomarker for Discriminating Active and Remission Phase in ANCA-Associated Vasculitis,112
2413,"The Impact of Chronologic versus Biologic Age on the Risk of Severe Infection, End-Stage Renal Disease, and Death in Older Adults with ANCA-Associated Vasculitis",161
2414,Longitudinal Trajectories of Renal Function in ANCA-Associated Vasculitis: Findings from the Expanded Mass General Brigham Cohort,129
2415,A Real-World Descriptive Study of Renal Outcomes Among Patients with ANCA-Associated Vasculitis Initiating Remission Induction Therapy,134
2416,Renal Survival Rate of ANCA-associated Vasculitis in Korea: A Nationwide Population-Based Study Using Claims Data,113
2417,ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain,103
2418,Relapse of Patients with ANCA-associated Vasculitis Who Are on Dialysis,71
2419,"Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Dual Positive Anti-Neutrophil Cytoplasmic Antibody and Anti-Glomerular Basement Membrane Antibody: A Single Center Experience",210
2420,Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group,109
2421,Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis,73
2422,Impact of ANCA Specificity on Risk of Major Adverse Cardiovascular Events in ANCA-associated Vasculitis,103
2423,Large Vessel Involvement and the Risk of Severe Infections in Patients with Giant Cell Arteritis – a Population-based Study,123
2424,Increased Risk of Severe Infections in Early Giant Cell Arteritis: A Population- based Study,92
2425,Calprotectin (S100A8/S100A9) and Serumamyloid A Are Not Superior to C Reactive Protein and Erythrocyte Sedimentation Rate in Monitoring Disease Activity in Giant Cell Arteritis – Treated with or Without Tocilizumab,214
2426,Characterization of Senescent Cells in Temporal Arteries of Patients with Giant Cell Arteritis Reveal an Inflammatory Phenotype and Strong Dependence from IL-6,159
2427,Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register,95
2428,Characterization of Arterial Dendritic Cells in Polymyalgia Rheumatica and Giant Cell Arteritis,95
2429,CXCL9/IL-6 and MMP3/CD141 Ratio Allow to Discriminate Between Isolated PMR and GCA/PMR Overlap,94
2430,18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry,158
2431,Recommendations for Early Referral of Patients with Suspected Polymyalgia Rheumatica: An Initiative from the International Giant Cell Arteritis and Polymyalgia Rheumatica Study Group,182
2432,Diagnostic Performance of a Newly-Launched Canadian Fast-Track Ultrasound Clinic Performed by Rheumatologists for Diagnosis of Giant Cell Arteritis,147
2433,Impact of Exposure to Environmental Air Pollution on the Onset of Giant Cell Arteritis,86
2434,FDG Uptake in Limb Arteries at Diagnosis of Giant Cell Arteritis and Risk of Relapse: An Observational Cohort Study,115
2435,Ultrasound Is Comparable to Computed Tomography Angiography in Identifying Aortic Aneurysms in Patients with Giant Cell Arteritis,129
2436,Applanation Tonometry of the Temporal Arteries in Participants with Suspected Giant Cell Arteritis: A Proof of Concept,118
2437,A Study Defining the Optimal Sonographic Parameters for Intima-Media Thickness in Diagnosing Giant Cell Arteritis,113
2438,A Retrospective Analysis of Prevalence of Positive Temporal Artery Biopsies in African American Patients with Giant Cell Arteritis (GCA) in a Large Academic Health Center,170
2439,Systole and Diastole Ultrasound Wall Thickness Shows Significant Differences That Affect the Diagnosis and Assessment of Giant Cell Arteritis,141
2440,Subclinical Giant Cell Arteritis in Polimialgia Rheumatica: A Biomarker of High Relapse Risk,92
2441,Role of Mitochondria in Activation of Platelets in Giant Cell Arteritis,71
2442,"Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study",98
2443,Immuno-permissive Antigen-presenting Cells in Giant Cell Arteritis,66
2444,The Use of the Southend GCA Probability Score (GCAPS) in Assessing the Risk of Giant Cell Arteritis in Australian Ophthalmological and General Medical Hospital Cohorts,167
2445,Concordance of Relapse Symptoms with Initial Baseline Presentation Features Among Patients with Giant Cell Arteritis,116
2446,Tocilizumab versus Methotrexate in Giant Cell Arteritis: A Retrospective Study to Compare Efficacy and Rapidity of These Steroid-sparing Agents in GCA Patients,159
2447,C-X-C Motif Chemokine Receptor 4-targeted Molecular Imaging in Giant Cell Arteritis – a Head-to-head Comparison with FDG PET,124
2448,"Evaluation of the Pretest Probability Score, Ultrasound and Biopsy on GCA Diagnose: Data from Real Clinical Practice",116
2449,Janus Kinase Inhibitors in Giant Cell Arteritis in Clinical Practice. Real-World Clinical Practice Study and Literature Review,126
2450,Relapse in Giant Cell Arteritis Treated with Tocilizumab. Predictive Factors,76
2451,Giant Cell Arteritis Is Associated with Worse Hospital Outcomes in Aortic Aneurysm/Dissection Hospitalizations: A Nationwide United States Population-Based Study,161
2452,"Comparison of Clinical, Laboratory and Imaging Features of Relapses Between Takayasu and LV-GCA Patients. an Italian Monocentric Study",134
2453,Influence of Histological Tempol Artery Biopsy Findings on Outcomes of Biopsy-proven Giant Cell Arteritis in Italian Patients : A Long Single Center Follow-up Study,164
2454,Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment,80
2455,Visual Manifestations in Giant Cell Arteritis: Identification of Risk Factors from the ARTESER Registry,103
2456,Sex Differences in Giant Cell Arteritis: Data from the ARTESER Registry,71
2457,Optic Nerve Sheath Measurement on Ultrasound: A Novel Diagnostic Test for Giant Cell Arteritis,94
2458,Magnetic Resonance Imaging Reflects Disease Activity in the “Giant Cell Arteritis Treatment with Ultra-short Glucocorticoids and Tocilizumab” Trial (The GUSTO Trial),165
2459,Concordance Between the 1990 ACR Classification Criteria and the New 2022 ACR/EULAR 2022 Criteria in Giant Cell Arteritis,121
2460,Exploring the Limit of Image Resolution for Human Expert Classification of Vascular Ultrasound Images in Giant Cell Arteritis and Healthy Subjects: The GCA-US-AI Project,169
2461,Pregnancy Outcomes Among Patients with Vasculitis Using Administrative Claims Data,82
2462,The Role of β-catenin in Synovial Lining Fibroblast Differentiation,67
2463,Degranulating PR3+ Myeloid Cells Characterize Proliferative Lupus Nephritis,75
2464,"Unclosing Premature Mortality Gap Among Gout Patients in the US General Population, Independent of Serum Urate and Atherosclerotic Cardiovascular Risk Factors",158
2465,Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial,146
2466,Time-Dependent Evaluation of Weighted Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis,162
2467,Integrated Single Cell Multi-omics Analysis in At-Risk for Future Rheumatoid Arthritis (RA) and Early RA Reveals Shared Transcription Factor Profiles in Multiple Cell Lineages,175
2468,Wnt Signaling Drives Pathogenic Stromal Inflammation in Inflammatory Arthritis,78
2469,Longitudinal Multi-Omics Single Cell Analysis Reveals Abatacept Treatment Shifts Peripheral Lymphocyte Subpopulations in Seropositive RA with Reduction of Mature B Cells and Retention of Transitional and Naive B Cells,217
2470,Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response,100
2471,Deciphering Rheumatoid Arthritis Disease Activity-Associated Gene Signatures and Cell Subsets Through Single Cell Transcriptomics,129
2472,Characterizing Spatial Organization of Immune Infiltrates in Rheumatoid Arthritis Synovia Using Spatial Transcriptomic Analysis,127
2473,Translocation of Intestinal Bacteria to Axial and Peripheral Joints in a Model of Spondyloarthropathy,101
2474,Synovial Tissue Single-Cell Analysis Demonstrates Differential Fibroblast Populations Between RA and PsA Which Display Distinct Function,136
2475,Proteomic and Genomic Profiling of Plasma Exosomes from Ankylosing Spondylitis Patients,87
2476,Synovial Shaping of Skin-derived Migrating Immune Cells Determines Initiation of Inflammation in Psoriatic Arthritis,116
2477,Upregulation of RANKL in the Skin of Patients with Psoriatic Arthritis,70
2478,Neutrophils Induce Contact-Dependent Expansion of Arthritogenic Th17 Cells and Are Necessary for Disease in Experimental Ankylosing Spondylitis,143
2479,Blockade of OX40/OX40L Signaling Using anti-OX40L Ameliorates Systemic Lupus Erythematosus,90
2480,Development of Engineered Smith-Specific Regulatory T Cells to Treat Lupus Nephritis,84
2481,Targeting of Endothelial Dysfunction in Lupus Nephritis: Effect on Human Renal Endothelial Cell Gene Expression and Outcomes in Murine Lupus Nephritis,150
2482,Intermittent Fasting Attenuates Cognitive Dysfunction in Murine Systemic Lupus Erythematosus,92
2483,Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus,102
2484,UV Light Exposure Induces a Type I Interferon Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes,133
2485,Cognitive Functioning Among Individuals with Systemic Lupus Erythematosus: A Population-Based Study,99
2486,Gene by Respiratory Disease Interactions Associated with Developing Rheumatoid Arthritis,88
2487,TET2 Clonal Hematopoiesis and Incident Rheumatoid Arthritis: Results from the UK Biobank,88
2488,"Assessment of Association Between Hydroxychloroquine Use and Toxic Retinopathy, Overall and by Indication, in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System",212
2489,Development of a Hydroxychloroquine Retinopathy Prediction Score,64
2490,Endometriosis Increase Risk of Antiphospholipid Syndrome: A Propensity Score Matched Cohort Study,97
2491,Addressing Native American Health Disparities in Rheumatoid Arthritis by Training Primary Care Providers: Expanding the Reach of the RAE Initiative,147
2492,Lupus Patient Navigator Program to Improve Healthcare Barriers for Minority Patients,84
2493,Ageism in Rheumatology: The Health Care Professional’s Perspective,66
2494,The Impact of Social Inequities on Presentation of Childhood-Onset Systemic Lupus Erythematosus (cSLE) at a Large Tertiary Center,129
2495,Reporting of Race and Ethnicity in Lupus Publications in High-impact Rheumatology Journals,90
2496,"Health Care Segregation, but Not Metropolitan Area Segregation, Magnifies Racial Disparities in Hospital Outcomes of Pediatric Lupus",132
2497,Transcriptional Derepression of CHD4/NuRD-regulated Genes in the Muscle of Patients with Dermatomyositis and anti-Mi2 Autoantibodies,132
2498,Mitochondrial-Mediated Neutrophil Activation in Dermatomyositis (DM) and Inclusion Body Myositis (IBM): Insights into Pathogenesis and Therapeutic Implications,159
2499,Efficacy and Safety of Car-T-Cell Treatment in Refractory Antisynthetase Syndrome – Data of the First Three Patients,116
2500,"B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature",100
2501,Clonally Expanded B Cells in Anti-Histidyl-tRNA Synthetase Syndrome Patients Exhibit an Autoreactive-Prone Memory Phenotype and Bind Jo-1 Autoantigen,149
2502,Monoclonal Anti-MDA5 Autoantibodies Derived from a Patient with Dermatomyositis Target the Hel2i Domain of the MDA5 Protein,123
2503,"Quadriceps Muscle Fat Composition but Not Muscle Energetics Is Associated with Knee Osteoarthritis: Initial Results from the Study of Muscle, Mobility, and Aging",161
2504,Association Between Gut Microbiome-related Metabolites and Symptomatic Hand Osteoarthritis in Two Independent Cohorts,117
2505,Associations Between Body Composition Measurements of Obesity and the Radiographic Progression of Hand Osteoarthritis: Data from the Dong-gu Study,146
2506,Low Serum Adiponectin Levels Were Associated with Radiographic Progression of Hand Osteoarthritis in a 6-year Follow-up of the Dong-gu Study,140
2507,Higher Pain and Functional Impairment in Erosive Hand Osteoarthritis Than in Treated Rheumatoid Arthritis: A Comparative Study Between DIGICOD and ESPOIR Cohorts,161
2508,Synovitis and the Risk of Incident Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study,98
2509,A Consensus Based Algorithm to Screen for Lung Disease in Children with Systemic Juvenile Idiopathic Arthritis,110
2510,Uveitis as Predictor of Disease Flare After the First Course of Anti-TNF Withdrawal in Oligo and Polyarticular Juvenile Idiopathic Arthritis: A Multicentric Italian Experience,175
2511,Elevation of the IL-17 Cytokine Family Distinguishes Kawasaki Disease from Other Pediatric Inflammatory Disorders,113
2512,Defining Cutoffs for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score,150
2513,Anifrolumab Normalizes the Type I Interferon Signature in a Cohort of Patients with Type I Interferonopathies,109
2514,Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases,190
2515,Tolerability and Effectiveness of Antifibrotics in Rheumatoid Arthritis-associated Interstitial Lung Disease,108
2516,Definition of Rheumatoid Arthritis Flare Based on SDAI and CDAI,63
2517,Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy,171
2518,Preinflammatory Mesenchymal (PRIME) Cell Signature Genes Enrichment Predicts Treatment Response and Joint Prognosis in Rheumatoid Arthritis,139
2519,CD68 and Fibrinoid Necrosis Are Synovial Biomarkers of Severity in Early Rheumatoid Arthritis and Are Associated with a Better Response to Methotrexate: Analysis of the UCLouvain Brussels ERA Cohort,198
2520,Optimizing the Care of the Rheumatic Patient with Rheumatologist-Pharmacist Co-management,89
2521,Comparative Risk of Serious Psychiatric Events with Belimumab versus Oral Immunosuppressant Use in Patients with Systemic Lupus Erythematosus,141
2522,Should SLE Patients Entering Clinical Trials Be Required to Have at Least One BILAG a And/or Two BILAG B Scores?,112
2523,Phase 2 Safety and Efficacy of Subcutaneous (s.c.) Dose Ianalumab (VAY736; Anti-BAFFR mAb) Administered Monthly over 28 Weeks in Patients with Systemic Lupus Erythematosus (SLE) of Moderate-to-Severe Activity,208
2524,"Efficacy and Safety of ABBV-599 High Dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: A Phase 2, Double-blind, Placebo-controlled Trial",215
2525,"Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Achievement and Sustained Response with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE",212
2526,Safety and Efficacy of Mycophenolate Mofetil in New-onset Systemic Lupus Erythematosus with High Titer of Anti-dsDNA Antibody and Without Major Organ Involvement: A Multicenter Randomized Controlled Trial,204
2527,"Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort",173
2528,The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life,114
2529,Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis,88
2530,Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis,78
2531,Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis,107
2532,"HXB-319, a New Generation Mesenchymal Stromal Cell (MSC) Therapy, Alleviates Neutrophilic Inflammation, and End-organ Damage in Pulmonary Renal Syndromes by Inducing FoxP3+ Tregs, and by Promoting TNFα-stimulated gene-6 (TSG-6) over Expression",243
2533,Factors Influencing Time to Diagnosis in U.S. Patients with Systemic Lupus Erythematosus,88
2534,Does Physical Activity Modify the Relationship Between Pain and Corticosteroid Injection Utilization in Adults with or at High Risk for Knee Osteoarthritis?,156
2535,"Influence of Adiposity on Physical Function, Physical Activity, and Self-Reported Symptom Severity for Individuals with Arthritis Prior to Beginning a Physical Activity Promotion Intervention",191
2536,Suicidal Ideation and Self-Efficacy in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort,116
2537,Selection of Indicators Reporting Response Rate in Pharmaceutical Trials for Systemic Lupus Erythematosus: Preference and Relative Sensitivity,142
2538,Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus,81
2539,Cytokines Regulate the Fibrotic Response of Growth Factors in Joint Fibroblast-like Synoviocytes,96
2540,The Effect of Inflammatory Conditions on the Regulation of Canonical and Non-canonical NF-kB Pathways via Bcl11b,112
2541,Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders,100
2542,Role of TGF-β Activated Kinase 1 in Cytokine-Driven Juvenile Idiopathic Arthritis Synovial Fibroblasts Activation,113
2543,ZCCHC6 Modulates the Global Phosphorylation Landscape in TNF-a-induced Rheumatoid Arthritis Synovial Fibroblasts,112
2544,Chronic IL-6 Trans-Signaling Enhances Stem Cell-Like Characteristics of Rheumatoid Arthritis Synovial Fibroblasts,113
2545,Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias,184
2546,Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1,133
2547,Superior SARS-CoV-2 Antibody Response Achieved in Rituximab-treated Patients When Vaccinated Against COVID-19 Before Compared to After Rituximab Initiation – Guidance for Future Vaccination Strategies,200
2548,Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis,133
2549,Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis,116
2550,Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis,104
2551,Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases,148
2552,The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica,81
2553,The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease,84
2554,Could the Adenosine Pathway Identify Cases with a Progressive Fibrosing Phenotype Between Patients with Autoimmune Interstitial Lung Disease? An Initial Approach,161
2555,A Phase II Clinical Study to Investigate the Efficacy and Safety of Hemay005 Tablets in Patients with Active Behçet`sDisease,124
2556,Identification of Clinical Phenotypes in Sarcoidosis Using a Cluster Analysis,77
2557,Understanding Age as a Risk Factor for Complications After Total Knee Arthroplasty: What Can We Learn from Machine Learning?,124
2558,Diabetes Mellitus Impacts Primary Total Hip Arthroplasty Outcomes: A National Cohort Study,90
2559,"Region, Race, and Hospital Factors Impact Length of Stay and Hospital Charges Post-primary Total Knee Arthroplasty",114
2560,Relation of Pain Sensitivity to Forces While Walking in Adults with and Without Knee Pain: The Multicenter Osteoarthritis (MOST) Study,134
2561,Comparing Patellar Tendon Characteristics Between Adults with and Without Knee Pain,83
2562,Single-cell RNA Sequencing Reveals the CRTAC1+ Population Actively Contributes to the Pathogenesis of Spinal Ligament Degeneration by Inducing Macrophage Activation,164
2563,Risk Factors for Bone Loss in Systemic Lupus Erythematosus,58
2564,"Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States",170
2565,Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program,135
2566,Risk Evaluation of Osteoporotic Fractures Following Lung Transplantation (LT): A Retrospective Cohort Study Conducted at an International Transplant Center,155
2567,Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids,197
2568,Prevalence and Disease-Specific Factors Associated with Osteoporosis in Systemic Sclerosis: A Cross-Sectional Analysis of Two Large European Cohorts,148
2569,Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study,166
2570,A Novel Approach for Mixed-methods Research Using Language Learning Models: A Report Using Patients’ Perspectives on Barriers to Hip and Knee Replacement,153
2571,Strategies to Embrace Living with Lupus Fearlessly (SELF): A Promising Digital Intervention for Lupus Self-Management,117
2572,DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection,92
2573,Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs,142
2574,Safety and Efficacy of Sodium-glucose Co-transporter 2 Inhibitors in Patients with Psoriasis and Concomitant Type 2 Diabetes Mellitus: A Population-based Cohort Study,166
2575,Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA,126
2576,The Molecular Stratification of Rheumatoid Arthritis Using High-throughput Technologies Is Directly Associated with Disease Activity and Clinical Response,154
2577,Differential Responses to Initial Treatment Strategies for Rheumatoid Arthritis Among Those with Lower Body Mass and Adiposity,126
2578,Impact of Concomitant Methotrexate on Disease Activity After Tapering Abatacept in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study,144
2579,Clinical and Radiographic Results of Tapering and Withdrawing CsDMARDs versus Stable Treatment in Patients with Rheumatoid Arthritis in Remission: 3-year Results from a Randomized Controlled Trial,196
2580,Microbial Metabolism of Methotrexate Contributes to Its Pharmacokinetics in Vivo,80
2581,"Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study",154
2582,Anti-infliximab Antibodies as a Marker of Drug Survival and Tapering in Ankylosing Spondylitis Patients: 12 Years Follow-up,123
2583,Characteristics of Difficult-To-Treat Axial Spondyloarthritis: Results of a Multicentric Retrospective Study,108
2584,Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials,122
2585,Effect of Ixekizumab Treatment on MRI Structural Lesions in the Sacroiliac Joints of Patients with Radiographic Axial Spondyloarthritis; A Post-hoc Analysis of a Placebo and Active Controlled RCT,195
2586,The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis,157
2587,Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis,132
2588,Inflammatory Fibrosis Precedes Loss of Kidney Function in Lupus Nephritis,73
2589,"Prevalence, Determinants and Outcomes of Target Attainment in SLE Patients with Clinically Active Disease in a Large Multinational Prospective Lupus Cohort",155
2590,Validation of a Flare Risk Index Informed by Select Immune Mediators in Systemic Lupus Erythematosus in a Confirmatory Cohort,125
2591,Cluster Analysis Reveals Subgroups in Patients with Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Implication for Long-term Prognosis Prediction,170
2592,End-of-Life in Systemic Lupus Erythematosus Beset by Increased Flares and Higher Treatment Burden: Data from a Prospective Large Multinational Cohort,149
2593,Clinicopathologic Features of Patients with Giant Cell Arteritis and Thoracic Aorta Repair: A Single Center Experience over Two Decades,135
2594,Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab,127
2595,Clinical Manifestations and Immunomodulatory Treatment in Patients with Relapsing Polychondritis,96
2596,Risk of Gastrointestinal Perforation Among Patients with Giant Cell Arteritis Who Received Tocilizumab,102
2597,The Prognostic Value of the “2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis”: Data from the Italian Society of Rheumatology Vasculitis Study Group,163
2598,Immune Checkpoint Inhibitors-Induced Large Vessel Vasculitis: Data from a Multicenter Study,91
2599,Causal Associations Between Gut Microbiota and Rheumatic Diseases: A Mendelian Randomization Study,98
2600,The Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine in Patients with Systemic Autoimmune Rheumatic Diseases Using Immunomodulators: An Emulated Target Trial,164
2601,"The Problem of Pain in Rheumatology: A Population-based Study of Annual Trends in Pain Management Modalities in Patients with Autoimmune Rheumatic Diseases in the United States, 2007-2021",187
2602,Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database,211
2603,An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases,168
2604,First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients,118
2605,Efficacy and Safety of Therapeutic Interventions for the Treatment of Still’s Disease: A Systematic Review and Meta-analysis Informing the EULAR/PReS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease,272
2606,Thrombosis in Patients with VEXAS Syndrome: A Retrospective Cohort Study,72
2607,Identification of Biomarkers Predicting Steroid Resistance in Immune Checkpoint Inhibitor-Induced Arthritis,107
2608,Autoantibody Profile of Autoimmune Driven Interstitial Lung Disease as Compared to Idiopathic Pulmonary Fibrosis and Association of Autoantibodies with Survival,160
2609,Prevalence of Pulmonary Hypertension in a Cohort of Patients with Interstitial Pneumonia with Autoimmune Features and Its Effect on Lung Disease Progression and Mortality,170
2610,Are Patients Classified as IPAF More Likely to Also Meet SLE Criteria by 2019 EULAR/ACR Than by SLICC?: An Abstract,115
2611,Accurate Stratification of Cancer Risk in a Real-World Cohort Using the International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening,160
2612,"Rapid Onset of Response in Adult Dermatomyositis Patients Receiving Anti-interferon β (PF-06823859): Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study",173
2613,Frequency of Atherosclerotic Cardiovascular Disease Following a Diagnosis of Idiopathic Inflammatory Myopathy: Data from a Large National Registry,146
2614,Machine Learning Identifies New Sporadic Inclusion Body Myositis Endotypes Associated with Unique Autoantibody Profiles,119
2615,Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies,92
2616,"High-intensity Resistance Training Improves Quality of Life, Muscle Endurance and Strength in Patients with Myositis",116
2617,Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies,181
2618,Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA,159
2619,A Predictive Model for Progression to Clinical Arthritis Based on Lymphocyte Subsets and ACPA in At-risk Individuals with Arthralgia,132
2620,Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis,88
2621,"Cytokine and Chemokine Elevations in ACPA+ Individuals Suggest Possible Viral, Mucosal and/or Innate Responses Are Related to the Transition to Future Clinical RA",162
2622,A Novel Blood-Based Assay Differentiates Seropositive and Seronegative Rheumatoid Arthritis from Healthy Individuals and Those with Other Inflammatory Diseases or Osteoarthritis,177
2623,Measuring Frailty in SLE: Agreement Among Methods,49
2624,Updated Analyses of Cancer Incidence and Risk Factors in a Large International SLE Cohort,89
2625,Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Systemic Lupus Erythematosus,115
2626,Association Between Frailty and Readmissions in Hospitalized Patients with Systemic Lupus Erythematosus (SLE),109
2627,Under Assault: Ongoing Brain Dysfunction Identified on Resting State-functional MRI (rs-fMRI) in SLE Patients in Clinical Remission,131
2628,"Trends, Sociodemographic and Clinical Factors Associated with Avascular Necrosis and Related Arthroplasties in Hospitalized Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis",191
2629,FT011 for the Treatment of Systemic Sclerosis. Results from a Phase II Study,76
2630,Trajectories of Forced Vital Capacity (FVC) in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD),126
2631,A Randomized Controlled Trial to Compare the Efficacy and Safety of Tacrolimus with Mycophenolate Mofetil in Patients with Systemic Sclerosis – Interstitial Lung Disease ( INSIST TRIAL),185
2632,"Head-To-Head Comparison of the Effectiveness of Tocilizumab, Rituximab, Mycophenolate Mofetil, and Cyclophosphamide in Patients with SSc-ILD from the EUSTAR Database",165
2633,Fecal Microbiota Transplantation in Patients with Systemic Sclerosis and Lower Gastrointestinal Tract Symptoms: Data from the ReSScue Phase 2 Randomized Clinical Trial,167
2634,6 Months-follow up Data of Systemic Sclerosis Patients Treated with CD 19 Targeting CAR-T Cells,95
2635,Study of the Role of interleukin-17 in Giant Cell Arteritis,59
2636,Clonal Hematopoiesis Is Associated with Giant Cell Arteritis,60
2637,Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning,102
2638,Spatially Resolved Cellular Signatures Predict Corticosteroid Treatment Response in Giant Cell Arteritis,104
2639,Impact of IL-6 Receptor Small Nucleotide Polymorphism Asp358Ala on T Cell Activity and Clinical Outcomes in Patients with Giant Cell Arteritis,142
2640,Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis,139
